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Abstract  20 
Background 21 
Low and high birthweight is known to increase the risk of acute and longer term adverse 22 
outcomes, such as stillbirth, infant mortality, obesity, type 2 diabetes, and cardiovascular 23 
diseases. Gestational dyslipidaemia is associated with a numbers of adverse birth outcomes, 24 
but evidence regarding on birth weight is still inconsistent to reliably inform clinical practice 25 
and treatment recommendations. 26 
Objective 27 
To explore the relationship between maternal gestational dyslipidaemia and neonatal health 28 
outcomes namely, birth weight, metabolic factors, and inflammatory parameters.  29 
Methods 30 
We searched systematically Embase, MEDLINE, PubMed, CINAHL Plus, and Cochrane 31 
Library up to 1st August 2016 (with an updated search in MEDLINE at the end of July 2017), 32 
for longitudinal studies that assessed the association of maternal lipid levels during 33 
pregnancy with neonatal birth weight, or metabolic and inflammatory parameters up to 3 34 
years old.  35 
Results 36 
Data from 46 publications including 31,402 pregnancies suggests that maternal high 37 
triglycerides and low high-density-lipoprotein cholesterol levels throughout pregnancy are 38 
associated with increased birth weight, higher risk of large-for-gestational age and 39 
macrosomia; and lower risk of small-for-gestational age. The findings were consistent across 40 
the studied populations, but stronger associations were observed in women who were 41 
overweight or obese prior to pregnancy. 42 
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Conclusions 43 
This meta-analysis suggested that the potential under-recognised adverse effects of 44 
intrauterine exposure to maternal dyslipidaemia may warrant further investigation into the 45 
relationship between maternal dyslipidaemia and birth weight in large prospective cohorts or 46 
in randomised trials.  47 
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Abbreviations: 49 
LBW: low birth weight 50 
SGA: small for gestational age 51 
LGA: large for gestational age 52 
GDM: gestational diabetes mellitus 53 
RCT: Randomised Controlled Trial 54 
TC: total cholesterol 55 
HDL: high-density lipoprotein  56 
LDL: low-density lipoprotein 57 
VLDL: very low-density lipoprotein 58 
TG: triglycerides 59 
FFAs: total free fatty acids 60 
BMI: Body Mass Index 61 
MCP-1: Monocyte Chemoattractant Protein-1 62 
IL-6: interleukin 6 63 
TNF-α: Tumour Necrosis Factor alpha 64 
11β HSD1: 11-beta-Hydroxysteroid Dehydrogenase Type 1  65 
CRP: C-reactive protein 66 
T1: the first trimester 67 
T2: the second trimester 68 
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T3: the third trimester 69 
mg/dL: milligrams per decilitre 70 
mmol/L: millimoles per litre 71 
RC: regression coefficients 72 
OR: odds ratio 73 
MD: mean difference 74 
GWAS: genome-wide association study  75 
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Introduction  76 
Low and high birth weight has been linked to the risk of stillbirth and infant mortality.1 In  a 77 
longer life course, both low birth weight(LBW) or small for gestational age(SGA), and large 78 
for gestational age(LGA) or macrosomia are known to increase the future risk of obesity, 79 
type 2 diabetes, and cardiovascular disease.2, 3 The estimated prevalence of macrosomia in 80 
developed countries varies from 5% to 20%, and a parallel increase in macrosomic births was 81 
observed in both developed and developing countries over the last two to three decades.4 82 
These life course associations have often been attributed to the impact of an adverse 83 
intrauterine environment, particularly, fuels (glucose, lipids, and amino acids) transported 84 
from the maternal end.5 Previous reviews have shown that maternal obesity and gestational 85 
diabetes mellitus(GDM) are two identified risk factors of low and high birthweight.6-8 86 
However, as one of common metabolic disorders, the adverse effects of gestational 87 
dyslipidaemia on neonates birth weight/birth weight centiles are not widely recognized in 88 
clinical practice. 89 
Dyslipidaemia has been considered a risk factor for a number of adverse health outcomes, in 90 
particular cardiovascular disease and type 2 diabetes.9, 10 Previous reviews have shown that 91 
dyslipidaemia during pregnancy are associated with increased risk of GDM, preeclampsia, 92 
and pre-term delivery11-13, but epidemiological evidence on birthweight is conflicting14-16. 93 
Furthermore, previous evidence indicates that excessive maternal intrauterine lipid exposures 94 
may program the development of foetus organs from early life, resulting in metabolic 95 
dysfunction.17, 18 If maternal dyslipidaemia is a significant contributor to birth weight and 96 
implicated in neonatal metabolic dysfunction, then interventions before and during pregnancy 97 
to mitigate dyslipidaemia might improve offspring’s adverse birth and metabolic health 98 
outcomes. 99 
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We performed a comprehensive systematic review and meta-analysis to explore the 100 
association, and quantify the magnitude of effect between maternal dyslipidaemia and 101 
neonatal outcomes namely, birthweight, metabolic factors, and inflammatory parameters.  102 
Methods  103 
Search strategy and selection criteria 104 
The protocol for this review was registered on PROSPERO (CRD42016048568) and the 105 
review is reported in accordance with the PRISMA19 and MOOSE20 guidelines. We searched 106 
systematically Embase, MEDLINE, PubMed, Scopus, CINAHL Plus, and Cochrane library 107 
(CENTRAL) up to August 1, 2016, without language or year restrictions. An updated search 108 
was made in MEDLINE before manuscript submission until the end of July 2017. The search 109 
of bibliographic databases combined index and free text terms relating to lipids (e.g. “lipids”, 110 
“lipoproteins”, “fatty acids”, “triglycerides”, “cholesterol”) with those relating to pregnancy 111 
(e.g. “pregnan*”, “gestation*”, “gravidity”, “mothers”) and birthweight (e.g. “birth weight”, 112 
“small for gestational age”, “large for gestational age”, “macrosomia”). The full strategies are 113 
provided in S1 Appendix. Cohort and Randomised Controlled Trial (RCT) filters were used 114 
to target longitudinal observational studies and the secondary analysis of RCT studies.21 115 
Additional searches were conducted in Grey Literature Report and Open Grey. Reference 116 
lists of included studies were screened and checked for relevance.  117 
Search results, after removal of duplicates, were screened for relevance using title and 118 
abstract information. Fully texts of relevant articles were assessed for eligibility against the 119 
selection criteria. Screening and selection were undertaken by two reviewers independently 120 
in consultation with a third reviewer when required.  121 
This review included studies of healthy pregnant women and pregnant women with GDM or 122 
obesity, which investigated the association between maternal lipid levels during pregnancy 123 
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(total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein 124 
cholesterol (LDL-C), very-low-density lipoprotein cholesterol (VLDL-C), triglycerides (TG), 125 
and total free fatty acids (FFAs)) and neonatal anthropometric, metabolic, and inflammatory 126 
parameters.  127 
Studies of pregnant women with conditions that could influence maternal metabolic status 128 
before pregnancy (hepatitis, polycystic ovary syndrome, familial hyperlipidaemia, acquired 129 
immunodeficiency syndrome, type I & type 2 diabetes, hypertension, thrombophilia, history 130 
of thromboembolism, rheumatologic disorders, cardiac dysfunction, or history of taking 131 
relevant lipid-lowering medications) were excluded.  132 
The primary outcome was birthweight measured within the first week after delivery. 133 
Neonatal anthropometric parameters, including LBW, SGA, LGA, and macrosomia, were 134 
considered as different indexes of birthweight. Secondary outcomes included: anthropometric 135 
parameters in children less than three years old (e.g. weight gain after delivery, Body Mass 136 
Index (BMI) and skinfold thickness); biological indicators (glucose, TC, HDL-C, LDL-C, 137 
VLDL-C, TG, FFAs and insulin levels; and insulin resistance) and neonatal inflammatory 138 
factors (Monocyte Chemoattractant Protein-1 (MCP-1), interleukin 6 (IL-6), Tumour 139 
Necrosis Factor (TNF-α) and 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11β HSD1) 140 
and C-reactive protein(CRP), as well as leptin levels) measured in cord blood or blood 141 
samples taken from neonates(<3 years old). Due to the diverse definition of GDM, obesity, 142 
SGA, LGA, and macrosomia in different populations, we accepted the definition specified by 143 
authors. 144 
Data extraction and quality assessment 145 
A STROBE-based pre-designed form22 was used for data extraction, including the following 146 
information: study characteristics(study name, design, language, and location), 147 
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participants(setting, eligibility/exclude criteria, and sample size) , maternal characteristics 148 
(age, parity, pre-pregnancy BMI, and gestational length), follow-up (enrolment time, length 149 
of follow-up, data collection methods, and loss to follow-up rate), exposures (definition, 150 
fasting status, measured gestational weeks, and measurement methods ) and outcomes 151 
(definition and measurement time point)(S2 Appendix).  152 
The Newcastle-Ottawa Scale was used to characterise and stratify the methodological quality 153 
of included studies (S3 Appendix).23 Studies quality was classified as ‘low’ (≤5), ‘medium’(6 154 
& 7), or ‘high’(8 & 9) quality. In addition, domains relating to sample selection, 155 
comparability between groups, and method of outcome assessment were considered 156 
separately.  157 
Data extraction and quality assessment were conducted by two reviewers independently in 158 
consultation with a third reviewer when required (S4 Appendix). Missing information was 159 
requested from authors by email (S5 Appendix). 160 
Data synthesis 161 
Included studies were categorised by trimester based on the mean/median gestational age for 162 
the lipid measurement (first trimester (T1): 1-13, second trimester (T2): 14-27, and third 163 
trimester (T3): ≥28 gestation weeks). For studies reporting lipid levels multiple times within 164 
one trimester, data from the trimester with the largest sample size was adopted. Studies with 165 
different types of population (example GDM or obesity) were divided into two or three 166 
subsets to enable us to assess and report separately. Lipid measurements reported in 167 
milligrams per decilitre (mg/dL) were converted to millimoles per litre (mmol/L) using a 168 
standard unit conversion factors.24  169 
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Results of birthweight were reported in various ways, for instance, regression coefficients 170 
and correlation coefficients. Findings were summarised in tables and visually represented as 171 
horizontal histogram, displaying the direction as well as statistical significance of results 172 
comprehensively (post analysis).  173 
Summary estimates were pooled using random effects meta-analysis, according to assessment 174 
of outcomes (birthweight, LGA, SGA, and macrosomia), timing of lipids 175 
measurement(T1/T2/T3) and statistic reported in the primary study (regression coefficients, 176 
odds ratio (OR), or mean difference (MD)). Unadjusted and adjusted estimates reported in the 177 
articles were entered into random-effects models separately. Confounding factors that were 178 
adjusted (maternal age, pre-pregnancy BMI, gestational weight gain, gestational glucose level, 179 
pre-term birth, gestational lipid levels, gestational age, and neonatal gender) for each result 180 
were recorded for further sensitivity analyses. The I2 statistic was used to quantify the degree 181 
of heterogeneity beyond that expected by chance in each analysis.25 The potential for 182 
publication bias could not be assessed via funnel plots as the requirement for ten or more 183 
studies per meta-analysis was not met.26 Due to the heterogeneity in baseline characteristics 184 
of included studies, we were not able to compare non-GDM women to GDM women. 185 
Sensitivity analysis was performed by choice of co-variates controlled for in the model. All 186 
analyses were conducted using Review Manager version 5.3 (Nordic Cochrane Centre, 187 
Copenhagen, Denmark) and R 3.3.2(The R Foundation for Statistical Computing).  188 
Results  189 
Study selection 190 
Of the 13,705 unique records identified by the searches, 46 publications14-16, 27-69 reporting 191 
from 42 studies were included in the review (Figure 1). These studies included 31,402 192 
pregnancies. Of the 46 included publications, 16 contributed to the quantitative analysis due 193 
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to the diversity of reporting formats (regression coefficients, correlation coefficients, mean 194 
differences, trend analyses, or without exact effect estimates) and lack of data required for 195 
calculations. No additional eligible studies were found in the updated search till July 2017. 196 
Characteristics of included studies 197 
Table describes the baseline characteristics of the 46 included publications. Most articles 198 
were published in English language and as full text articles with only one44 study written in 199 
German, and one43 published as an abstract. The studies were published between 1985 and 200 
2016. The number of pregnancies ranged from 38 to 5,535. Based on the World Bank Income 201 
Classification of countries 70, 25 out of 42 studies were from high income economies14, 16, 27, 202 
28, 35, 41, 44-49, 51, 53, 55-62, 66-68, 16 from upper middle economies15, 30-34, 37, 38, 40, 42, 43, 50, 54, 63, 65, 69, 203 
and one middle income39. Forty studies were prospective cohorts14, 15, 28-36, 38-50, 52, 54-57, 59-69, 204 
three were retrospective cohorts27, 37, 58, and three were secondary analyses of cohorts in 205 
RCTs16, 51, 53.  206 
Quality of included studies 207 
Forty-five publications (excluding the abstract43) were assessed for methodological quality. 208 
Ten, 21, and 14 studies were assessed as methodologically high15, 29, 41, 47-49, 52, 54, 60, 67, 209 
moderate14, 16, 27, 30-32, 37, 38, 40, 44, 46, 50, 51, 55-57, 61, 62, 64, 68, 69 and low quality28, 33-36, 39, 42, 45, 53, 58, 59, 210 
63, 65, 66 respectively(S6 Appendix). Three (7%) of 45 included studies had low risk for study 211 
selection while 40(93%) had medium risk. For comparability bias, 15(33%) had low risk, 212 
13(29%) had medium risk, and 17(38%) had high risk. Sixteen (36%) studies were regarded 213 
to have a low risk of outcome assessment bias, with the rest (29 studies) having medium risk. 214 
Maternal lipid levels during pregnancy and birth weight 215 
Figure 2 shows the relationship between maternal lipid levels during pregnancy and 216 
birthweight (S7 Appendix). There were strong associations noted for HDL-C and TG 217 
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throughout pregnancy with birthweight. For HDL-C, both studies55 reporting in T1, six15, 16, 31, 218 
37, 49, 55 out of 1115, 16, 31, 34, 37, 49, 50, 55, 59, 62 studies reporting in T2, and 1114, 15, 28, 41, 49, 54, 55, 61, 65, 219 
68 out of 1814-16, 28, 39, 41, 42, 46, 49, 50, 54, 55, 58, 61, 63, 65, 68 studies reporting in T3 showed an inverse 220 
association with birthweight, while one15 in T2 and one16 in T3 reported a positive 221 
association. For TG, four52, 55, 57 out of five35, 52, 55, 57 studies reporting in T1, ten15, 31, 34, 37, 49, 55, 222 
59, 62, 67 out of 1215, 16, 31, 34, 37, 49, 50, 55, 59, 62, 67 studies reporting in T2, and 2015, 16, 39, 41, 46, 49, 50, 223 
54-56, 58, 61, 63-65, 67, 69 out of 2714-16, 28, 36, 39, 41, 42, 46, 49-51, 53-56, 58, 61, 63-65, 67, 69 studies reporting in 224 
T3 found a positive association with birthweight, while three14, 28, 51 studies in T3 reported an 225 
inverse association. Of the seven studies reporting the association between maternal FFAs 226 
level in T3 and birthweight36, 46, 49, 53, 56, 61, 68, four reported a positive association49, 53, 56, 68, 227 
while none reported inverse association. For TC, seven15, 16, 27, 37, 48, 49, 55 out of 1215, 16, 27, 31, 48-228 
50, 55, 59, 62 studies in T2, and eight15, 16, 48, 54-56, 65, 69 out of 2214-16, 28, 36, 39, 41, 42, 45, 46, 48-50, 53-56, 58, 229 
61, 63, 65, 69 studies in T3 reported a positive association, while one55 in T2 and three28, 41, 55 in 230 
T3 found an inverse association. There was no evident association between maternal LDL-C 231 
level and birthweight14, 16, 28, 31, 37, 39, 41, 42, 46, 50, 54, 55, 58, 59, 62, 63, 65, 68 or between maternal 232 
VLDL-C level and birthweight46, 68.  233 
Figure 3 shows the pooled estimates for the effect of maternal lipids throughout pregnancy on 234 
birthweight using all available data (S7 Appendix). In general, the results of meta-analyses 235 
are consistent with the overall results summary (Figure 2). Maternal HDL-C was inversely 236 
associated with birthweight, particularly in T3 (adjusted RC, -70.17g per mmol/L, p<0.001). 237 
Increased maternal TG levels were significantly associated with birthweight for T1 (adjusted 238 
RC, 86.72g per mmol/L, p<0.001) and T3 (adjusted RC, 89.58g per mmol/L, p=0.01). 239 
Positive associations between TC and birthweight were observed in T1(adjusted RC, 22.67g 240 
of birthweight per mmol/L maternal lipid, p=0.02), T2 (adjusted RC, 24.74g per mmol/L, 241 
p=0.01), and T3(adjusted RC, 9.14g per mmol/L, p=0.13).  242 
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Stronger associations were observed among pregnant women with pre-pregnancy overweight 243 
or obesity in the two relevant studies (S5 Appendix).50, 55 The degree of heterogeneity within 244 
all meta-analyses in T3 was detected with I2 values ranging from 0 to 93%. The heterogeneity 245 
decreased markedly when studies controlled for pre-pregnancy BMI, gestational weight gain, 246 
glucose level, and gestational age (S7 Appendix). 247 
Maternal lipid levels during pregnancy and LGA, SGA, and macrosomia 248 
Figure 4 shows the pooled adjusted OR for LGA as well as SGA, according to each type of 249 
maternal lipids in T3 (S8 & S9 Appendix). Pooled estimates for rising maternal HDL-C level 250 
revealed potentially decreased odds of LGA (OR, 0.77; 95% CI, 0.59 to 1.01; p=0.06), and 251 
significantly increased odds of SGA (OR, 1.96; 95% CI, 1.04 to 3.71; p=0.04). In contrast, 252 
increased maternal TG levels were associated with increased odds of LGA (OR, 1.08; 95% 253 
CI, 1.01 to 1.15; p=0.02), and decreased odds of SGA (OR, 0.66; 95% CI, 0.49 to 0.90; 254 
p=0.007). In addition, ten30, 38-40, 53, 54, 56, 58, 65, 69 out of 1114, 30, 38-40, 53, 54, 56, 58, 65, 69 studies 255 
reporting the association between maternal TG and LGA in T3 reported positive statistically 256 
significant associations. Of six studies investigating the relationship between maternal HDL-257 
C and macrosomia30, 33, 34, 38, 47, 65, four studies reported d creased risk of macrosomia (three 258 
statistically significant)30, 33, 34, 47, especially for T2 with higher HDL-C(S10 Appendix). For 259 
the relationship of TG with macrosomia, five33, 38, 43, 47, 64 out of six30, 33, 38, 43, 47, 64 studies 260 
reported statistically significant positive OR values across three trimesters. No association 261 
was observed between maternal TC as well as LDL-C levels and LGA, SGA, and 262 
macrosomia.  263 
Maternal lipid levels during pregnancy and other outcomes of interest 264 
For secondary outcomes, positive correlations were found by all six publications 265 
investigating the association between different maternal lipids and different cord blood lipids, 266 
but results are inconsistent with each other36, 44-46, 53, 66. No association was observed between 267 
Page 24 of 136
World Obesity Journals
Obesity Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
14 
 
maternal lipids and infant postnatal weight, weight gain, or sum of skinfolds thickness up to 2 268 
years old16, 29, 51, 52. No study investigated the relationship of maternal lipid levels during 269 
pregnancy with neonatal glucose, insulin, inflammatory factors and leptin levels in our 270 
searches. 271 
Discussion  272 
Summary of the findings 273 
This is the first systematic review pooling data from 40 longitudinal observational studies and 274 
two RCT secondary analysis studies providing quantitative estimates of the magnitude of 275 
association between maternal lipid levels at various stages of pregnancy and neonatal health 276 
outcomes. Throughout pregnancy, low maternal HDL-C and high TG levels are associated 277 
with increased birthweight. Low HDL-C and high TG increased the risk of LGA/macrosomia 278 
and lowered the risk of SGA babies. Maternal TC level throughout pregnancy and FFAs level 279 
in the third trimester are positively associated with a small increase in birthweight. 280 
Associations are stronger among populations with pre-pregnancy obesity. The findings 281 
provide evidence for the critical role of dyslipidaemia in gestational metabolism and neonatal 282 
health, and will contribute to future research and management of gestational dyslipidaemia. 283 
Potential mechanisms 284 
The results are mostly consistent with previous published evidence. Maternal lipid 285 
metabolism is mainly in lipogenesis state in the earlier half of pregnancy, but then switches 286 
into catabolic state.71, 72 When the lipid accumulation exceeds the storage capacity of adipose 287 
tissue, the buffering function of the adipocytes is decreased, leading to elevated serum FFAs 288 
and TG.73-75 Compared to pregnant women with smaller pre-pregnancy BMI, women who are 289 
overweight or obese will not only progress to catabolic state earlier, but also have less 290 
capacity to inhibit lipolysis.18 Women with obesity prior to pregnancy usually present with 291 
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more central adipose accumulation and severe dyslipidaemia76, 77, resulting in steep 292 
concentration gradient across the placenta.78 293 
Both in vivo and epidemiological evidence suggest that excessive maternal intrauterine lipid 294 
exposure could affect the development of foetus organs systematically, which can then alter 295 
initial foetus metabolism and feeding behaviours permanently.18, 79 Previous animal studies 296 
observed that foetal metabolic abnormalities mediated by maternal obesity and high-fat diet 297 
often manifest as increased body weight, fat mass, blood glucose, cholesterol and blood 298 
pressure levels; and decreased insulin sensitivity and ectopic lipid storage in newborns.18 The 299 
latest multi-ancestry genome-wide association study (GWAS) meta-analysis also 300 
demonstrated that cholesterol biosynthesis is one of the most important metabolic pathways 301 
involved in birthweight.17 Strengths and weakness 302 
The major strengths of this study are the comprehensive searches, adherence to robust review 303 
methodology and thorough analyses. Special care was taken in the handling of missing data, 304 
which was addressed by personal contact with the authors in an attempt to minimise reporting 305 
bias. The inclusion of longitudinal studies ensured the temporal association between 306 
exposures and outcomes, which also permitted a trimester-specific analysis. The major 307 
limitation of the study was the substantial heterogeneity, possibly due to the diversity of 308 
settings, study populations, lipid measurement methods and diverse gestational age of the 309 
studied populations. However, this heterogeneity was addressed by subgroup analysis.  310 
It would be intriguing to explore the effects of maternal dyslipidaemia independent of 311 
maternal hyperglycaemia. Unfortunately, this was not feasible due to the nature of data 312 
reported in individual study. GDM women are known to have higher TG levels and lower 313 
HDL-C levels compared with non-GDM women.11 However, elevated maternal TG levels 314 
and lower HDL-C levels are associated with the risk of LGA and macrosomia in both GDM 315 
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women38, 53, 58 and non-GDM women30, 39, 40, 52, 54, 69. For women with type 1 diabetes/GDM, 316 
maternal hyperglycaemia is not the sole contributor to increased birth weight since foetuses 317 
may develop LGA despite them having optimal glycaemic control.80 Several other studies 318 
found that lipid levels during pregnancy, similar to glucose levels, are also strong metabolic 319 
determinants for foetal growth15, 29, 31, 32, 35, 37, 41, 47, 53, 56, 61, 64. Our sensitivity analyses result 320 
also shown there is little effect on the relationship between gestational HDL-C/TG levels and 321 
birth weight when removing those studies controlled for glucose (S7.13 & S7.23). 322 
Collectively, this evidence suggests that maternal dyslipidaemia may be an independent, 323 
unrecognised risk factor of LGA/macrosomia. 324 
Unfortunately, paucity of the required primary data prevented the pre-specified subgroup 325 
analyses on the basis of different definitions used for GDM and obesity across studies. Thus, 326 
this should be acknowledged as a source of clinical heterogeneity when interpreting the 327 
findings of the present study. Another limitation of this study is that we are unable to control 328 
for the effect of GDM treatment on lipid levels. However, it has been noticed that initiation 329 
of therapy (diet control, insulin, or metformin) may modestly influence TG levels81, yet to a 330 
direction that would obscure rather than magnify differences between normal and GDM 331 
pregnancies. Similarly, our sensitivity analyses shown a moderate decrease on triglycerides 332 
effect estimate when removing studies that excluded pre-term births (S7.25). 333 
It should be acknowledged that our primary outcome, birth weight, is a quite inexact measure 334 
of foetal growth, although it has been widely measured and utilized in clinical and research 335 
areas. We tried to extend our target outcomes from birth weight parameters to other neonatal 336 
growth parameters, biological indicators, and inflammatory factors, however, we did not find 337 
sufficient studies.  338 
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Implications 339 
Our results provides compelling evidence on the role of maternal circulating HDL-C and TG 340 
levels on birth outcomes, and suggest that the under-recognised adverse effects of intrauterine 341 
exposure to maternal dyslipidaemia may need further investigation in large prospective 342 
cohorts or in randomised trials. Although the importance of screening for preconceptional 343 
dyslipidaemia has been noted in recent guidelines to alert for risk assessment for GDM82, 83, 344 
its independent adverse effects remain largely underestimated in routine clinical practice and 345 
recommendations regarding the management of dyslipidaemia preconceptionally or during 346 
pregnancy are still lacking. Our findings do question the current clinical practice and support 347 
the monitoring of gestational dyslipidaemia before or during pregnancy.  Moreover, our 348 
findings may be a call for action regarding the implementation of strategies to address 349 
maternal dyslipidaemia (such as carefully planned dietary interventions, increasing physical 350 
activity, and/or Omega-3 fatty acids supplementation). Meanwhile, gestational dyslipidaemia, 351 
as an important feature of obesity and GDM, might be a potential treatment target for clinical 352 
interventions. These steps need to be evaluated by global health policy makers through 353 
randomised controlled trials, evidence synthesis and consensus.84-86  354 
Conclusion 355 
Our findings demonstrate that maternal low HDL-C and high TG levels are positively 356 
associated with neonatal birthweight. No effect was documented for total or LDL cholesterol. 357 
Findings are of clinical importance in considering the management of gestational 358 
dyslipidaemia, for example using lifestyle interventions and omega-3 fatty acid 359 
supplementation to improve maternal and neonatal outcomes.   360 
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Table Baseline characteristics of included studies 625 
Study ID Study design Locations 
Population 
(N) 
TC HDL LDL TG VLDL FFAs Tri. Outcomes 
Ye et al.201554 
Prospective 
observational study 
China 
non-GDM 
(n=1,243) 
√ √ √ √ 
  
3 
Birthweight 
LGA, SGA 
Wang et al.201531 
Prospective cohort 
study 
China 
General 
(n=636) √ √ √ √   
2 Birthweight 
Crume et al.201549 
Prospective cohort 
study 
American 
General 
(n=804) 
√ √ 
 
√ 
 
√ 2,3 Birthweight 
Hwang et al.201567 
Prospective cohort 
study 
Korea 
non-GDM 
(n=1,011)    
√ 
  
2,3 Birthweight 
Kulkarni et al.201315 
Prospective cohort 
study 
India 
non-GDM 
(n=631) 
√ √ 
 
√ 
  
2,3 Birthweight 
Vrijkotte et al.201252 
Prospective cohort 
study 
Netherlands 
non-GDM 
(n=4,008) √   
√ 
  
1 LGA, SGA 
Retnakaran et 
al.201214 
Prospective cohort 
study 
Canada 
non-GDM 
(n=472) 
√ √ √ √ 
  
3 
Birthweight 
LGA 
Hou et al.201440 
Prospective 
observational study 
China 
non-GDM 
(n=2,790) √ √ √ √   
3 LGA 
Kramer et al.201429 
Prospective cohort 
study 
Canada 
General 
(n=340) 
√ √ 
 
√ 
  
3 
Infant weight 
gain at 3 months 
Son et al.201058 
Retrospective 
longitudinal 
observational study 
Korea 
GDM 
(n=104) 
√ √ √ √ 
  
3 
Birthweight 
LGA 
Ahmad et al. 200669 
Controlled prospective 
study 
Malaysia 
non-GDM 
(n=246) √   
√ 
  
3 
Birthweight 
LGA 
Di et al. 200559 
Prospective 
observational study 
Italy 
OGTT+ 
(n=83) √ √ √ √   
2 
Birthweight 
LGA 
Couch et al.1998(1)46 
Prospective 
observational study 
American 
GDM (n=20) 
√ √ √ √ √ √ 3 
Birthweight 
Couch et al.1998(2)46 Non-GDM (n=20) 
Cord vein lipids 
profile 
Ortega et al. 199645 
Prospective cohort 
study 
Spain 
General 
(n=292) √ √ √ √ √ √ 3 
Birthweight 
Cord arteriovenous 
lipids profile 
Alberti-Fidanza et al. 
199566 
Prospective 
observational study 
Italy 
General 
(n=70) √ √  
√ 
  
1-3 
Mixed venous-
arterial cord blood 
lipids profile 
Schaefer-Graf et al. 
200853 
Secondary analysis of 
RCT study 
German 
GDM 
(n=150) √   
√ 
 
√ 3 
Birthweight,  
cord blood lipids 
LGA 
Swierzewska et al. 
201542 
Prospective 
observational study 
Poland 
General 
(n=136) √ √ √ √   
3 Birthweight 
Sommer et al. 201541 
Prospective cohort 
study 
Norway 
General 
(n=699) √ √ √ √   
3 
Birthweight,  
sum of skinfolds 
Slagjana et al. 201439 
Prospective cohort 
study 
Yugoslavia 
non-GDM 
(n=200) 
√ √ √ √ 
  
3 
Birthweight 
LGA, SGA 
Laleh et al. 201338 
Prospective cohort 
study 
Iran 
GDM 
(n=112) √ √ √ √   
3 
LGA, 
macrosomia 
Whyte et al. 201362 
Prospective cohort 
study 
Ireland 
General 
(n=189) √ √ √ √   
2 Birthweight 
Zhou et al. 201233 
Prospective cohort 
study 
China 
General 
(n=1,000) 
√ √ √ √ 
  
2 Macrosomia 
Vrijkotte et al. 201160 
Prospective cohort 
study 
Netherlands 
General 
(n=2,052) √   
√ 
  
1 
Birthweight 
Postpartum 
growth 
Vinod et al.2011(1)55 
Prospective cohort 
study 
American 
Overweight  
(n=71) √ √ √ √ 
  
1-3 Birthweight 
Vinod et al.2011(2)55 
Normal weight 
(n=72) 
Zawiejska et al. Prospective Poland GDM 
 
√ 
 
√ 
  
2 Birthweight 
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Study ID Study design Locations 
Population 
(N) 
TC HDL LDL TG VLDL FFAs Tri. Outcomes 
200834 observational study (n=357) Macrosomia 
Clausen et al. 200547 
Prospective cohort 
study 
Norway 
General 
(n=2,050) √ √ √ √   
2 Macrosomia 
Mathews et al. 200348 
Prospective cohort 
study 
UK 
General 
(n=798) √      
2,3 Birthweight 
Olmos et al.2014(1)50 
Prospective  
observational study 
Chile 
GDM + lean 
(n=128) 
√ √ 
 
√ 
  
2,3 Birthweight Olmos et al.2014(2)50 
GDM + overweight 
(n=105) 
Olmos et al.2014(3)50 
GDM + obese 
(n=46) 
Emet et al.201363 
Prospective 
observational study 
Turkey 
General 
(n=801) 
√ √ √ √ 
  
3 
Birthweight, 
infant weight at 
3 months 
Liu et al.201637 
Retrospective cohort 
study 
China 
General 
(n=1,546) 
√ √ √ √ 
  
2 Birthweight 
Brunner et al. 201351 
Secondary analyses of 
RCT study 
German 
General 
(n=208)    
√ 
  
3 
Birthweight, 
postpartum 
growth, skinfolds 
thickness 
Knopp et al.199264 
Prospective 
observational study 
American 
NS- (n=521) 
PS+ (n=264) 
GDM (n=96)    
√ 
  
3 Birthweight 
Knopp et al.198568 
Prospective 
observational study 
American 
General 
(n=283)  
√ √ 
 
√ √ 3 Birthweight 
Schaefer-Graf et al. 
201136 
Prospective 
observational study 
German 
non-GDM 
(n=190) √   
√ 
 
√ 3 
Birthweight, 
Cord blood 
metabolic 
parameters  
Nolan et al.199557 
Prospective 
observational study 
Australia 
General 
(n=388)    
√ 
  
1 Birthweight 
Lin et al.201343 
Prospective 
observational study 
China 
General 
(ND)    
√ 
  
ND Macrosomia 
Friis et al.201261 
Prospective 
observational study 
Norway 
General 
(n=207) √ √  
√ 
 
√ 3 Birthweight 
Lei et al.201632 
Prospective cohort 
study 
China 
General 
(n=5,535)  
√ 
 
√ 
  
2 LGA, SGA 
Kitajima et al. 200156 
Prospective 
observational study 
Japan 
OGTT + 
(n=146) √   
√ 
 
√ 3 
Birthweight 
LGA 
Mossayebi et al. 
201465 
Prospective cohort 
study 
Iran 
General 
(n=154) √ √ √ √   
3 
Birthweight 
LGA, 
macrosomia 
Geraghty et al. 201616 
Secondary analyses of 
RCT study 
UK 
non-GDM 
(n=331) 
√ √ √ √ 
  
2,3 
Birthweight 
Postpartum 
growth, sum of 
skinfolds 
Jin et al. 201630 
Prospective cohort 
study 
China 
non-GDM 
(n=934) 
√ √ √ √ 
  
1-3 
LGA, SGA, 
macrosomia 
Brockerhoff 198644 
Prospective 
observational study 
German 
ND 
(n=112)  
√ √ 
 
√ 
 
2 
Cord blood 
lipids profile 
Harmon et al. 201135 
Prospective 
observational study 
American 
non-GDM 
(n=38)    
√ 
 
√ 1 Birthweight 
Robin et al. 200727 
Retrospective cohort 
study 
American 
General 
(n=957) 
√      2 Birthweight 
Charles et al. 201628 
Perspective 
observational study 
Mediterranean 
countries 
General 
(n=1062) √ √ √ √   3 Birthweight 
Abbreviation: Trimester(Tri), Total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol 
(LDL-C), very low-density lipoprotein cholesterol (VLDL-C), triglycerides(TG), free fatty acids(FFAs), large-for-gestational age(LGA), 
small for gestational age(SGA), randomized controlled trial(RCT), and no documented(ND). 
 626 
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Title: Figure 2. Results summary of the association of maternal lipid levels with birth weight throughout 
 pregnancy Notes: The numbers in parenthesis: The number of studies shown in this figure/the overall 
number of studies reporting the target associations. Studies reporting statistically insignificant results 
without its direction or those that did not report their results are not shown in the figure.  
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Title: Figure 3 Summary of findings of meta-analysis for the associations between maternal lipids and birth 
weight throughout pregnancy  
Notes: The number of participants (studies) included into quantitative analysis/ overall number of 
participants (studies) that reported the outcome of interest.  
The number of participants (studies) included into quantitative analysis/ overall number of participants 
(studies) that reported the outcome of interest.  
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Title: Figure 4 Summary of findings of meta-analysis for the associations between maternal lipids and LGA/ 
SGA in the third trimester  
Notes: The number of participants (studies) included into quantitative analysis/ overall number of 
participants (studies) that reported the outcome of interest.  
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S1 Appendix Sample search in Medline 
1. exp Lipids/ or lipid$.mp. 
2. lipoprotein$.mp. or exp Lipoproteins/ 
3. exp Fatty Acids/ or fat* acids.mp. 
4. triglycerides.mp. or exp Triglycerides/ 
5. exp Lipoproteins, VLDL/ or exp Cholesterol, VLDL/ or VLDL.mp. 
6. LDL.mp. or exp Cholesterol, LDL/ or exp Lipoproteins, LDL/ 
7. IDL.mp. or exp Lipoproteins, IDL/ 
8. exp Lipoproteins, HDL/ or exp Cholesterol, HDL/ or HDL.mp. 
9. exp Cholesterol/ or cholesterol.mp. or exp Cholesterol Esters/ 
10. hyperlipid?emia$.mp. or exp Hyperlipidemias/ 
11. dyslipid?emia$.mp. or exp Dyslipidemias/ 
12. hypertriglycerid?emia$.mp. or exp Hypertriglyceridemia/ 
13. hypercholesterol?emia.mp. or exp Hypercholesterolemia/ 
14. metabolic.mp. 
15. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 
16. exp Maternal Health/ or maternal.mp. 
17. exp Pregnanes/ or pregnan*.mp. 
18. exp Pregnancy/ or gestation*.mp. 
19. gravidity.mp. or exp Gravidity/ 
20. mother$.mp. or exp Mothers/ 
21. 16 or 17 or 18 or 19 or 20 
22. (birth weight or birthweight).mp. or exp Birth Weight/ or exp Infant, Low Birth Weight/ 
23. overweight.mp. or exp Obesity/ or exp Overweight/ or exp Body Weight/ 
24. (SGA or Small for gestational age).mp. or exp Infant, Small for Gestational Age/ 
25. (LGA or Large for gestational age).mp. 
26. exp Fetal Macrosomia/ or macrosomia.mp. 
27. exp "Growth and Development"/ or exp Growth/ or (growth or development).mp. or exp Fetal Growth Retardation/ 
or exp Fetal Development/ or exp Child Development/ 
28. weight gain.mp. or exp Weight Gain/ 
29. (hyperglyc?emia or hypoglyc?emia).mp. or exp Hyperglycemia/ or exp Hypoglycemia/ 
30. (insulin* or hyperinsulinism or IR).mp. or exp Insulin/ or exp Insulin Resistance/ or exp Hyperinsulinism/ 
31. exp Glucose Intolerance/ or glucose.mp. or exp Glucose/ or exp Glucose Metabolism Disorders/ 
32. skinfold thickness.mp. or exp Skinfold Thickness/ 
33. (monocyte chemoattractant protein-1 or MCP-1).mp. 
34. (interleukin 6 or IL-6).mp. 
35. exp Tumor Necrosis Factor-alpha/ or tumour necrosis factor-alpha.mp. 
36. exp 11-beta-Hydroxysteroid Dehydrogenase Type 1/ or HSD1.mp. 
37. exp Leptin/ or leptin.mp. 
38. exp Inflammation/ or inflammat*.mp. 
39. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 
30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 
40. (neonatal or fetal or foetal or fetus or foetus or infant or offspring or new born).mp. or exp Infant/ 
41. 15 and 21 and (39 and 40) 
42. (animal or mouse or mice or rodent or sheep or mutton or pig or hoggory or hog or swine or rabbit$).mp. 
43. 41 not 42 
44. cohort studies/ or longitudinal studies/ or follow-up studies/ or prospective studies/ or retrospective studies/ or 
cohort.ti,ab. or longitudinal.ti,ab. or prospective.ti,ab. or retrospective.ti,ab. 
45. "randomized controlled trial".pt. 
46. (random$ or placebo$ or single blind$ or double blind$ or triple blind$).ti,ab. 
47. (retraction of publication or retracted publication).pt. 
48. or/44-47 
49. (animals not humans).sh. 
50. ((comment or editorial or meta-analysis or practice-guideline or review or letter or journal correspondence) not 
"randomized controlled trial").pt. 
51. (random sampl$ or random digit$ or random effect$ or random survey or random regression).ti,ab. not "randomized 
controlled trial".pt. 
52. or/49-51 
53. 48 not 52 
54. 43 and 53 
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S2 Appendix Data extraction form 
 
A. Reference information 
1. ID number 
2. Title 
3. Author 
4. Journal 
5. Publication Year 
6. Language 
7. Sponsor 
B. Study design 
1. Study design 
2. Setting 
3. Locations 
4. Data collection 
C. Participants 
1. Eligibility criteria (source and methods of selection of participants) 
2. Matching criteria (if applicable) 
a. Matching criteria 
b. Attempts were made within the design or analysis to balance the comparison groups for potential 
confounders (YES/NO). 
c. The groups are c mparable at baseline, including all major confounding and prognostic factors 
(YES/NO).  
3. Sample Size 
a. Number of both exposed and unexposed groups 
b. Report numbers of individuals at each stage of study 
c. Give reasons for non-participation at each stage (YES/NO) 
d. Does the size of samples have enough power to detect the difference of primary outcomes? 
(YES/NO) 
4. Demographic, clinical and social characteristics 
a. Age 
b. Ethnicity 
c. Pre-pregnant BMI/weight 
d. Marital status 
e. Education 
f. Other potential confounders information 
D. Follow-up 
1. Enrolment time 
2. Length of follow-up 
a. Length of follow-up (average and total amount) 
b. All groups were followed up for an equal length of time (or analysis was adjusted to allow for 
differences in length of follow-up) 
3. Methods of follow-up 
4. Lost to follow-up 
a. Attrition rate in each group 
b. How many participants in each group were no outcome data available? (number & proportion) 
c. Does it comparable? (YES/NO) 
E. Exposure 
1. Definition of exposures 
2. When did they take samples 
3. Exposure measurement 
F. Outcomes 
1. Primary outcomes (definition and measurement) 
2. Secondary outcomes (definition and measurement) 
G. Statistical methods 
1. Statistical methods, including those used to control for confounding 
2. Describe any methods used to examine subgroups and interactions 
3. How missing data were addressed 
4. Explain how lost to follow-up was addressed 
5. Describe any sensitivity analysis 
H. Results 
1. Number of outcomes events or summary measures over time 
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2. Give unadjusted estimates and, if applicable, confound der-adjusted estimates and their precision (e.g. 95% 
confidence interval). Make clear which confounders were adjusted for and why they were included 
3. Report category boundaries when continuous variables were categorized 
4. Alpha value and beta value 
I. Limitations 
1. Interpretation 
Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from 
similar studies, and other relevant evidence.  
2. Generalizability (external validity) 
J. Other notes 
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S3 Appendix Newcastle-Ottawa Scale 
Selection 
1. Representativeness of exposed cohort population 
1) Truly representative of the average, community-dwelling target pregnant women ★ 
2) Somewhat representative of the average, community-dwelling target pregnant women★ 
3) Selected group of pregnant women, e.g. only certain socio-economic groups/areas 
4) No description of the derivation of the cohort 
 
2. Selection of the unexposed cohort 
1) Drawn from the same source as the exposed cohort★ 
2) Drawn from a different source 
3) No description of the derivation of the unexposed cohort 
 
3. Ascertainment of exposures 
1) Laboratory diagnosed ★ 
2) Secure record (e.g. health care/clinical record) ★ 
3) Written self-report 
4) Other/ no description 
 
4. Demonstration that outcome of interest was not present at start of study 
1) Yes★ 
2) No 
 
Comparability 
1. Comparability of cohort based on the design or analysis 
1) Study controls for  
①  Outcomes measured at delivery: gestational age ★ 
②  Outcomes measured over 1 month after delivery: neonatal age ★ 
2) Study controls for any two of additional factors (e.g. neonatal gender, maternal age, parity, socio-economic 
level, cigarette exposures, delivery mode and so on) ★ 
 
Outcome 
1. Assessment of outcomes 
1) Independent blind assessment★ 
2) Record linkage★ 
3) Self-report 
4) Other/ no description 
 
2. Was follow up long enough for outcomes to occur 
1) Yes, if the study follow their subjects until outcomes occur★ 
2) No, if the study follow their subjects until outcomes occur 
 
3. Adequacy of follow up of cohorts 
1) Complete follow up : all subjects accounted for★ 
2) Subjects lost to follow up unlikely to introduce bias: number lost <= 20%, or description of those lost 
suggesting no different from those followed★ 
3) Follow up rate <80% and no description of those lost 
4) No statement 
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S4 Appendix Basic characteristics extraction form 
Study 
ID 
Basic 
information 
Participants 
Maternal 
characteristics 
Follow-up Exposures Outcomes 
Quality 
score 
Ye et al. 
2015 
 
Study design: 
Prospective 
observational 
study 
 
Language: 
English 
 
Location: 
China 
 
 
 
Setting: 
Maternal and Child Health centres (MCH) 
of Hefei. 
Eligibility criteria: 
Women (≥18 years) who given birth in 
MCH centres of Hefei around 36th – 41st 
gestation week. 
Exclude criteria: 
1)  Gestational diabetes, overt diabetes, 
hypertension and heart disease. 2) Preterm 
births (before 37 weeks) or multiple 
pregnancies. 3) No information on birth 
weight.  
Sample size : n=1,243 
x ± SD or n (%) 
Age (year) 
27.9 ± 4.3 
Primiparous 
1012 (81.4) 
Pre-pregnancy 
BMI (kg/m2) 
20.5 ± 2.5 
Gestational length 
39.6 ± 1.0 
Fasting blood 
No Statement 
Enrolment time 
Gestational age at entry 
(36th – 41st gestation week) 
(1st Jan 2011 – 31st July 
2012) 
Length 
Follow up until birth 
Methods 
Clinical follow-up 
Data collection 
Questionnaire, clinical 
medical records 
Loss to follow-up 
0 
Maternal serum 
TG, TC, HDL, 
LDL were 
measured close to 
delivery (36-41 
weeks, in most 
case 1 week to 
delivery) 
Birth weight was 
retrieved from medical 
records after delivery.  
LGA: infants with birth 
weight ＞ 90th percentile 
for local population after 
adjusting for gestational 
age and sex.  
SGA: birth weight ＜10th 
AGA: 10th ≤birth weight 
≤ 90th  
8 
 
Wang et 
al. 2015 
Study design: 
Cohort 
 
Language: 
English 
 
Location: 
China 
Setting: 
No statement 
Eligibility criteria: 
1) Chinese women with a singleton 
pregnancy and a live delivery; 2) have 
GDM screening at 24-28 weeks of 
gestation; 3) presented for booking at or 
before 16 weeks and gave birth at or after 
36 weeks; 4) compete antenatal and birth 
data. 
Exclude criteria: 
Type 1 or type 2 diabetes; hyperlipidaemia, 
hypertension, cardiovascular diseases or 
metabolic syndrome before pregnancy; a 
history of severe systemic disease (liver 
cirrhosis, chronic renal failure, severe 
anaemia or immune disorders); and 
untreated endocrinopathies 
(hyperadrenalism, hypoadrenalism, 
hyperthyroidism or hypothyroidism) 
Sample size: n= 636  
Median (25th-75th) 
Age (year) 
Non-GDM: 
29 (27-31) 
GDM: 31 (29-34) 
Parity 
No statement 
Pre-pregnancy 
BMI (kg/m2) 
Non-GDM:  
20.03 (18.59-
21.55) 
GDM:  
21.02 (19.24-
22.56) 
Gestational length 
Non-GDM: 
39 (39-40) 
GDM: 39 (38-40) 
Fasting blood 
Yes. 
Enrolment time: 
Gestational age at entry (at 
or before 16th gestation 
week) 
(1st Jan 2013 – 31st Dec 
2013) 
Length: 
At least follow up until birth 
Methods: 
No statement 
Data collection: 
laboratory diagnosis 
Loss to follow-up: 
0 
 
Maternal overnight 
fasting blood was 
taken at the time of 
OGTT (24th -28th 
weeks) for TC, 
HDL, LDL and 
TGs laboratory 
analyses (standard 
enzymatic 
procedures on 
automatic 
chemistry 
analyser).  
Birthweight. 
 
6 
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Study 
ID 
Basic 
information 
Participants 
Maternal 
characteristics 
Follow-up Exposures Outcomes 
Quality 
score 
(110 GDM and 526 non-GDM) 
Crume et 
al.2015 
Study design: 
Prospective 
birth cohort 
study 
 
Language: 
English 
 
Location: 
American 
Setting: 
Healthy Start Study (n=1,063) conducted in 
the prenatal obstetrics clinics at University 
of Colorado Hospital in Aurora, Colorado. 
Eligibility criteria: 
Women (≥16 years) expecting a singleton 
birth, living in Colorado, and planning to 
deliver at University of Colorado Hospital. 
Exclude criteria: 
Women with serious chronic diseases 
(cancer, psychiatric diseases, steroid-
dependent asthma, pre-existent diabetes), as 
well as those who subsequently experienced 
a foetal death or delivered a severely 
premature infant (<32 week gestation) were 
excluded. 
Sample size : n=804 
x ± SD or n (%) 
Age (year) 
27.7 ± 6.1 
Primiparous 
287 (35.8) 
Pre-pregnancy 
BMI (kg/m2) 
25.7 ± 6.3 
Gestational length 
39.4 ± 1.3 
Fasting blood 
Yes 
Enrolment time 
Gestational age at entry 
(≤24 gestation week) 
(All women were enrolled 
and delivered as of Nov 1, 
2013) 
Length 
Follow up at least until birth 
Methods 
In-person research visits and 
hospital preconception visit 
Data collection 
Questionnaires, clinical 
diagnoses and medical 
records 
Loss to follow-up 
0  
Maternal fasting 
venous blood 
samples were taken 
at both two 
research visits 
(first, median 17 
week, range 11-20 
week; second, 
median 27 week, 
range 20-34 week) 
for TGs, TC, HDL-
c and FFA 
laboratory analyses 
using manufacturer 
pre-packaged 
enzymatic kits and 
the AU400e 
Chemistry 
Analyser. 
Birth weight was 
measured using a 
calibrated scale.  
8 
Hwang 
et 
al.2014 
Study design: 
Prospective 
cohort study 
 
Language: 
English 
 
Location: 
Korea 
Setting: 
The MOCEH study, a multicentre 
prospective hospital- and community-based 
cohort study in South Korea (n=1,751) 
Eligibility criteria: 
Pregnant women at mid-stage (15-28 
gestation weeks) of a normal (not at risk) 
pregnancy who were willing to participate 
the MOCEH study.  
Exclude criteria: 
Twins (n=31), spontaneous abortion (n=23), 
intrauterine growth restriction (n=3), foetus 
congenital anomaly (n=12).  
Drop out (n=221), pregnancy complications 
(hypertension or/and diabetes, n=34). 
No information on dietary intake data 
x ± SD or n (%) 
Age (year) 
30.1 ± 3.6 
Primiparous 
No statement 
Pre-pregnancy 
BMI (kg/m2) 
21.3 ± 3.1 
Gestational length 
38.9 ± 1.4 
Fasting blood 
No statement 
Enrolment time 
Gestational age at entry 
(12-28 gestation week) 
(Aug 2006 to Dec 2010) 
Length 
Follow up until 5 years after 
delivery. 
Methods 
Clinical visits 
Data collection 
Questionnaires and medical 
records 
Loss to follow-up 
221(17.94%) 
Maternal serum TG 
was analysed twice 
at mid-pregnancy 
(12-28 gestational 
weeks) and at late 
pregnancy (29-42 
gestational weeks) 
by means of an 
enzymatic method 
using an 
autonalyzer. 
Birthweight was 
obtained from birth 
records.  
. 
9 
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Study 
ID 
Basic 
information 
Participants 
Maternal 
characteristics 
Follow-up Exposures Outcomes 
Quality 
score 
(n=135), total energy consumption <500 
or >4000 kcal/day (n=5), No information on 
serum TG concentration at mid- or late 
pregnancy (n=276) 
Sample size : n=1,011 
Kulkarni 
et al. 
2013 
Study design: 
Population-
based birth 
cohort study 
 
Language: 
English 
 
Location: 
India 
Setting: 
The Pune Maternal Nutrition Study 
(PMNS), a prospective birth cohort based 
on six rural villages in India. 
Eligibility criteria: 
Women with a singleton pregnancy of <21 
weeks’ gestation (n=797). 
Exclude criteria: 
Spontaneous abortions, fetal anomalies, 
multiple pregnancy, medical terminations 
late booking, Late abortions (n=12), late 
terminations (n=14), still birth (n=8), 
maternal death (n=1), congenital anomalies 
(n=9), baby not measured (n=51), mother 
diabetic (n=1), mother hypertensive (n=1), 
preterm (n=69) 
Sample size : n=631 
 
x ± SD or n (%) 
Age (year) 
21.4 ± 3.6 
Primiparous 
226 (35.8) 
Pre-pregnancy 
BMI (kg/m2) 
18.0 ± 1.9 
Gestational length 
39.4 ± 1.7 
Fasting blood 
Yes 
Enrolment time 
Gestational age at entry 
(<21 gestation week) 
(June 1994 to April 1996) 
Length 
Follow up until birth. 
Methods 
No statement 
Data collection 
Questionnaires and clinical 
measurement 
Loss to follow-up 
131 (16.44%) 
Maternal fasting 
venous blood 
samples was 
collected at 18 and 
28 weeks for total 
cholesterol HDL-C 
and triglycerides 
using standard 
enzymatic kits. 
Measured by one of five 
trained fieldworkers 
within 72h of birth. 
Birthweight: measured 
by a Salter spring 
balance. 
 
8 
Vrijkotte  
et 
al.2012 
Study design: 
Prospective 
cohort study 
 
Language: 
English 
 
Location: 
Netherlands 
Setting: 
The Amsterdam Born Children and Their 
Development (ABCD) cohort study 
Eligibility criteria: 
Pregnant women visit to the obstetric care 
provider around the 12th week of gestation 
agree to participant the ABCD biomarker 
study (n=4389) 
Exclude criteria: 
Women who had multiple gestation or who 
had no data on the gestational age at blood 
sampling, women with diabetes (pre-
existent as well as pregnancy induced), and 
x ± SD or n (%) 
Age (year) 
30.9 ± 4.9 
Primiparous 
2314 (57.7) 
Pre-pregnancy 
overweight or 
obese 
830 (20.7) 
Gestational length 
No statement 
Fasting blood 
No. 
Enrolment time 
Gestational age at entry 
(around 12th gestation week) 
(Jan 2003 to Mar 2004) 
Length 
Follow up at least until 
birth. 
Methods 
Obstetric care provider visit 
and the Youth Health Care 
Registration and the Dutch 
Perinatal Registration 
(PRN). 
Maternal additional 
non-fasting blood 
samples were taken 
during routine 
blood collection for 
laboratory TC and 
TG levels 
assessment during 
their first prenatal 
visit to the obstetric 
care provider at 
around the 12th 
week of gestation. 
Information on 
pregnancy outcomes was 
obtained from the Youth 
Health Care Registration 
and the Dutch Perinatal 
Registration (PRN). 
SGA: birth weight below 
the 10th percentile for 
gestational age based on 
gender- and parity-
specific standards from 
the PRN. 
LGA: birth weight above 
8 
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Study 
ID 
Basic 
information 
Participants 
Maternal 
characteristics 
Follow-up Exposures Outcomes 
Quality 
score 
those using lipid-altering medication (e.g. 
antiepileptic drugs, steroids, insulin, 
antidepressants, thyroid hormones, or sleep 
medication) were excluded. 
Sample size : n=4,008 
Data collection 
Questionnaires and Health 
care registration system.  
Loss to follow-up 
381 (8.68%) 
the 90th percentile for 
gestational age based on 
the same gender0and 
parity-specific standards 
from the PRN. 
Retnakar
en et al. 
2012 
Study design: 
Prospective 
cohort study 
 
Language: 
English 
 
Location: 
Canada 
Setting: 
Ongoing prospective observational cohort 
study 
Eligibility criteria: 
White, Asian and South Asian pregnant 
women with term (37-41 weeks’ gestation 
inclusive) singleton pregnancies were 
recruited at the second or early in the third 
trimester. 
Exclude criteria: 
Women with gestational diabetes. 
Sample size: n=472 
x ± SD or 
Median(IQR) 
Age (year) 
Lowest tertile 
birthweight: 
33.6±4.0 
Middle tertile 
birthweight: 
34.5±4.3 
Highest tertile 
birthweight: 
33.6±4.0 
Primiparous 
251 (53.18) 
Pre-pregnancy 
BMI (kg/m2) 
Lowest: 22.6(20.7-
25.4) 
Middle: 22.6(20.8-
25.8) 
Highest: 23.6(22.3-
27.4) 
Gestational length 
Lowest: 38.6±1.1 
Middle: 39.2±1.0 
Highest: 39.6±1.1 
Fasting blood 
Yes. 
Enrolment time 
Gestational age at entry 
(around 24th-28th gestation 
week) 
(No statement about 
recruitment time) 
Length 
Follow up until 3 months 
postpartum period 
Methods 
No statement 
Data collection 
No statement 
Loss to follow-up 
0 
Maternal fasting 
serum samples 
were obtained at 
the time of the oral 
glucose tolerance 
test (late second to 
early third 
trimester, median 
30 week) for 
laboratory total 
cholesterol, HDL-
c, LDL-c and 
triglycerides levels 
measurements. 
Birthweight was 
measured at delivery. 
LGA: sex-specific birth 
weight for gestational 
age was above the 90th 
percentile of Canadian 
foetal growth curves for 
the relevant ethnic group 
(white, Asian or South 
Asian) 
Macrosomia: 
birthweight over 4,000 g 
7 
Hou et 
al.2014 
Study design: 
Prospective 
observational 
Setting: 
Hospital-based study 
Eligibility criteria: 
 Median (25th-75th) 
Age (year) 
26 (24-29) 
Enrolment time 
Gestational age at entry 
(around 28th – 37th gestation 
Maternal fasting 
venous blood was 
collected at the 
LGA: birth weight were 
above the 90th percentile 
for gestational age in 
7 
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Study 
ID 
Basic 
information 
Participants 
Maternal 
characteristics 
Follow-up Exposures Outcomes 
Quality 
score 
study 
 
Language: 
English 
 
Location: 
China 
Pregnant women with naturally conceive, 
singleton pregnancy during 28-37 week 
gestation were enrolled into this study 
Exclude criteria: 
Diabetes, abnormal glucose tolerance, 
chromosomal abnormality, inherited 
metabolic diseases thyroid disease, and risk 
for foetal chromosomal abnormality 
New-borns with preterm birth, inherited 
metabolic diseases, congenital abnormalities 
and congenital heart diseases. 
Sample size : n=2,790 
Primiparous 
No statement 
Pre-pregnancy 
BMI (kg/m2) 
19.93 (18.55-
21.63) 
Gestational length 
39 (38-40) 
Fasting blood 
Yes. 
week) 
(No statement about 
recruitment time) 
Length 
Follow up until delivery 
Methods 
Clinical visit 
Data collection 
Questionnaire, clinical 
measurement and diagnosis 
Loss to follow-up 
0 
enrolment time for 
laboratory TC, 
HDL-C,LDL-C 
and TG assay.  
accordance with 
Neonatal Birth Weight 
for Gestational Age and 
Percentile in 15 cities in 
China. 
Kramer 
et al. 
2014 
 
Study design: 
Prospective 
cohort study 
 
Language: 
English 
 
Location: 
Canada 
Setting: 
Ongoing prospective observational cohort 
study 
Eligibility criteria: 
Women with singleton delivery between 
April 2005 and January 2011, at term (≥37 
weeks gestation, with infant 
birthweight >2500 g) 
Exclude criteria: 
No 
Sample size : n=340 
(GDM, n=90; non-GDM, n=250) 
x ± SD or n (%) 
Age (year) 
No statement 
Primiparous 
340 (100) 
Pre-pregnancy 
BMI (kg/m2) 
No statement 
Gestational length 
No statement 
Fasting blood 
Yes. 
Enrolment time 
Gestational age at entry 
(around 24th-28th gestation 
week) 
(Apr 2005 - Jan 2011) 
Length 
Follow up until 3-month 
postpartum period 
Methods 
Clinical investigation unit 
Data collection 
Questionnaire, clinical 
measurement 
Loss to follow-up 
0 
Maternal fasting 
serum samples 
were obtained at 
the time of the oral 
glucose tolerance 
test (late second to 
early third 
trimester, median 
30 week) for 
laboratory total 
cholesterol, HDL-c 
and triglycerides 
levels 
measurements. 
Infant weight gain at 3 
months: the difference 
between weight at 3 
months and birthweight. 
SD scores for weight 
gain at 3 months were 
determined for the study 
population, which was 
then stratified into two 
groups: infants weight 
rapid weight gain in the 
first 3 months (≥0.5 SD) 
and those without (<0.5 
SD) 
7 
Harmon 
et 
al.2011 
Study design: 
Prospective 
observational 
study 
 
Language: 
English 
 
Location: 
Setting: 
Normal weight (BMI 20-25 kg/m2) and 
obese (BMI 30-38 kg/m2) women with NGT 
were enrolled at <15 weeks’ gestation from 
the University of Colorado Hospital vicinity  
Eligibility criteria: 
Singleton pregnancies, being aged 18-35 
years, being English speaking, and having a 
fasting blood glucose (FBG) <95 mg/dL. 
x ± SEM  
Age (year) 
Normal weight: 
31.2 ± 2.3 
Obese: 26.5 ± 4.2 
Parity 
Normal weight: 
0.4 ± 0.6 
Obese: 1.2 ± 0.9 
Enrolment time 
Gestational age at entry 
(<15th gestation week) 
Length 
Follow up until birth. 
Methods 
No statement 
Data collection 
Questionnaire, clinical 
Both early (14-16 
weeks) and late 
(26-28 weeks) in 
gestation, all 
women had non-
esterified free fatty 
acids (FFAs) 
measured. 
Triglycerides were 
Birthweight. 6 
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Study 
ID 
Basic 
information 
Participants 
Maternal 
characteristics 
Follow-up Exposures Outcomes 
Quality 
score 
American birthweight >2500 g) 
Exclude criteria: 
Having a history of diabetes, hypertension, 
triglycerides>300 mg/dL, chronic diseases; 
tobacco or alcohol use; or treatment with 
steroids/β-blockers. Women with positive 
gestational diabetes diagnosis at baseline or 
24-28 weeks’ gestation were excluded. 
Sample size : n=38 
Pre-pregnancy 
BMI (kg/m2) 
Normal weight: 
22.4 ± 1.9 
Obese: 
33.1 ± 3.4 
Gestational length 
Normal weight: 
39.4 ± 0.3 
Obese: 39.6 ± 0.3 
Fasting blood 
No statement 
measurement 
Loss to follow-up 
4 (8.20%) 
measured in early 
gestation only. 
Son et 
al.2010 
Study design: 
Retrospective 
longitude 
observational 
study 
 
Language: 
English 
 
Location: 
Korea 
Setting: 
No statement. 
Eligibility criteria: 
Pregnant women diagnosed with GDM by 
the OGTT with complete maternal 
overnight fasting blood samples within 2 
weeks of GDM diagnosis. 
Exclude criteria: 
Women having hypertensive disorder (n=9), 
thyroid disorder (n=4), connective tissue 
disease (n=3). Patients who delivered before 
35 weeks of gestation (n=14) and cases of 
foetal congenital malformation (n=10) or 
multifetal gestations (n=6) were also 
excluded. 
Sample size : n=104 
x ± SD  
Age (year) 
32.7 ± 4.1 
Parity 
0.7 ± 0.8 
Pre-pregnancy 
BMI (kg/m2) 
23.2 ± 4.1 
Gestational length 
38.3 ± 1.2 
Fasting blood 
Yes 
Enrolment time 
Gestational age at entry 
(24th -30th gestation week) 
Length 
Follow up until birth. 
Methods 
No statement 
Data collection 
clinical measurement 
Loss to follow-up 
0 
Maternal fasting 
serum TG, total 
cholesterol, low-
density lipoprotein 
(LDL) and high-
density lipoprotein 
(HDL) cholesterol 
concentrations at 
24th -32th gestation 
week 
Hypertriglyceridem
ia was defined as a 
TG level greater 
than the 75th 
percentile value 
(<3.33 mmol/L) 
Infants with birthweights 
above the 90th percentile 
were classified as LGA, 
based on gestational age 
and sex-adjusted 
birthweights from a 
Korean national 
database.  
5 
Ahmad. 
2006 
Study design: 
Controlled 
prospective 
study 
 
Language: 
English 
 
Setting: 
Four antenatal clinics (ANC): Hospital 
Universiti Sains Malaysia, Kota Bharu 
Health Cinic, Kubang Kerian Health Clinic 
and Kedai Lalat Health Clinic. 
Eligibility criteria: 
Pregnant women attending the antenatal 
clinics at gestation between 24 to 32 weeks 
x ± SD  
Age (year) 
30.87 ± 6.70 
Gravidity 
3.76 ± 2.69 
BMI (kg/m2) 
23.36 ± 4.04 
Gestational length 
Enrolment time 
Gestational age at entry 
(24th -32th gestation week) 
Length 
Follow up until delivery. 
Methods 
Antenatal clinics visit and 
appointment 
Maternal fasting 
lipid profile was 
taken at between 
24 to 32 weeks 
gestation for 
laboratory 
analyses. (total 
cholesterol and 
At delivery, weight of 
the newborn were noted. 
LGA: Neonatal birth 
weight above the 90th 
percentile of gender 
specific birth weight 
curve of Malaysia. 
7 
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Study 
ID 
Basic 
information 
Participants 
Maternal 
characteristics 
Follow-up Exposures Outcomes 
Quality 
score 
Location: 
Malaysia 
 
gestation. 
Exclude criteria: 
Diabetic (diagnosed diabetic prior to 
conception and gestational diabetes 
requiring insulin); Hypertension or 
preeclampsia (hypertensive disorder), lupus 
and antiphospholipid syndrome, fetal 
anomaly diagnosed through ultrasound 
during booking or noted abnormal at birth; 
multiple gestation; pre-term delivery. 
Sample size: n=246 
39.00 ± 1.29 
Fasting blood 
Yes. 
Data collection 
clinical records 
Loss to follow-up 
50 (13.9%) 
triglycerides) 
Di et 
al.2005 
Study design: 
prospective 
observational 
study 
 
Language: 
English 
 
Location: 
Italy 
 
Setting: 
The diabetes Section of the Department of 
Endocrinology and Metabolism of the 
University of Pisa, Italy. 
Eligibility criteria: 
Pregnant Caucasian women with positive 
diabetic screening performed at 24 to 30th 
week of gestation, 
Exclude criteria: 
Women with hypertensive disorders, 
thyroid disorder, lupus and anti-
phospholipid syndrome. 
Sample size: n=180 (NGT=121) 
The main analysis of our interest is 
conducted on NGT women who delivered at 
term. (n=83) 
x ± SD or n (%) 
Age (year) 
33 ± 4 
Primiparous 
106 (59) 
Pre-pregnancy 
BMI (kg/m2) 
23.6 ± 4 
Gestational length 
39.3(39-40) 
Fasting blood 
Yes. 
Enrolment time 
Gestational age at entry 
(24th -28th gestation week) 
Length 
Follow up until delivery. 
Methods 
Antenatal clinics visit and 
appointment 
Data collection 
clinical records 
Loss to follow-up 
0 
Maternal overnight 
fasting lipid level 
(Total cholesterol, 
LDL-C, HDL-C, 
Triglycerides) at 
between 24th and 
28th week of 
gestation. 
Birthweight. 
 
Macrosomia: neonatal 
body weight over 4kg or 
as a neonatal weight 
greater than 90th 
percentile for gestational 
age (LGA), according to 
the reference table. 
5 
Schaefer
-Graf et 
al.2008 
Study design: 
Secondary 
analysis of 
RCT study 
 
Language: 
English 
 
Location: 
Setting: 
Two hospital based diabetic prenatal care 
clinics. 
Original study (n=199):  
Women diagnosed as GDM based on a 75-g 
OGTT in capillary blood. (capillary fasting 
glucose ＜120 mg/dl, postprandial glucose
＜200 mg/dl). 
This analysis (n=150):  
x ± SD 
Age (years) 
31.2 ± 4.9 
Parity 
2.05 ± 1.2 
Pre-pregnancy 
BMI (kg/m2) 
27.8 ± 6.2 
Gestational length 
Enrolment time 
Gestational age at entry  
(28.3 ± 2.4 weeks);  
(Jan 2000 - Jan 2003) 
Length 
Follow up until day 2 after 
delivery 
Methods 
Clinical visits (28, 32, 36, 
Maternal serum 
FFAs, cholesterol 
and triglycerides 
were measured 
every clinical visit 
(28, 32, 36 and 
close to delivery) 
using commercial 
kits. 
Birth weight and length 
were obtained shortly 
after delivery, and 
neonatal skinfold 
thickness at the flank 
was measured within 
48h.  
Infants with birth weight 
<10th percentile were 
5 
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Study 
ID 
Basic 
information 
Participants 
Maternal 
characteristics 
Follow-up Exposures Outcomes 
Quality 
score 
German Accepted insulin therapy; availability of 
complete maternal blood and cord blood 
samples. 
(weeks) 
39.2 ± 1.4 
Fasting blood 
No Statement 
39 weeks, labour and day 2 
postpartum) 
Data collection 
No statement 
Loss to follow-up 
49/199 (24.6 %) 
classified as SGA, and 
those with birth 
weight > 90th percentile 
as LGA based on 
gestational age and sex-
adjusted birth weight 
percentiles derived from 
a German national 
database. 
Cord blood samples 
ware taken immediately 
following delivery and 
serum was stored at -
80℃ for TGs, free fatty 
acids(FFAs) and 
cholesterol 
measurements. 
Swierze
wska et 
al. 2015 
Study design: 
Prospective 
observational 
study 
 
Language: 
English 
 
Location: 
Poland 
Setting: 
No statement 
Eligibility criteria: 
136 Caucasian women were included into 
this study: 106 diagnosed with GDM and 31 
pregnant women with normal glucose 
tolerance. 
Exclude criteria: 
No statement 
Sample size :136 
GDM group: 106 
NGT group: 31 
x ± SD or n (%) 
Age (year) 
GDM: 30.2±0.36 
NGT: 28.87±0.6 
Primiparous 
 No statement. 
Pre-pregnancy 
weight (kg) 
GDM:25.29±0.4 
NGT: 23.05±0.52 
Gestational length 
(days) 
No statement 
Fasting blood 
No statement. 
Enrolment time 
Gestational age at entry  
(No statement);  
(2012 - 2013) 
Length 
Follow up until birth. 
Methods 
No statement 
Data collection 
Survey, interview 
Loss to follow-up 
0 
Maternal venous 
blood samples 
were collected 
twice (27-32 wks 
and 34-39 wks of 
gestation) to assess 
lipid profile (total 
cholesterol, HDL 
and LDL 
cholesterol, 
triglycerides).  
Macrosomia was 
diagnosed in newborn 
with the firth weight of 
≥4000 g, and LGA if the 
birth weight exceeded 
the 90th percentile. 
5 
Sommer 
et 
al.2015 
Study design: 
Population-
based, multi-
ethnic, 
Setting: 
The STORK Groruddalen study (n=823), a 
population-based cohort study of healthy 
pregnant women attending Child Health 
x ± SD or n (%) 
Age (year) 
29.3  ± 4.8 
Primiparous 
Enrolment time 
Gestational age at entry 
(<20 gestation week)  
In practice, the STORK 
Maternal fasting 
total-, HDL- and 
LDL-cholesterol 
and triglycerides 
Birth weight was 
measured with calibrated 
electronic scales 
immediately after birth.  
9 
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Study 
ID 
Basic 
information 
Participants 
Maternal 
characteristics 
Follow-up Exposures Outcomes 
Quality 
score 
prospective 
cohort 
 
Language: 
English 
 
Location: 
Norway 
Clinics for antenatal care in three 
administrative city districts in Oslo, 
Norway. 
Eligibility criteria for STORK study: 
1. lived in the study districts; 2. Planned to 
give birth at one of two study hospitals; 3. 
were<20 weeks pregnant; 4. Could 
communicate in Norwegain or any of the 
eight translated languages; 5. Were able to 
give a written consent to participate.  
Exclude criteria for STORK study: 
Women with pregestational diabetes or in 
need of intensive hospital follow-up during 
pregnancy were excluded 
In/Exclusion criteria for this analysis: 
Women with singleton pregnancy who 
completed both two clinic visits are eligible 
for this analysis. Women who was abortions 
or stillbirths < GW 28, complications 
mother/baby, preterm birth, mother included 
late in pregnancy, south American origin 
were excluded from this analysis. 
Sample size: n=699 (for birthweight); 
n=512 (for sum of skinfolds) 
 
319 (45.6) 
Pre-pregnancy 
BMI (kg/m2) 
24.6  ± 4.8 
Gestational length 
(days) 
281 ± 9 
Fasting blood 
Yes. 
study also includes 77 
(9.4 %) and 11 (1.3%) 
women entry into this study 
at 20-24 gestation week and 
later than gestational week 
24, respectively.   
(May 2008 to May 2010) 
Length 
Follow up at least until 3 
days after birth. 
Methods 
Clinic visits 
Data collection 
Questionnaires, clinical 
measurement and laboratory 
diagnosis. 
Loss to follow-up 
37(5.29%) 
were measured 
from venous blood 
with a colorimetric 
method at the 
central laboratory 
at clinic visit 2 
(week 28). 
To assess neonatal 
subcutaneous fat, 
skinfolds were measured 
to the nearest 0.2mm 
with a skinfold calliper 
at subscapular, 
suprailiac, thigh and 
triceps sites within 72 
hours after birth. 
Slagjana 
et 
al.2014 
Study design: 
Population-
based, multi-
ethnic, 
prospective 
cohort 
 
Language: 
English 
 
Location: 
Norway 
Setting: 
The Outpatient Department of the 
University Endocrinology, Diabetes and 
Metabolic Disorders Clinic 
Eligibility criteria: 
GDM women with singleton pregnancy, and 
the neonates were delivered at the 
University Gynaecology and Obstetrics 
Clinic. 
Exclude criteria: 
None 
Sample size: n=200 
x ± SD or n (%) 
Age (year) 
LGA: 31.4±5.6 
AGA: 31.1±5.6 
SGA: 32.9±5.1 
Primiparous 
No statement 
Pre-pregnancy 
BMI (kg/m2) 
LGA: 28.4±6.1 
AGA: 26.5±4.9 
SGA: 25.0±4.6 
Enrolment time 
No statement on recruitment 
date and entry gestational 
age. 
Length 
Follow up until birth. 
Methods 
Clinic visits 
Data collection 
Clinical measurement and 
laboratory diagnosis. 
Loss to follow-up 
Maternal overnight 
fasting blood 
samples were 
collected at the 
second half of 
pregnancy(LGA; 
28.6±7.7; AGA: 
28.0±7.1; SGA: 
23.8±7.6) for Total 
cholesterol, HDL-
C,LDL-C and 
triglycerides 
LGA: birth weight above 
the 90th percentile. 
SGA: birth weight below 
the 10th percentile for 
gestational age. 
AGA: birthweight 
between LGA and SGA. 
5 
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Study 
ID 
Basic 
information 
Participants 
Maternal 
characteristics 
Follow-up Exposures Outcomes 
Quality 
score 
Gestational length 
(weeks) 
LGA: 39.3±1.5 
AGA: 38.2±1.9 
SGA: 36.4±3.7 
Fasting blood 
Yes. 
0 laboratory 
assessment.  
 
Laleh et 
al.2013 
Study design: 
Prospective 
cohort 
 
Language: 
English 
 
Location: 
Iran 
Setting: 
Shariati Hospital affiliated to Tehran 
University of Medical Sciences, Tehran, 
Iran 
Eligibility criteria: 
Pregnant women were diagnosed with 
GDM. 
Exclude criteria: 
Women with a history of systemic 
underlying diseases (cardiovascular, renal, 
thyroid, liver, autoimmune and connective 
tissue disorder), substance abuser, overt 
diabetes mellitus (except previous history of 
GDM), multifetal gestations and major fetal 
malformation. 
Sample size: n=112 
x ± SD or n (%) 
Age (year) 
27.23±4.19 
Parity 
2.74 (66.1) 
Pre-pregnancy 
weight (kg2) 
67.40±10.00 
Gestational length 
(days) 
No statement 
Fasting blood 
Yes. 
Enrolment time 
Gestational age at entry  
(27.02 ± 0.68 weeks);  
(Mar 2011 - May 2012) 
Length 
Follow up until birth. 
Methods 
Clinic visits 
Data collection 
A combination of interviews 
and questionnaires in timing 
of glycemic screening (24-
28 weeks) 
Loss to follow-up 
20 (15.15%) 
Maternal blood 
samples were 
collected at 28-32, 
32-36 and 36 
weeks of 
gestational age 
until delivery time 
to determine 
fasting serum 
levels of lipids 
(TGs, total 
cholesterol and 
HDL-c). LDL-c = 
TC-HDL-(TG/5), if 
TG>400mg/dl, it 
was measured 
directly in serum. 
SGA: birthweight <10th 
percentile. 
LGA: birthweight >90th 
percentile. 
Macrosomia: >4000 g 
7 
Whyte et 
al. 2013 
Study design: 
Prospective 
cohort 
 
Language: 
English 
 
Location: 
Ireland 
Setting: 
The Perinatal day centre of University 
Maternity practice. 
Eligibility criteria: 
White European women with an ongoing 
singleton pregnancy were enrolled when 
they were referred to the Perinatal day 
centre for OGTT screening test. 
Exclude criteria: 
Women who were unable to give informed 
consent or who were less than 18 years of 
age were excluded. 
x ± SD or n (%) 
Age (year) 
32±5 
Primigravidas 
67(35.4) 
Pre-pregnancy 
BMI (kg/m2) 
No statement 
Gestational length 
(days) 
277±14 
Fasting blood 
Enrolment time 
Gestational age at entry  
(when women attend OGTT 
screening test);  
(Mar 2011) 
Length 
Follow up until birth. 
Methods 
Clinic visits 
Data collection 
Clinical measurements, 
diagnosis, hospital’s 
Maternal fasting 
venous blood 
sample was 
obtained to 
measure the TC, 
HDL-C, LDL-C 
and TG when 
women attend 
OGTT screening 
test. 
After delivery, 
birthweight was 
obtained from the 
Hospital’s computerized 
database. 
5 
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Study 
ID 
Basic 
information 
Participants 
Maternal 
characteristics 
Follow-up Exposures Outcomes 
Quality 
score 
Sample size: n=189 Yes. computerized database. 
Loss to follow-up 
0 
Zhou et 
al.2012 
Study design: 
Prospective 
cohort 
 
Language: 
English 
 
Location: 
China 
Setting: 
Routine obstetric care in the Nanjing drum 
tower hospital 
Eligibility criteria: 
Nulliparous pregnant women < 20 weeks 
gestation visited the antenatal department 
and had booked to deliver their infants at 
Nanjing Drum Tower Hospital. 
Exclude criteria: 
Women with family history of dyslipidemia, 
chronic diseases that may affect the lipid 
profile such as hypertension, diabetes 
mellitus and systemic lupus erythematosus, 
or used a medication that affected the lipid 
profile. 
Sample size: n=1,000 
x ± SD or n (%) 
Age (year) 
28.6±3.4 
BMI (kg/m2) 
22.54±2.86 
Gestational length 
(weeks) 
39.3±1.2 
Fasting blood 
Yes. 
Enrolment time 
Gestational age at entry  
(20 gestation week);  
(Jun 2009 to Jan 2010) 
Length 
Follow up until birth. 
Methods 
Clinic visits 
Data collection 
Clinical measurement and 
laboratory diagnosis 
Loss to follow-up 
15 (1.5%) 
Maternal overnight 
fasting blood at 20 
weeks gestation 
were measured for 
serum TG, TC, 
LDL-c and HDL-c. 
Hypo-HDL-
cholesterolemia 
was defined as 
fasting serum 
HDL-C levels 
below the optimal 
cut-off value. 
Infants with birthweight 
<10th percentile were 
classified as SGA based 
on gestational age and 
sex adjusted birth weight 
percentiles, and those 
with birth weight above 
4,000 g were classified 
as macrosomia.  
5 
Vrijkotte 
2011 
Study design: 
Prospective 
community-
based cohort 
study 
 
Language: 
English 
 
Location: 
Netherlands 
Setting: 
Amsterdam Born Children and their 
Development (ABCD) study 
Eligibility criteria: 
All pregnant women living in Amsterdam 
were invited to enrol in the ABCD study at 
their first prenatal visit to an obstetric care 
provider at about the 12th week of gestation. 
Exclude criteria: 
Women who gave birth to twins, delivered 
preterm (<37 wks), with known diabetes 
(pre-existent as well as pregnancy related) , 
or whose infants had congenital 
abnormalities were excluded. Women who 
used lipid-altering medication, such as 
antiepileptic drugs, steroids, insulin, 
antidepressants, thyroid hormones, or sleep 
x ± SD or n (%) 
Age (year) 
31.0±4.8 
Pre-pregnancy 
BMI (kg/m2) 
<18.5: 115(4.6%) 
18.5-24.9: 
1869(74.7%) 
25.0-29.9: 
388(15.5%) 
≥30: 130(5.2%) 
Primigravidas 
1412(56.4) 
Gestational length 
(weeks) 
37-40 wks: 
1779(71.6%) 
Enrolment time 
Gestational age at entry  
(around 12 gestation week);  
(Jan 2003 to Mar 2004) 
Length 
Follow up until 12 months 
after birth. 
Methods 
Clinic visits 
Data collection 
Clinical measurement and 
laboratory diagnosis 
Loss to follow-up 
0 
Maternal non-
fasting serum 
samples were taken 
during routine 
blood collection for 
screening purposes 
after the first 
prenatal check-up 
for lipid laboratory 
measurements (TG 
and TC). 
Birthweight for 
gestational age SDS was 
determined based on 
sex-and partiy-specific 
standards from the 
Dutch Perinatal 
Registry. In the first 
year, weight and length 
were measured on 
average 8 times. Weight, 
length and BMI were 
expressed as SDS by 
using internal sex-
specific reference curve 
from the ABCD study. 
To further explore 
postnatal growth, the 
7 
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Study 
ID 
Basic 
information 
Participants 
Maternal 
characteristics 
Follow-up Exposures Outcomes 
Quality 
score 
medication also were excluded. 
Sample size: n=2,502 
41.-43 wks:  
707(28.4%) 
Fasting blood 
No. 
amount of accelerated 
growth was defined as 
an increase >0.67 SDS 
between 2 time points 
(between 1 and 6 months 
of age) 
Vinod et 
al. 2011 
Study design: 
Ongoing 
prospective 
cohort study 
 
Language: 
English 
 
Location: 
American 
Setting: 
University of Michigan Health System 
Eligibility criteria: 
Eligible participants were 18-45 years of 
age, between 6 and 10 weeks gestation with 
a singleton pregnancy, and intended to 
deliver at the study hospital. 
Exclude criteria: 
Participants who did not complete the study 
and delivered a live infant. 1% of women 
were excluded from any analysis because of 
missing data. 
Sample size: n=143 
x ± SD or n (%) 
Age (year) 
≤30: 79(55.2) 
>30: 64(44.8) 
Pre-pregnancy 
BMI (kg/m2) 
Normal weight: 
72 (50.4) 
Overweight/Obese: 
71 (49.6) 
Primigravidas 
54 (37.8) 
Gestational length 
(days) 
274.0 ± 13.2 
Fasting blood 
No. 
Enrolment time 
Gestational age at entry  
(6-10 gestation week);  
(No statement on entry date) 
Length 
Follow up until birth. 
Methods 
Clinic visits 
Data collection 
Interview, Questionnaire, 
Medical records, Clinical 
measurement and laboratory 
diagnosis 
Loss to follow-up 
(1%) 
Maternal non-
fasting venous 
blood were 
collected at five 
time points during 
pregnancy: 6-10, 
10-14, 16-20, 22-
26 and 32-36 
weeks gestation for 
laboratory lipid 
measurements (TC, 
HDL-C, LDL-C 
and TG) 
Infant birthweight was 
collected at delivery. 
The residual values from 
each fit were used to 
represent the gestational 
age-adjusted birthweight 
(aBW). 
6 
Zawiejsk
a et al. 
2008 
Study design: 
prospective 
observational 
study 
 
Language: 
English 
 
Location: 
Poland 
Setting: 
Department of Obstetrics and Women 
Diseases for a tertiary-level, specialistic 
antenatal care. 
Eligibility criteria: 
GDM diagnosed following WHO criteria, 
singleton pregnancy, live birth and no fetal 
malformation suspected during gestation or 
detected postpartum. 
Exclude criteria: 
None. 
Sample size: n=357 
Median (min-
max) 
Age (year) 
29 (17-48) 
Pre-pregnancy 
BMI (kg/m2) 
24.2 (16.7-46.1) 
Primigravidas 
No statement 
Gestational length 
(weeks) 
38 (32-42) 
Fasting blood 
Enrolment time 
Gestational age at entry  
(GDM diagnosis week);  
(1993 to 2005) 
Length 
Follow up until birth. 
Methods 
Clinic visits 
Data collection 
Clinical measurement and 
laboratory diagnosis 
Loss to follow-up 
0 
Maternal overnight 
fasting blood 
sample were taken 
for laboratory lipid 
assessment (TC, 
HDL and 
triglycerides) at 
their first booking 
weeks (GDM 
diagnosis week) 
Birth weight and the 
proportion of LGA 
(defined as a birth 
weight >90th percentile 
for local population after 
adjusting for gestational 
age and sex) was studied 
at the end-point. 
5 
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Study 
ID 
Basic 
information 
Participants 
Maternal 
characteristics 
Follow-up Exposures Outcomes 
Quality 
score 
Yes. 
Clausen 
et 
al.2005 
Study design: 
Prospective 
cohort study 
 
Language: 
English 
 
Location: 
Norway 
Setting: 
Aker Hospital in the Oslo city area  
Eligibility criteria: 
All pregnant women living in Oslo area 
were offered an ultrasound investigation at 
17-19 weeks of gestation 
Exclude criteria: 
Pre-gestational diabetes, multiple 
pregnancies, preterm births, missing 
medical records, no information on birth 
weight, lost for follow-up 
Sample size: n=2,050 
x ± SD or n (%) 
Age (year) 
29.9±4.4 
The 1st trimester 
BMI (kg/m2) 
23.0±3.7 
Primigravidas 
1030(50.3) 
Gestational length 
(weeks) 
39.7±1.3 
Fasting blood 
Yes 
Enrolment time 
Gestational age at entry  
(17-19th gestation week);  
(1995-1996) 
Length 
Follow up until birth. 
Methods 
Clinic visits 
Data collection 
Clinical measurement and 
laboratory diagnosis 
Loss to follow-up 
244(10.6%) 
Maternal fasting 
blood samples 
were drawn at 17-
19th gestation 
weeks for 
laboratory lipid 
measurements 
(TGs, TC, HDL-C, 
non-HDL-
cholesterol). 
Macrosomia: birth 
weight above 4,500 g or 
a z-score above the 95 
percentiles. 
 
7 
Mathews 
et 
al.2003 
Study design: 
Prospective 
cohort study 
 
Language: 
English 
 
Location: 
United 
Kingdom 
Setting: 
The geographic catchment area of St Mary’s 
Hospital, Portsmouth, United Kingdom 
Eligibility criteria: 
White nulliparous women attending their 
first hospital antenatal clinic were stratified 
by self-reported smoking status. Simple 
random selection was carried out within 
each stratum. 
Exclude criteria: 
Preterm birth, insufficient blood for assays 
and still birth 
Sample size:  
Subjects for birth weight and early 
pregnancy nutrition analyses: n=798 
x ± SD or n (%) 
Age (year) 
 25.4±4.9  
Pre-pregnancy 
BMI (kg/m2) 
 23.1± 3.9 
Gestational length 
(days) 
Boys: 280.3±9.9 
Girls: 281.3±9.5 
Fasting blood 
NS 
Enrolment time 
Gestational age at entry  
(14-17th gestation week, 
range: 9-20 wk);  
(May 1994 – Feb 1996) 
Length 
Follow up until birth 
Methods 
Clinical visits 
Data collection 
Questionnaire, Clinic 
measurement and laboratory 
diagonosis 
Loss to follow-up 
0 
Maternal blood 
samples were 
obtained from 
subjects at two 
time points (early 
pregnancy: at 
around 16 gestation 
week, later 
pregnancy: at 
around 28 gestation 
week) for total 
cholesterol 
laboratory analyses 
Infants were weighed at 
delivery to the nearest 5 
g on digital scales. 
8 
Olmos et 
al.2014 
Study design: 
Prospective 
observational 
study  
 
Language: 
English 
Setting: 
Obstetricians 
Eligibility criteria: 
Women aged 18-42 years with singleton 
pregnancy, under the care of an Obstetrician 
of the University Health Care Network, 
having GDM confirmed recently (<14 days) 
x ± SD or n (%) 
Age (year) 
 Normal weight: 
32.7±5.0  
Overweight:  
32.7±5.3 
Obese: 
Enrolment time 
Gestational age at entry  
(after GDM diagnosis 
week);  
(Jan 2009 – Jun 2013) 
Length 
Follow up until birth 
Maternal fasting 
lipid (triglycerides, 
total cholesterol, 
HDL-C) level were 
measured in the 2nd 
and 3rd trimesters. 
All lipid 
Birth weight z-scores.  
 
Macrosomia: a birth 
weight above 90th 
percentile, was used, 
applying to that effect 
the tables of the Chilean 
6 
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Study 
ID 
Basic 
information 
Participants 
Maternal 
characteristics 
Follow-up Exposures Outcomes 
Quality 
score 
 
Location: 
Chile 
by an oral glucose tolerance test (OGTT) 
test.  
Exclude criteria: 
Women unable to give informed consent or 
who were less than 18 years of age were 
excluded. 
Sample size: n=279 
Normal weight group: n=128 
Overweight group: n=105 
Obese group: n=46 
32.3±4.7 
Primiparous 
 No statement 
Pre-pregnancy 
BMI (kg/m2) 
Normal weight: 
22.3±1.5 
Overweight: 
26.1±3.1 
Obese: 33.1±2.7  
Gestational length 
(weeks) 
Normal weight: 
38.0±1.3 
Overweight: 
37.7±1.7 
Obese: 37.6±1.7 
Fasting blood 
Yes. 
Methods 
Clinic visits 
Data collection 
Clinical measurements and 
diagnosis, and laboratory 
diagnosis 
Loss to follow-up 
0 
parameters were 
calculated as z-
scores based on 
Alvarez paper.  
Ministry of Health, in 
use since 2004. 
Emet et 
al.2013 
Study design: 
Prospective 
observational 
study 
 
Language: 
English 
 
Location: 
Turkey 
Setting: 
Antenatal care,  
Eligibility criteria: 
1,000 pregnant patients between 17 and 48 
years of age were included in this 
prospective longitudinal and uni-centre 
study. 
Exclude criteria: 
Patients with type I-II diabetes mellitus and 
hypothyroidism, multiple gestations, 
dyslipoproteinemia were excluded from the 
study. Also, patients on special diets 
because of underlying diseases or personal 
preferences such as gluten or casein-free 
diets, vegetarian diet, liver or renal failure 
diet, etc., or patients using medications that 
effect lipid metabolism were excluded as 
well. Patients whose pregnancies were 
x ± SD or n (%) 
Age (year) 
 28.5±5.5  
Parity 
 0.94±0.98 
Pre-pregnancy 
BMI (kg/m2) 
No statement 
Gestational length 
(weeks) 
38.9±1.8 
Fasting blood 
Yes 
Enrolment time 
Gestational age at entry  
(<14 gestation week);  
(Jan 2010 – Dec 2011) 
Length 
Follow up until birth 
Methods 
Clinic visits 
Data collection 
Questionnaire, interview, 
clinical and laboratory 
diagnosis 
Loss to follow-up 
76(8.68%) 
Maternal lipid 
profile (TG, TC, 
HDL, LDL) were 
tested at the first 
antenatal visit (<14 
weeks) and the last 
trimester (>28 
weeks) 
Birthweight was 
recorded. 
Third month infant 
weight was also 
surveyed. 
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Study 
ID 
Basic 
information 
Participants 
Maternal 
characteristics 
Follow-up Exposures Outcomes 
Quality 
score 
terminated before 24 gestational week, 
patients who dropped out of routine 
antenatal and patients who gave birth 
outside the hospital were also not included 
in this analysis 
Sample size: n=801 
Liu et al. 
2016 
Study design: 
Retrospective 
cohort study 
 
Language: 
English 
 
Location: 
China 
Setting: 
The first affiliated hospital of Sun Yat-sen 
University 
Eligibility criteria: 
Singleton pregnant women who underwent 
a FPG test at the first prenatal care, and 
delivered in our centre were recruited for 
the present study. 
Exclude criteria: 
Pregnant women with overt DM before, 
pregnancy or treated with insulin during 
gestation were excluded in the present study 
Sample size: n=1,546 
x ± SD 
Age (year) 
GDM: 31.85±4.24 
NGT: 29.42±3.82 
Primiparous 
GDM: 234 (84.7) 
NGT: 969 (76.2) 
Pre-pregnancy 
BMI (kg/m2) 
GDM: 21.20±3.00 
NGT: 20.47±2.60 
Gestational length 
(days) 
GDM: 
271.33±11.70 
NGT: 
273.94±11.91 
Fasting blood 
YES. 
Enrolment time 
Gestational age at entry  
(10th -24th gestation week);  
(Jan - Dec 2013) 
Length 
Follow up until birth 
Methods 
Clinic visit 
Data collection 
Questionnaire, clinical 
measurements and 
diagnosis, laboratory 
diagnosis. 
Loss to follow-up 
0 
Maternal fasting 
venous plasma 
were obtained at 
the first prenatal 
visit (24-28 
gestational weeks) 
for the examination 
of lipid profiles 
(triglyceride, 
cholesterol, LDL, 
HDL) 
Neonatal birth weight 
was measured with a 
calibrated electronic 
scale. 
7 
Brunner 
et al. 
2013 
Study design: 
Secondary 
analyses of 
RCT study 
 
Language: 
English 
 
Location: 
German 
Setting: 
The Impact of Nutritional Fatty Acid on 
Infant Adipose Development (INFAT) 
study, an open-label randomized controlled 
trial 
Eligibility criteria: 
Healthy pregnant women with singleton 
pregnancies and a pre-pregnancy BMI 
between 18 and 30 kg/m2 were enrolled and 
randomly assigned to either an intervention 
(n=104) or a control group (n=104) from the 
x ± SD or n (%) 
Age (year) 
 31.8±4.7  
Primiparous 
 122(58.5) 
Pre-pregnancy 
BMI (kg/m2) 
 22.3±3.0  
Gestational length 
(weeks) 
39.6±1.5 
Enrolment time 
Gestational age at entry  
(before 15th gestation week);  
(No statement on 
recruitment date) 
Length 
Follow up until 2 years old. 
Methods 
Clinic visits 
Data collection 
Clinic measurement, 
Maternal blood 
was collected at the 
32nd week of 
gestation in the 
morning after an 
overnight fast for 
serum triglycerides 
laboratory 
measurement.  
The infants were 
examined at birth (for 
skinfolds: 3-5 days post-
partum), at 6 weeks, 
4months, 1 and 2 years 
post-partum. 
Birthweight was 
retrieved from the 
medical record. 
Anthropometric 
measurements of the 
7 
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Study 
ID 
Basic 
information 
Participants 
Maternal 
characteristics 
Follow-up Exposures Outcomes 
Quality 
score 
15th week of gestation until 4 months post-
partum. 
Exclude criteria: 
None. 
Sample size : n=208 
Fasting blood 
YES 
medical records, clinic 
diagnosis, laboratory 
analyses 
Loss to follow-up 
0 
infants were taken by 
trained investigators 
according to 
standardized procedures. 
Skinfolds were 
measured in triplicate 
with a Holtain calliper at 
the left body axis at four 
sites (triceps, biceps, 
subscapular and 
suprailiac) .  
Knopp et 
al.1992 
Study design: 
Prospective 
observational 
study 
 
Language: 
English 
 
Location: 
American 
Setting: 
Obstetrical practices at the two main Group 
Health hospitals in the King County. 
Subjects participating in this study were 
prenatal registrants at Group Health 
Cooperative of Puget Sound (WA), a 
prepaid health care program that enrols 
~10% of the King County population and 
corresponds closely to census estimates in 
King County with respect to age, race, and 
sex, abased on 1970 and 1980 census data. 
Eligibility criteria: 
3517 women between 24 and 32 wk of 
gestation (average 28 wk), of whom 2019 
consented to participate. This analyses 
groups consist of 521 negative screenees 
chosen randomly from 1,654 subjects in this 
group and 365 women with positive glucose 
screening test. Of these women, 264 had 
GTT- and 96 had GTT+ and were designated 
as having GDM. 
Exclude criteria: 
Five other GDM subjects treated with 
insulin were not included in this analysis. 
Sample size: n=881 
Negative screenees(NS-): n=521 
x ± SD 
Age (year) 
NS-: 28±5 
PS+: 30±5 
GDM: 31±5 
Multipara (%) 
NS-: 53.0 
PS+: 52.4 
GDM: 57.3 
Pre-pregnancy 
BMI (kg/m2) 
No statement 
Gestational length 
NS-: 39.8±1.5 
PS+: 39.6±1.6 
GDM:39.4±1.5 
Fasting blood 
Yes. 
Enrolment time 
Gestational age at entry  
(24th – 32nd gestation week);  
(Jan 1985 – May 1986) 
Length 
Follow up until birth 
Methods 
Clinic visit 
Data collection 
Medical records, laboratory 
measurement. 
Loss to follow-up 
0 
Maternal overnight 
fasting blood 
samples collected 
at between 24th and 
32nd gestation was 
measured by 
laboratory for 
plasma 
triglycerides. 
Birthweight was 
adjusted for differences 
in gestational age by 
dividing the observed 
birth weight by the 50th 
percentile birth weight 
for that gestational age, 
giving a birth-weight 
ratio.  
6 
Page 70 of 136
World Obesity Journals
Obesity Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 24 
Study 
ID 
Basic 
information 
Participants 
Maternal 
characteristics 
Follow-up Exposures Outcomes 
Quality 
score 
Positive screenees(PS+): n=264 
GDM: n=96 
Knopp et 
al.1985 
Study design: 
Prospective 
observational 
study 
 
Language: 
English 
 
Location: 
American 
Setting: 
Group Health Cooperative of Puget Sound, 
a prepaid health program. 
Eligibility criteria: 
Subjects were identified at 26-28 wk 
gestation by a prospective random sampling 
scheme, were invited to participate, and, 
after consent was given, had 
anthropomorphic measurements and blood 
sampled at home at 36 wk gestation by a 
visiting research nurse. 
Exclude criteria: 
Women were excluded if they aborted or 
delivered before 36 wk or had fasted <12 h. 
women who were not Caucasian, were 
under 18 yr of age, or had a twin pregnancy 
were also excluded.  
Sample size: n=283 
x ± SD or n (%) 
Age (year) 
 28.0±3.8 
Primiparous 
 102 (36) 
Pre-pregnancy 
BMI (kg/m2) 
No statement 
Gestational length 
(days) 
283.4±18.6 
Fasting blood 
Yes 
Enrolment time 
Gestational age at entry  
(26-28 gestation week);  
(No statement on 
recruitment date) 
Length 
Follow up until birth. 
Methods 
Clinic visit, home visit 
Data collection 
Interview, hospital records, 
clinical and laboratory 
measurements. 
Loss to follow-up 
10 (3.5%) 
Maternal fasting 
blood sampled at 
home at 36 wk 
gestation by a 
visiting research 
nurse for 
laboratory lipid 
measurements 
(HDL-C, VLDL-C, 
LDL-C and FFA) 
Birth weight data were 
extracted from hospital 
records.  
Birth weight was 
adjusted for gestational 
age and expressed as the 
birth weight ratio as 
determined from the 
expected date of 
confinement by dividing 
the observed birth 
weight by the median 
expected for gestational 
age using the University 
of Oregon (sea level) 
tables. 
7 
Schaefer
-Graf et 
al.2011 
Study design: 
Prospective 
observational 
study 
 
Language: 
English 
 
Location: 
German 
Setting: 
Vivantes Medical Center Department of 
Obstetrics in Berlin 
Eligibility criteria: 
1)documented normal 75-g oral glucose 
tolerance test according to Carpenter and 
Coustan criteria (5.0/10.0/8.6 mmol/L) with 
three glucose values in capillary blood using 
the hexokinase method; 2) accurate 
gestational age, confirmed by an ultrasound 
examination before 20 weeks of gestation; 
3) singleton pregnancy; 4) absence of 
identified fetal anomalies; 5) delivery after 
34 weeks; 6) signed informed consent 
Exclude criteria: 
No statement 
x ± SD or n (%) 
Age (year) 
 30.0±0.4  
Parity 
 2.07±0.09 
Pre-pregnancy 
BMI (kg/m2) 
 25.7± 0.4 
Gestational length 
38.8±0.1 
Fasting blood 
Yes 
Enrolment time 
Gestational age at entry  
(No statement on 
recruitment gestation week);  
(Aug 2007 – Aug 2008) 
Length 
Follow-up until 48h after 
birth 
Methods 
Hospital stay 
Data collection 
Laboratory diagnosis. 
No statement around how 
did they get maternal 
baseline information.  
Loss to follow-up 
Maternal overnight 
fast blood samples 
were taken from a 
radial vein either 
on the morning of 
admission for 
surgery in cases of 
primary Caesarean 
section or at the 
last visit o the 
obstetrical clinic, 
no longer than 1 
week before 
delivery. Serum 
triacylglycerols, 
free fatty acids and 
Birth weight was 
obtained shortly after 
delivery and neonatal 
skinfold thickness at the 
flank was measured 
within 48 h to calculate 
fat mass.  
LGA: birthweight <10th 
percentile. 
SGA: birthweight >90th 
percentile. 
Cord blood samples 
from one of the 
umbilical arteries were 
taken immediately after 
delivery.  
5 
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Study 
ID 
Basic 
information 
Participants 
Maternal 
characteristics 
Follow-up Exposures Outcomes 
Quality 
score 
Sample size: n=190 0 cholesterol were 
measured in 
laboratory. 
Serum glucose, insulin, 
triacyglycerols, free 
fatty acids and 
cholesterol were 
measured in cord blood. 
Nolan et 
al.1995 
Study design: 
Prospective 
observational 
study 
 
Language: 
English 
 
Location: 
Australia 
Setting: 
Obstetric clinic at the Mercy Hospital for 
Women 
Eligibility criteria: 
Women with singleton pregnancies had 
routine 3rd-trimester oral glucose t lerance 
tests performed and have been included for 
analyses in this study. 
Exclude criteria: 
No statement 
Sample size: n=388 
x ± SD or n (%) 
Age (year) 
 28.4±5.3  
Primiparous 
 No statement 
BMI at wk 20 
(kg/m2) 
24.7±4.2 
Gestational length 
No statement 
Fasting blood 
No. 
Enrolment time 
Gestational age at entry  
(≤20th  gestation week);  
(1991) 
Length 
Follow up until birth 
Methods 
clinic visits 
Data collection 
Clinic records, clinic visits, 
laboratory measurements 
Loss to follow-up 
0 
During the 
morning of the first 
clinic visit (average 
sampling time: 
12.2±6.2 weeks), 
all women had 
non-fasting serum 
TG and cholesterol 
measured within 
their routine 
antenatal screening 
blood analyses. TG 
and cholesterol 
were assayed by 
enzymatic 
colorimetric 
methods. 
Birth weight was record.  
Birth weight ratio 
(BWR) for all infants 
was calculated by 
dividing the observed 
birth weight by the 50th 
percentile birth weight 
for gestational age. 
6 
Friis et 
al.2012 
Study design: 
Prospective 
observational 
study 
 
Language: 
English 
 
Location: 
Norway 
Setting: 
A subcohort of the STORK study,  
Eligibility criteria: 
women of Scandinavian heritage (n= 1031) 
who registered for obstetric care at Oslo 
University Hospital - Rikshospitalet  
Exclude criteria: 
Multiple pregnancies, known pre-
gestational diabetes, and severe chronic 
diseases (lung, cardiac, gastrointestinal or 
renal). 
Sample size: n=207 
x ± SD or n (%) 
Age (year) 
 31±3.5  
Primiparous 
 91(44) 
Pre-pregnancy 
height(cm)/weight 
(kg2) 
 168/66 
Gestational length 
40.1±1.4 
Fasting blood 
Yes 
Enrolment time 
Gestational age at entry  
(14th -16th gestation week);  
(2001-2008) 
Length 
Follow up until 4 days 
postpartum 
Methods 
Clinic visits 
Data collection 
Interview, clinic 
measurements, hospital 
records 
Loss to follow-up 
Maternal fasting 
blood samples 
were collected at 
30-32th gestation 
weeks for total 
cholesterol, HDL, 
triglycerides, free 
fatty acids 
laboratory 
measurements.  
Birthweight  
 
6 
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Study 
ID 
Basic 
information 
Participants 
Maternal 
characteristics 
Follow-up Exposures Outcomes 
Quality 
score 
0 
Lei et 
al.2016 
Study design: 
Prospective 
cohort study 
 
Language: 
English 
 
Location: 
China 
Setting: 
The Department of Obstetrics of 
Guangdong Women and Children Hospital, 
Guangzhou, Guangdong Province 
Eligibility criteria: 
Pregnant women were recruited before 20 
gestation wks 
Exclude criteria: 
Multiple pregnancy, conception by means 
of gonadotropin ovulation inducti n or in 
vitro fertilization, ischemic heart disease, 
stroke, peripheral vascular disease, 
dyslipidaemia, diagnosis of diabetes or/and 
hypertension before the current to 
participate in the study. 
Sample size: n=5,535 
x ± SD or n (%) 
Age (year) 
29.07±5.04 
Primiparous 
3152 (56.95) 
Pre-pregnancy 
BMI (kg/m2) 
20.87±2.81  
Gestational length 
38.20±2.81 
Fasting blood 
Yes. 
Enrolment time 
Gestational age at entry  
(<20th gestation week);  
(Jan 2012 – Dec 2014) 
Length 
Follow up until birth 
Methods 
Clinic visits 
Data collection 
Laboratory assessment, 
medical surveillance. 
Loss to follow-up 
485 (8.06%) 
Maternal fasting 
venous blood 
samples were 
drawn before 20 
weeks to assess 
metabolic profile 
(TG and HLD-C). 
High level of TG 
was defined as 
≥3.49 mmol/L 
(≥75th percentile). 
Low level of HDL-
C was defined as 
<1.3 mmol/L 
(<25th percentile) 
A newborn was 
considered SGA or LGA 
if birth weight as smaller 
or greater than the 
estimated 10th/90th 
percentile for the baby’s 
gender and gestational 
age according to the 
Chinese data published 
before. 
6 
Kitajima 
et 
al.2001 
Study design: 
Prospective 
observational 
study 
 
Language: 
English 
 
Location: 
Japan 
Setting: 
Nagasaki University Hospital 
Eligibility criteria: 
Japanese pregnant women who had positive 
diabetic screen test results (at least 
135mg/dl of plasma glucose level at 1 hour 
after 50-g oral glucose challenge) and a 
normal 75-g oral GTT. 
Exclude criteria: 
Women with pregestational or gestational 
diabetes mellitus were excluded. We also 
excluded women with hypertensive 
disorder, thyroid disorder, lupus, and 
antiphospholipid syndrome. Subjects who 
delivered before 37 weeks’ gestation and 
cases of foetal congenital malformation or 
multifetal gestation were also excluded. 
Sample size: n=146 
x ± SD or n (%) 
Age (year) 
 32±4  
Primiparous 
 65(44%) 
Pre-pregnancy 
BMI (kg/m2) 
 21.2±2.7  
Gestational length 
39.0±1.2 
Fasting blood 
Yes. 
Enrolment time 
Gestational age at entry  
(24-32 gestation week);  
(Nov 1992 and Oct 1999) 
Length 
Follow up until delivery. 
Methods 
Clinic visits 
Data collection 
Self-report, clinic 
measurements and diagnosis 
Loss to follow-up 
0 
Maternal fasting 
blood samples 
were drawn to 
measure serum 
triglyceride, free 
fatty acids and total 
cholesterol levels 
at 24-32 gestation 
week through 
laboratory 
measurements.  
Maternal 
hyperlipidaemia 
was defined as a 
value higher than 
the 75th percentile 
value of each lipid 
concentration. 
Neonatal birth weight 
above the 90th 
percentile of the gender 
specific Japanese birth 
weight curve was 
defined as LGA. 
 
6 
Mossaye Study design: Setting: x ± SD Enrolment time Maternal blood Macrosomia was defined 5 
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Study 
ID 
Basic 
information 
Participants 
Maternal 
characteristics 
Follow-up Exposures Outcomes 
Quality 
score 
bi et al. 
2014 
Cohort study 
 
Language: 
English 
 
Location: 
Iran 
The prenatal clinic of the Shahid Akbar 
Abadi Hospital 
Eligibility criteria: 
All women were 
generally healthy pregnant women carrying 
a single foetus, between 25 weeks and 32 
weeks of their gestational age, BMI between 
17.5 kg/m2 and 29 kg/m,2 without a history 
of diabetes prior to or during previous 
pregnancies and with a negative result from 
the diabetes screening test in the current 
pregnancy, hypertensive disease and 
preeclampsia, thyroid diseases, lupus, 
antiphospholipid antibody syndrome, and 
other collagen vascular diseases. 
Exclude criteria: 
Exclusion criteria were preterm labour prior 
to 37 weeks of gestational age and any 
abnormality or disorder in the foetus or 
neonate. 
Sample size: n=154 
Age (year) 
26.6±5.17  
Parity 
1.7±0.79 
Pre-pregnancy 
BMI (kg/m2) 
 22.6±2.3  
Gestational length 
No statement 
Fasting blood 
Yes. 
Gestational age at entry  
(25-32th gestation week);  
(2010-2011) 
Length 
Follow up until birth 
Methods 
Clinic visits 
Data collection 
Clinic measurement and 
diagnosis. Laboratory 
measurements.  
Loss to follow-up 
16 (8%) 
sample for 
checking fasting 
triglyceride (TG), 
total cholesterol, 
low-density 
lipoprotein (LDL), 
and high-density 
lipoprotein (HDL) 
after 10-12 hours 
of fasting at 25-32th 
gestation week. 
(gestational age at 
the time of blood 
sampling: 30±2.1) 
as neonate birth weight 
higher than 4000 g. 
LGA was defined as 
neonate’s birth weight 
higher than 3412 g for 
infants at 38 weeks of 
gestational age, 3622 g 
for infants at 39 weeks 
of gestational age, 3798 
g for infants at 40 weeks 
of gestational age, and 
3930 g for infants at 41 
weeks of gestational age. 
This definition was 
according to the 
neonates’ weight higher 
than 75% of their 
predicted value 
according to their 
gestational age. 
Geraghty 
et al. 
2016 
Study design: 
Secondary 
analyses of 
RCT study 
 
Language: 
English 
 
Location: 
Ireland 
Setting: 
Randomised cOntrol trial of Low glycaemic 
index diet vs no dietary intervention in 
pregnancy to prevent recurrence of a large 
baby (ROLO) study, which was carried out 
in The National Maternity Hospital, Dublin, 
Ireland. 
Original study: 
Eight hundred secundigravida women who 
did not have gestational diabetes but had 
previously given birth to a macrosomic 
baby (birth weight equal to or above 4.0 
kg), and were therefore at increased risk of 
delivering another macrosomic infant, were 
randomised to receive low glycaemic index 
(GI) dietary advice or usual antenatal care, 
x ± SD or n (%) 
Age (year) 
 33.10±3.90  
BMI at 14 weeks’ 
gestation(kg/m2) 
26.40±4.60  
Gestational length 
(days) 
282.80±7.50 
Fasting blood 
Yes 
Enrolment time 
Gestational age at entry  
(<14th gestation week);  
(No statement on 
recruitment time) 
Length 
Follow up until 2 years old. 
Methods 
Clinic visits and follow-up 
appointments 
Data collection 
Clinic measurements, 
laboratory measurements. 
Loss to follow-up 
0 
Maternal fasting 
blood samples 
were taken in early 
pregnancy 
(approximately 14th 
gestation weeks) 
and late pregnancy 
(28th gestation 
weeks) for serum 
total cholesterol, 
HDL-C and 
triglyceride 
laboratory 
measurements. 
LDL-C 
concentration was 
Infants were measured at 
birth, 6 months and 2 
years of age for weight 
and recumbent length 
along with abdominal 
circumference and 
bicep, tricep, 
subscapular and thigh 
skinfold thicknesses.  
7 
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Study 
ID 
Basic 
information 
Participants 
Maternal 
characteristics 
Follow-up Exposures Outcomes 
Quality 
score 
which did not include dietary advice. 
Eligibility criteria: 
No statement. 
Exclude criteria: 
No statement. 
Sample size : n=331 
estimated using the 
Friedewald 
equation.  
Jin et 
al.2016 
Study design: 
Cohort study 
 
Language: 
English 
 
Location: 
China 
Setting: 
Women’s Hospital, Zhejiang University 
School of Medicine 
Eligibility criteria: 
1) pregnant at 28–37 gestational weeks; 2) 
had integrated medical records and clear 
gestational age; 3) singleton pregnancy; and 
4) naturally conceived. 
Inclusion criteria for newborns were 
singleton and 5-min-postpartum Apgar 
scores ≥ 7. 
Exclude criteria: 
1) multiple pregnancy; 2) had diabetes 
mellitus, chromosomal abnormalities, 
inherited metabolic diseases or thyroid 
diseases before pregnancy; 3) experienced 
serious infection during early pregnancy; 
and 4) conceived with assisted reproductive 
techniques. 
Exclusion criteria for newborns were 
chromosomal abnormalities, inherited 
metabolic diseases and congenital 
abnormalities. 
Sample size: n=934 
x ± SD or n (%) 
Age (year) 
 29.21±3.76  
Primiparous 
 778(83.3%) 
Pre-pregnancy 
BMI (kg/m2) 
 20.66±2.70 
Gestational length 
38.84±1.22 
Fasting blood 
Yes. 
Enrolment time 
Gestational age at entry  
( 7-10th gestation week);  
(30 Jun 2010 - 30 Jun 2011) 
Length 
Follow up until birth. 
Methods 
Clinic visits 
Data collection 
Questionnaire, medical 
records, laboratory 
measurements and diagnosis 
Loss to follow-up 
0 
Maternal venous 
blood samples 
were taken after 
overnight fasting 
from all the 
participants at the 
first (7–10 
gestational weeks), 
second (21–24 
gestational weeks) 
and third (33–37 
gestational weeks) 
trimester of 
pregnancy. Every 
sample was 
assayed for TC, 
TG, HDL-C and 
LDL-C 
concentrations 
through laboratory. 
Newborns were 
classified into 
appropriate for 
gestational age (AGA), 
SGA and LGA based on 
Neonatal Birth Weight 
for Gestational Age and 
Percentile in 15 Cities of 
China. 
LGA: birth weight above 
the 90th percentile. 
SGA: birth weight below 
the 10th percentile for 
gestational age. 
AGA: birthweight 
between LGA and SGA. 
 
According to the birth 
weight, neonates could 
be stratified into low 
birth weight (<2500 g), 
normal birth weight 
(2500–4000 g) and 
macrosomia (>4000 g) 
groups. 
7 
Tian et 
al. 2013 
Study design: 
Prospective 
observational 
study 
 
Setting: 
No statement 
Eligibility criteria: 
Maternal and neonatal characteristics were 
investigated between 2581 newborns with 
No statement No statement Hypertriglyceridem
ia and 
hypercholesterolem
ia was diagnosed 
according to the 
Macrosomia Not 
applicabl
e 
Page 75 of 136
World Obesity Journals
Obesity Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 29 
Study 
ID 
Basic 
information 
Participants 
Maternal 
characteristics 
Follow-up Exposures Outcomes 
Quality 
score 
Language: 
English 
 
Location: 
China 
normal birth weight (controls,2500-3999g) 
and 306 macrosomia (birth weight over 
4000g).  
Exclude criteria: 
Pregnancy with twins, premature labour and 
other complications were all excluded. 
Sample size: No statement 
criteria of 
Hyperlipidaemia of 
National 
Cholesterol 
Education 
Program. 
Couch et 
al.1998 
Study design: 
Perspective 
observational 
study 
 
Language: 
English 
 
Location: 
American 
Setting: 
The Department of Obstetrics and 
Gynaecology, Hartford Hospital, Hartford, 
Connecticut, and private physicians’ offices 
affiliated with Hartford Hospital 
Eligibility criteria: 
Women with GDM and healthy pregnant 
women with a negative diabetes screening 
test were recruited. 
Exclude criteria: 
Women with hypertension, 
hyperlipidaemia, renal or liver disease, heart 
disease, thyroid disorder, multiple 
gestations or parity >5 were excluded from 
the study. 
Sample size: n=40 
x ± SD or n (%) 
Age (year) 
GDM: 31.6±2.7 
Controls:30.6±3.2  
Primiparous 
GDM: 8 (40%) 
Controls: 8 (40%) 
Maternal BMI 
(kg/m2) 
GDM:25.4±4.6 
Controls:23.7±3.8 
Gestational length 
GDM:38.3±1.7 
Controls:37.6±2.2 
Fasting blood 
Yes. 
Enrolment time 
Gestational age at entry  
(26-30th gestation week);  
(No statement on recruited 
time) 
Length 
Follow up until delivery 
Methods 
No statement 
Data collection 
Clinic diagnosis, clinic 
records. 
Loss to follow-up 
0(0%) 
Maternal plasma 
samples were 
collected between 
37-38 gestation 
weeks and 
analysed for TC, 
HDL, LDL, VLDL 
and FFA 
Cord vein samples were 
analysed for TC, HDL, 
LDL, VLDL and TG. 
 
6 
Ortega et 
al.1996 
Study design: 
Cohort study 
 
Language: 
English 
 
Location: 
Spain 
Setting: 
The INSALUD hospitals 
Eligibility criteria: 
Pregnant women carrying only a single 
child with no congenital malformations at 
37 or more weeks of gestation. Participants 
without registered maternal disease (either 
before or during pregnancy), vaginal 
bleeding, blood pressure over 140/90 mm 
Hg, protein or glucose in the urine, 
pregnancy-related immunization and drug 
or alcohol abuse. 
Exclude criteria: 
x ± SD or n (%) 
Age (year) 
 28.6±5.4  
Primiparous 
 NS 
Pre-pregnancy 
BMI (kg/m2) 
NS 
Gestational length 
39.6±1.3 
Fasting blood 
Yes. 
Enrolment time 
Gestational age at entry  
(32-35th gestation week);  
(October – December 1988) 
Length 
Follow up until delivery 
Methods 
Clinic visit 
Data collection 
Clinic diagnosis, obstetric 
case notes 
Loss to follow-up 
0(0%) 
Venous blood was 
collected at 32-35 
gestation weeks 
after overnight 
fasting. TC, HDL-
C, LDL-C, VLDL-
C and triglycerides 
were measured by 
laboratory.  
Birthweight was 
measured using a 
Marsden spring balance. 
Cord arteriovenous 
blood was obtained 
immediately after 
clamping and before 
delivery of the placenta. 
Blood samples were 
analysed for a series of 
lipid parameters (TC, 
HDL-C, LDL-C VLDL-
C and triglycerides). 
6 
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Study 
ID 
Basic 
information 
Participants 
Maternal 
characteristics 
Follow-up Exposures Outcomes 
Quality 
score 
None. 
Sample size: n=292 
Alberti-
Fidanza,
et 
al.1995 
Study design: 
Perspective 
observational 
study 
 
Language: 
English 
 
Location: 
Italy 
Setting: 
Three towns in the Perugia area (Gubbio, 
Perugia and Umbertide) 
Eligibility criteria: 
Volunteer pregnant women attending the 
Maternity Advisory Service were recruited 
at the 1st trimester. 
Exclude criteria: 
Women and newborns in pathological 
conditions were not included.  
Sample size: n=70 
For our interested association, the number 
of participants is 21. 
No statement Enrolment time 
Gestational age at entry  
(1st trimester);  
(No statement on recruited 
time) 
Length 
Follow up until 6 months 
post-partum 
Methods 
Clinic visits 
Data collection 
Laboratory measurements, 
clinic records,  
Loss to follow-up 
49(70%) 
At the 1st, 2nd and 
3rd trimester of 
pregnancy and at 
delivery, maternal 
venous blood was 
obtained for lipids 
assessments (TC, 
TG, HDL-C) 
Mixed venous-arterial 
cord blood was obtained 
at delivery for TC, TG 
HDL-C measurements. 
  
5 
Brockerh
off.  
1986 
Study design: 
Perspective 
observational 
study 
 
Language: 
Germany 
 
Location: 
German 
Setting: 
Obstetrics 
Eligibility criteria: 
No statement 
Exclude criteria: 
No statement 
Sample size: n=112 
 
No statement No statement Maternal blood 
was taken at 16th 
gestation week for 
VLDL-C, LDL-C 
and HDL-C 
assessments.  
Cord blood was obtained 
at delivery for TC and 
TG assessments.  
 
Robin et 
al. 2007 
Study design: 
Retrospective 
cohort study 
 
Language: 
English 
 
Location: 
American 
Setting: 
Hospital closest to the Greenwood Genetic 
Centre(GGC) in Greenwood, South 
Carolina 
Eligibility criteria: 
All women who were consecutively 
screened between 13 and 23 weeks’ 
gestation during 1996-2001. Women who 
delivered at the hospital closest to GGC 
x ± SD or n (%) 
Age (year) 
 NS 
Primiparous 
 NS 
Pre-pregnancy 
BMI (kg/m2) 
NS 
Gestational length 
Enrolment time 
Gestational age at entry  
(No statement);  
(1996-2001) 
Length 
Follow up until delivery 
Methods 
Clinic visits 
Data collection 
Maternal serum 
was taken between 
13 and 23 weeks’ 
gestation 
(mean:17.5 weeks, 
SD: 1.5 weeks) 
during 1996-2001. 
Frozen sera(-80℃) 
Birthweight. 7 
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Study 
ID 
Basic 
information 
Participants 
Maternal 
characteristics 
Follow-up Exposures Outcomes 
Quality 
score 
Exclude criteria: 
1) Age<21 or >34 years old;  
2) positive smoking history; 
3) not dated by ultrasound 
4) pregestational diabetes 
5) twin gestation 
6) race/ethnicity Hispanic, Asian, or 
Other 
7) preeclamptic pregnancies 
8) cardiac malformation 
9) missing or conflicting data 
10) foetal death 
11) >1 eligible pregnancy to same 
mother 
12) delivery before 37 gestation week 
Sample size: 
Low-TC group:100 
Mid-TC group: 757 
High-TC group:100 
NS 
Fasting blood 
NS 
Laboratory measurements, 
NIH clinical records,  
Loss to follow-up 
47(9.9%) for low-TC group; 
233(7.4%) for higher-TC 
group 
were shipped on 
dry ice from GGC 
to the NIH. TC in 
serum was 
analysed in 
laboratory.  
Charles 
et al. 
2016 
Study design: 
Perspective 
longitudinal 
study 
 
Language: 
English 
 
Location: 
Tunisia, 
Spain, Serbia, 
Malta, Italy 
and Greece 
Setting: 
Some centres (e.g. Malta) recruiting from a 
general population and others (eg. Greece 
and Italy) recruiting from an obstetric 
referral centre. 
Eligibility criteria: 
Pregnant Mediterranean women recruited in 
centres in Tunisia(n=112), Spain(n=187), 
Serbia(n=126), Malta(n=309), Italy(n=140), 
and Greece(n=178) who were not known to 
suffer from any form of carbohydrate 
metabolism problems outside their 
pregnancy (type 1 diabetes(T1DM), type 2 
diabetes(T2DM), LADA, or MODY). 
Exclude criteria: 
None. 
Sample size: n=1062 
x ± SD or n (%) 
Age (year) 
31.3±5.4  
Primiparous 
NS 
Maternal 
prepregnancy BMI 
(kg/m2) 
24.9±5.3 
Gestational length 
38.4±2.8 
Fasting blood 
Yes. 
Enrolment time 
Gestational age at entry  
(27.9±2.3);  
(No statement on recruited 
time) 
Length 
Follow up until delivery 
Methods 
No statement 
Data collection 
Laboratory measurements, 
clinic records 
Loss to follow-up 
0 
Maternal fasting 
lipid profile levels 
were assayed at the 
time of the OGTT. 
Cholesterol, HDL-
C, LDL-C and 
triglycerides were 
measured. 
Birthweight. 5 
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S5 Appendix Results extraction form 
Study 
ID 
 Maternal lipids 
Statistical Methods 
 TC HDL-C LDL-C TG FFAs 
Ye et 
al. 
2015  
x ± SD  
(mmol/L) 
6.6 ± 1.4 2.4 ± 0.5 3.3 ± 0.8 2.9 ± 1.2 — 
Statistical software: SPSS 16.0 
Two tailed statistical tests and a significant p value ＜ 0.05. 
Birth weight (g) 
(β, 95% CI) 
9.1 
(-6.4, 24.6) 
-69.5  
(-110, -28.2) 
35.4 
(10.1, 60.8) 
25.2 
(7.9, 42.6) 
— 
Multiple linear regression analysis adjusted for maternal 
glucose, maternal age, pre-pregnancy BMI, gestational 
weight gain, parity, neonatal sex and gestational age at 
delivery.  
SGA(n=39) 
(OR, 95% CI) 
0.94 
(0.74, 1.20) 
1.57 
(0.87, 2.83) 
0.75 
(0.50, 1.14) 
0.69 
(0.47, 1.03) 
— 
Logistic regression analysis adjusted for maternal age, pre-
pregnancy BMI, gestational weight gain, parity and maternal 
fasting blood glucose. 
AGA(n=873) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) — 
LGA(n=331) 
(OR, 95% CI) 
1.04 
(0.94, 1.15) 
0.62 
(0.47, 0.82) 
1.25 
(1.06, 1.47) 
1.15 
(1.03, 1.27) 
— 
Wang 
et al. 
2015  
Non-GDM (mmol/L) 
(Median, 25th-75th) 
ND 
1.88 
(1.65 – 2.12)  
ND 
1.95 
(1.59 - 2.42) 
— 
Statistical software: SPSS 17.0 
A significant p value ＜ 0.05. GDM (mmol/L) 
(Median, 25th-75th) 
ND 
1.81 
(1.50 – 2.09) 
ND 
2.18 
(1.84 – 2.82) 
— 
Birthweight 
(r, p) 
ND -0.12, p=0.01 ND 
0.19,  
p＜0.01 
— 
Partial correlation coefficients analysis adjusted for neonates’ 
sex and gestational age. 
Crume 
et al. 
2015  
1st visit (11-20 week) 
(x ± SD, mg/dL ) 
182.3±35.6 61.1±12.6 — 124.3±49.6 373.1±166.0 Statistical software: No statement 
2nd visit(20-34 week) 
(x ± SD, mg/dL ) 
209.9±40.3 63.1±13.1 — 162.2±62.1 365.1±151.4  
P value <0.0001 <0.0001 — <0.0001 0.3  
11-20 wk gestation       
Birth 
weight  
(β± SE, g, 
P) 
Model 1 
0.46±0.39 
P=0.2 
-0.54±1.17 
P=0.6 
— 
0.09±0.30 
P=0.7 
0.06±0.09 
P=0.5 
Regression analyses were performed to determine the 
association of maternal metabolic fuels and metabolic 
measures measured at each visit with neonatal outcomes. 
Model 1 adjusted for the residual value of the predictor from 
the other visit, infant sex, gestational age at birth, maternal 
age, race/ethnicity, parity postnatal age at time of PEAPOD 
(for outcomes other than birth weight). 
Model 2 is model 1 plus maternal smoking, total energy 
intake, and maternal physical activity during pregnancy, 
gestational weight gain. 
Model 3 is model 2 plus pre-pregnancy BMI 
Model 2 
0.42±0.42 
P=0.3 
-2.67±1.22 
P=0.03 
— 
0.50±0.24 
P=0.04 
0.05±0.09 
P=0.6 
Model 3 
0.44±0.41 
P=0.3 
-1.71±1.23 
P=0.2 
— 
0.41±0.24 
P=0.08 
-0.11±0.10 
P=0.2 
20-34 wk gestation      
Birth 
weight  
(x ± SE, 
g, β, P) 
Model 1 ND 
-1.12±1.12 
P=0.3 
— 
0.20±0.24 
P=0.4 
0.21±0.10 
P=0.03 
Model 2 ND 
-3.12±1.16 
P=0.07 
— 
0.39±0.24 
P=0.1 
0.31±0.11 
P=0.003 
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Study 
ID 
 Maternal lipids 
Statistical Methods 
 TC HDL-C LDL-C TG FFAs 
Model 3 ND 
-2.20±1.16 
P=0.06 
— 
0.30±0.24 
P=0.2 
0.24±0.10 
P=0.02 
 
The modification of effects of maternal cholesterol levels in late pregnancy on all neonatal body 
composition measures by pre-pregnancy BMI was reported in this study. A positive effect was noted for all 
neonatal outcomes (Birthweight, Fat mass, Fat free mass, Percent Fat mass) at higher pre-pregnancy BMIs, 
with a null effect for lean women and an inverse relationship on FM for underweight women. However, no 
β and P value around those associations was reported.  
This study also reported that their findings were not influenced by the exclusion of women identified with 
GDM (n=26), gestational hypertension (n=61), or pre-eclampsia (n=34). 
Hwang 
et al. 
2015  
15-28 wks 
(x ± SD, mg/dL) 
— — — 143.4±68.5 — Statistical software: SAS 9.3 
29-42 wks 
(x ± SD, mg/dL) 
— — — 273.4±123.3 — Statistical significance was defined as P<0.05. 
Birth weight (g), β(s.e.), p, R (%) Maternal serum TG levels was log-transformed before 
analyses due to its skewed distribution. Multiple regression 
analysis adjusted for maternal age, weight gain during 
pregnancy, log-transformed urinary cotinine, gestational age, 
gestational age at blood collection, neonatal gender and long-
transformed calorie intake.  
15-28 wks  — — — 
80.446 (31.738) 
P=0.0015, R=22.4 — 
29-42 wks  — — — 
131.067 (31.242) 
P<0.0001, R=19.8 
— 
Kulkar
ni et 
al. 
2013  
18 wks  
(x±SD,mmol/L) 
4.11 ± 0.85 1.12 ± 0.28 — 1.09 ± 0.36 — Statistical software: STATA version 11.2 
28 wks 
(x±SD,mmol/L) 
4.80 ± 0.89 4.80 ± 0.89 — 1.51 ± 0.52 —  
Birthweight (g): Model 0 (β，95% CI) Model 0: Multiple regression analyses was performed to 
explore the association of z-standardized maternal plasma 
glucose and lipid concentrations with neonatal measurements, 
adjusting for gestation at the time of measurements, sex, SES, 
parity, maternal age, maternal BMI before pregnancy and 
total energy intake at the time of measurements. 
18 wks 
39.07 
(10.57, 67.58) 
17.57 
(-11.64, 46.77) 
— 
14.76 
(-13.34 , 42.86) 
— 
28 wks 
54.34 
(24.85,83.88) 
-8.89  
(-38.72 ,20.95) 
— 
36.27 
(4.32,68.23) 
— 
Birthweight (g): multivariate analyses (β，95% CI)  
18 wks: model 1 
33.42  
(0.43,66.41) 
6.68 
(-24.08, 37.44) 
— 
4.24 
(-26.40, 34.87) 
— Multiple analyses adjusted for gestation, sex of the baby, 
parity, SES, and maternal age, BMI before pregnancy, total 
energy intake at the time of measurements and other lipid 
levels. 
Model 1 entered with maternal fasting glucose. 
Model 2 entered with maternal 2-h glucose 
28 wks: model 1 
52.52 
(19.11,85.92) 
-21.58 
(-52.62, 9.46) 
— 
23.93 
(-11.29, 59.15) 
— 
28 wks: model 2 
44.42 
(8.55,80.29) 
-20.29 
(-52.73, 12.14) 
— 
12.90 
(-24.25, 50.06) 
— 
Vrijkot SGA (n=364) 4.97 ± 0.86 — — 1.35 ± 0.61 — Statistical software: SPSS 16.0 and the statistical package R 
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Study 
ID 
 Maternal lipids 
Statistical Methods 
 TC HDL-C LDL-C TG FFAs 
te  et 
al. 
2012  
(x ± SD, mmol/L) 2.13.1 
 
Non-SGA (n=3548) 
(x ± SD, mmol/L) 
4.99 ± 0.87 — — 1.33 ± 0.54 — A P value <0.05 was considered statistically significant. 
LGA (n=364) 
(x ± SD, mmol/L) 
5.06 ± 0.91 — — 1.44 ± 0.61 —  
Non-LGA (n=3548) 
(x ± SD, mmol/L) 
4.98 ± 0.86 — — 1.32 ± 0.54 —  
Crude model 
Crude model: unadjusted associations between continuous TC 
and TG and the outcomes. 
SGA (OR, 95% CI) 
0.97 
(0.85-1.10) 
— — 
1.06 
(0.87-1.29) 
— 
LGA (OR, 95% CI) 
1.10 
(0.97-1.25) 
— — 
1.44 
(1.20-1.71) 
— 
Model 1 
Model 1 is multiple logistic regressions adjusted for maternal 
age, ethnicity, pre-pregnancy BMI, maternal education level, 
physical activity, smoking during pregnancy, and chronic 
hypertension. 
SGA (OR, 95% CI) 
0.98 
(0.86-1.12) 
— — 
0.97 
(0.79-1.19) 
— 
LGA (OR, 95% CI) 
1.08 
(0.95-1.22) 
— — 
1.48 
(1.23-1.78) 
— 
Retnak
aran et 
al. 
2012  
x ± SD, mmol/L       
Lowest tertile birth 
weight infant 
 [2020-3260 g] (n=156) 
6.48 ± 1.25 1.73 ± 0.36 3.72 ± 1.17 2.25 ± 0.72 — Statistical software: SAS 9.2 
Middle tertile birth 
weight infant  
[3260-3670 g] (n=157) 
6.55 ± 1.23 1.72 ± 0.37 3.72 ± 1.12 2.46 ± 0.75 —  
Highest tertile birth 
weight infant  
[3670-5700 g] (n=159) 
6.39 ± 1.15 1.66 ± 0.34 3.6 ± 1.04 2.49 ± 0.66 —  
p 0.5 0.2 0.5 0.006  Analysis of variance for continuous variables 
Birth weight (g, β,95 %CI) Multiple linear regression adjusted for length of gestation, 
infant sex, maternal demographic factors (age, ethnicity, 
family history of diabetes), smoking status, anthropometric 
measure (pre-pregnancy BMI, weight gain during pregnancy 
up to the time of OGTT), glucose tolerance status, other lipid 
levels, insulin, adipokines (adiponectin, leptin) and 
inflammatory proteins (C-reactive protein) 
Crude ND 
-120.54  
(-244.42 to 3.35) 
-15.22 
(-55.49 to 25.05) 
61.11  
(-1.18 to 123.40) 
— 
Adjusted ND 
-57.16 
(-189.42 to 75.09) 
-6.79  
(-46.98 to 33.39) 
-1.59 
(-70.67 to 67.49) 
— 
LGA (OR, 95% CI)  
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Study 
ID 
 Maternal lipids 
Statistical Methods 
 TC HDL-C LDL-C TG FFAs 
Crude ND 
0.89  
(0.69 - 1.15) 
0.80 
(0.61 - 1.05) 
1.26 
(0.98 - 1.62) 
— 
Logistic regression analysis adjusted the same covariate as in 
the multiple linear regression analyses, except for length of 
gestation and infant sex. 
Adjusted ND 
0.99 
(0.70 - 1.39) 
0.98  
(0.72 - 1.34) 
0.98 
(0.70 - 1.38) 
— 
White women LGA (OR, 95% CI) (n=388) 
Crude ND 
0.82 
(0.60 - 1.10) 
0.85 
(0.62 - 1.16) 
1.33 
(1.00 - 1.77) 
— 
Adjusted ND 
1.03 
(0.69 - 1.52) 
0.98 
(0.69 - 1.38) 
1.07 
(0.73 – 1.58) 
— Same statistical methods used in the LGA analyses. 
Hou et 
al. 
2014  
Mmol/L 
(median, 25th-75th) 
6.28  
(5.59-7.09) 
1.75 
(1.51-2.03) 
3.06  
(2.44-3.72) 
3.05  
(2.50-3.75) 
— 
Statistical software: SPSS 16.0 
P<0.05 was considered statistically significant. 
AGA(n=2236) 
6.30 
 (5.62-7.10) 
1.76 
 (1.52-2.05) 
3.07 
 (2.47-3.74) 
3.02 
 (2.48-3.69) 
— Mann-whitney U test 
LGA(n=554) 
6.18  
(5.49-7.04) 
1.70  
(1.48-1.95) 
2.95  
(2.30-3.65) 
3.19 
 (2.61-3.97) 
—  
p 0.017 0.000 0.003 0.000 —  
Outcome: LGA, (OR, 95% CI) Binary logistic regression analyses adjusted for maternal age, 
pre-pregnancy BMI, education level, smoking, annual 
household income, amniotic fluid volume, gestational 
hypertension, new-born sex, and gestational age at blood 
collection. 
The middle teritle value of maternal TC, HDL-C, LDL-C, TG 
and FFAs are 5.18-6.22, 1.04-1.55, 3.37-4.14 and 1.70-2.25. 
Lowest tertile value Ref 
0.202 
(0.026-1.562) 
Ref Ref — 
Middle teritle value 
0.967 
(0.712-1.313) 
Ref 
0.785  
(0.58-1.063) 
3.037 
(1.054-8.747) 
— 
Highest tertile value 
1.084 
(0.754-1.559) 
0.812 
(0.636-1.036) 
0.829 
(0.585-1.173) 
3.303 
(1.177-9.27) 
— 
Krame
r et al. 
2014 
Infant weight gain at 3 months (β,p) Statistical software: SAS 9.2 
The unit of maternal lipid levels: mmol/L 
Multiple linear regression analyses adjusted for infant age at 
3-month visit, sex duration of exclusive breastfeeding, 
maternal and paternal ethnicity, birthweight and length of 
gestation. 
GDM group  -26.3,0.57 -150.6, 0.40 -11.7, 0.81 -43.3, 0.62 — 
Non GDM group 37.0, 0.32 28.6, 0.80 43.5, 0.28 -14.2, 0.82 — 
Harmo
n et al. 
2011  
Mean ± SEM    mg/dL Eq/L 
Statistical software: Sigama Stat for Windows version 2.03 
Normal 
weight 
Early — — — 85 ± 5.6 366 ± 52 
Late — — — — 326 ± 29 
Obese 
Early — — — 152 ± 14.3 535 ± 55 
Late — — — — 547 ± 58 
None of the metabolic measures correlated with birth weight (data not shown). 
A forward stepwise regression was used to generate models 
between infant adiposity and maternal metabolic parameters. 
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Study 
ID 
 Maternal lipids 
Statistical Methods 
 TC HDL-C LDL-C TG FFAs 
Son et 
al. 
2010  
 Mean ± SD Mean ± SD  Median (IQR)  
Statistical software: SPSS 12.0 (SPSS Inc., Chicago, IL, 
USA) 
mmol/L 5.7 ± 1.1 1.7 ± 0.4 ND 2.5 (1.8-3.4) — p-value < 0.05 was considered significant. 
Non-LGA 5.8 ± 1.1 1.7 ± 0.5 ND 2.3 (1.8-3.1) — 
Differences between non-LGA group and LGA group were 
analysed using Student’s t-test 
 LGA 5.5 ± 0.9 1.6 ± 0.3 ND 3.2 (2.4-3.6) — 
 p 0.352 0.232 ND 0.001 — 
 
Birthweight (g, r, p) p>0.05 p>0.05 ND 
r = 0.17 
p = 0.07 
— Statistical Method was not stated. 
 
    
Hypertriglyceri
demia 
(TG≥3.33 
mmol/L) 
 Logistic regression model with confounding variables, 
including parity, age, prepregnancy BMI, gestational weight 
gain. 
 
LGA (OR, 95% CI) ND ND ND 
4.43  
(1.33-14.82) 
— 
Ahma
d et al. 
2006  
Birthweight ratio 
(g, r ,p) 
r = 0.147 
p = 0.021 
— — 
r = 0.122 
p = 0.057 
— 
 
Birthweight ratio: birthweight adjusted for gestational age. 
Statistical software: SPSS 11.0. α=0.05, p<0.05 
Univariate analysis.  
 
    
High TG 
(>2.78 mmol/L) 
  
 LGA  
(crude OR, 95% CI) 
ND — — 3.07 (1.33, 7.08) — 2 test. 
 
LGA 
 (adjusted OR, 95% CI) 
ND — — 1.476 (1.15-1.93) — 
Backward wald mode in binary logistic regression. Adjusted 
for BMI, fasting plasma glucose and 2 hours postprandial 
plasma glucose. 
Di et 
al. 
2005  
mmol/L (x ± SD) 6.34 ±1.3 1.68 ±0.4 4.01 ±1 1.99 ±0.64 — Statistical software: SAS 
birthweight (g, r2, p) ND ND ND 
r2=0.09 
p<0.05 
— Univariate regression analyses.  
 
    
Hypertriglyceri
demia (TG≥2.3 
mmol/L) 
 2 test. 
 LGA (crude OR, 95%CI) ND ND ND 5.6(0.93, 33.77) —  
Schaef
er-
Graf et 
al. 
2008  
 mg/dL   mg/dL mol/L Statistical software: SPSS 12.0 (Chicago, IL) 
x ± SD 253.7±55.6 — — 265.9±87.6 262.6±112.4 All statistical tests were two-tailed and a P value <0.05 was 
considered significant. Week 28,32,36      
Outcomes ND — — ND ND  
 Close to delivery (r, p) Bivariate correlation applying Spearman’s correlation test 
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Study 
ID 
 Maternal lipids 
Statistical Methods 
 TC HDL-C LDL-C TG FFAs 
 birthweight ND — — p>0.05 0.27, p=0.002  
 TGs in cord blood ND — — 0.19, p=0.003 ND  
 FFAs in cord blood ND — — ND 0.28, p=0.004  
 After adjustment for maternal pre-pregnancy BMI, weight gain, age parity, fasting and postprandial glucose 
from the profiles at 36 weeks and close to delivery, only maternal FFAs and TGs remained independently 
related to LGA (adjusted p= 0.008 and p=0.04, respectively). 
Maternal FFA levels were significantly higher in mothers with LGA infants than in mothers with AGA 
infants (362.8 ±101.7 vs. 252.4 ± 10.1 mol/L, p=0.002) 
Logistic regression analysis 
Swierz
ewska 
et al. 
2015 
No statistically significant correlation of lipid metabolism parameters with neonatal birth weight in the 
GDM and NGT group was found (data not shown). 
Statistical software: PQStat software. 
P value <0.5 was considered statistically significant. 
Multivariate linear regression for numerical factors and 
multivariate logistic regression were performed to assess the 
influence of the factors affecting neonatal birth weight. 
Somm
er et 
al. 
2015 
mmol/L(x ± SD)      
Statistical software: IBM SPSS Statistics21， lincom 
command in Stata IC 12 
Visit 1 5.0 ± 0.9 1.73 ± 0.39 2.71 ± 0.73 1.31 ± 0.55 — 
Visit 2 6.2 ± 1.1 1.93 ± 0.45 3.44 ± 0.99 1.98 ± 0.69 — 
 Birthweight (g)      Data were provided by authors through email. 
 
Model 0 is simple regression analyses. 
 
Model 1 is a multiple regression of the risk factor variables 
entered separately, adjusted for gestational week at inclusion, 
maternal age, parity, smoking status ethnic origin, offspring’s 
sex and gestational age. 
 
Model 2 = Model 1 + early pregnancy BMI + weight gain. 
 
Model 3: (risk variables are entered simultaneously into the 
regression, and adjusted for fasting glucose and 2-hour 
glucose, maternal age, gestational week, parity, ethnicity, 
smoking status, offspring's sex and gestational age)  
 
Model 4 = Model 3 + early pregnancy BMI + weight gain. 
 
Model 0 (β, 95%CI) 
-4.2 
 (-39.4, 31.0) 
-98.9  
(-188.1, -9.6) 
ND 
48.8  
(-14.8, 112.4) 
— 
 
Model 1 (β, 95%CI) 
-6.1  
(-37.5, 25.2) 
-105.4  
(-183.8, -27.0) 
ND 
94.4  
(37.8, 150.9) 
— 
 
Model 2(β, 95%CI) 
-4.8 
 (-34.0, 24.4) 
-118.8  
(-190.1, -47.5) 
ND 
85.4  
(37.0, 133.7) 
— 
 
Model 3(β, 95%CI) 
-115.4  
(-306.6, 75.8) 
47.6  
(-160.3, 255.6) 
ND 
97.4 
(-3.8, 198.6) 
— 
 
Model 4(β, 95%CI) 
-74.9 
(-260.1, 110.2) 
-21.9 
(-223.9, 180.2) 
ND 
83.4 
(-14.6, 181.5) 
— 
 Sum of skinfolds (mm)  
 
Model 0 (β, 95%CI) 
0.17 
(-0.14, 0.48) 
-0.521  
(-1.312, 0.270) 
ND 
0.583 
(0.015, 1.151) 
— 
 
Model 1 (β, 95%CI) 
0.10 
(-0.21,0.40) 
-0.608 
(-1.381, 0.164) 
ND 
0.839 
(0.280, 1.397) 
— 
 
Model 2(β, 95%CI) 
0.13 
(-0.17,0.42) 
-0.611  
(-1.321, 0.099) 
ND 
0.724 
(0.245, 1.202) 
— 
 
Model 3(β, 95%CI) 
-0.71  
(-2.37, 0.95) 
0.433  
(-1.412, 2.279) 
ND 
0.623 
(-0.308, 1.553) 
— 
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Model 4(β, 95%CI) 
-0.44 
(-2.08, 1.20) 
-0.022 
(-1.851, 1.808) 
ND 
0.577 
(-0.341, 1.494) 
— 
Slagja
na et 
al. 
2014 
mmol/L (x ± SD)      Statistical software: SPSS 14.0 
LGA (n=50) 6.0±1.0 1.3±0.4 3.8±1.0 3.8±1.8 — P<0.05 was considered statistically significant. 
AGA (n=135) 6.5±1.4 1.6±0.4 3.5±1.2 3.1±1.1 —  
SGA (n=15) 6.3±1.3 1.5±0.5 3.7±1.4 3.8±1.9 —  
 p (LGA vs. AGA)  p>0.05 0.001 p>0.05 0.012 — Student t test 
 p (AGA vs. SGA) p>0.05 p>0.05 p>0.05 0.012 —  
 Birthweight (g, r, p) ND ND ND 0.16, p=0.077 — correlation analysis 
 LGA  
(standardized β, p) 
-0.230, 
p=0.164 
ND ND 0.326, p=0.045 — Multiple linear regression 
Laleh 
et al. 
2013 
mg/dl (x ± SD)      Statistical software: SPSS 16.0 
28-32 wks 218.90±33.82 55.37±4.26 128.84±29.23 175.71±24.23 —  
32-36 wks 240.99±29.44 59.29±4.61 137.64±29.22 240.46±32.06 —  
36-40 wks 254.24±34.13 59.35±3.66 147.12±32.59 353.87±39.61 —  
A significant positive correlation between birth weight (LGA and macrosomia) and TG level in diabetic 
group after 32 weeks of gestational age (p<0.001) was found. (Bonferroni multiple comparison test) 
For determination of independent prediction of birth weight in the study group adjustment analyses of 
covariance (ANCOVA) was performed. After adjustment for maternal pre-pregnancyBMI, age, and parity, 
only TG level remind independently related to LGA (p=0.04). 
 
Whyte 
et al. 
2013 
 mmol/L (x ± SD ) Statistical software: SPSS 18.0 
Normal OGTT 
(n=167) 
5.08±0.89 1.54±0.41 2.74±0.78 1.84±0.86 — A p value <0.05 was considered significant. 
Abnormal OGTT 
(n=22) 
5.31±0.97 1.39±0.35 2.86±0.75 2.33±0.78 —  
Birthweight (kg) (x ± SD ) mmol/L   
 <2.99  — — 1.58±0.40 —  
 3.09-3.49 — — — 1.88±0.93 —  
 3.5-3.99 — — — 1.87±0.73 —  
 4.0-4.49 — — — 2.23±1.119 —  
 Maternal triglyceride levels increased by 0.248 mmol/L for each 1.0 kg increase in birth weight (p<0.03).  Univariate analysis 
 Maternal increased triglyceride levels were independently associated with increased birthweight (p<0.04). 
No relationship was found between fasting cholesterol and birth weight or other clinical variables 
Multivariate regression analysis adjusting for age, BMI and 
GDM. 
Zhou 
et al. 
mmol/L (x ± SD ) 6.04±1.48 2.19±0.45 2.76±0.71 2.44±1.45 — Statistical software: SPSS 12.0 
Macrosomia (n=89) 5.91±0.93 2.07±0.43 2.77±0.69 2.47±1.02 — Non-parametric Mann-Whitney Test was used to compare the 
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2012 difference between groups. 
Normal BW (n=890) 6.05±1.53 2.20±0.45 2.76±0.71 2.43±1.48 —  
 p >0.05 <0.05 >0.05 >0.05 —  
 Hypo-HDL-cholesterolemia   Unconditional logistic regression model. 
 Crude OR ND 1.67 ND ND —  
 Adjusted OR (95%CI) ND 1.63(1.02-2.60) ND ND — Adjusted for maternal age and BMI. 
 p ND 0.04 ND ND —  
 Macrosomia      
HDL-C was categorized in quartiles based on the distribution 
in all pregnant women, and risk in each quartile was 
estimated in reference to lowest or highest quartile of 
metabolic marker level. 
 HDL-c (mmol/L) Case (all, %) OR (95%CI) p   
 >2.49 14 (234, 6.0%) 1 —   
 2.18-2.49 23 (246, 9.3%) 1.59(0.78-3.27) 0.202   
 1.87-2.16 22(272, 8.1%) 1.47(0.72-2.99) 0.291   
 <1.87 30(238, 12.6%) 2.09(1.04-4.21) 0.039   
Vrijkot
te  et 
al. 
2011 
mmol/L (x ± SD )      Statistical software: SPSS 16.0 
Birth weight<2500g 4.63±0.79 — — 1.21±0.56 — A P value<0.05 was considered significant. 
2500g-4000g 4.97±0.86 — — 1.31±0.53 —  
Birth weight>4000g 5.01±0.89 — — 1.40±0.62 —  
 Standardised Birthweight, β(SE) Standardized birthweight (already adjusted for gestational age 
at birth, parity and sex) 
Univariate associations between TG and TC levels and BW 
SDS were explored by using regression analyses. 
Model 1 is multivariate analyses further adjusted for maternal 
age, maternal height, hypertension, maternal pre-pregnancy 
BMI, weight gain during early pregnancy, ethnicity, smoking, 
alcohol use, education level, and cohabitant status 
 TC(mmol/L) Univariate  Model 1 TG (mmol/L) Univariate  Model 1 
 Q1 (3.87±0.33) -0.12±0.07 -0.09±0.06 Q1 -0.03±0.07 -0.06±0.06 
 Q2(4.48±0.13) 0.07±0.07 0.09±0.06 Q2 0.03±0.07 0.00±0.06 
 Q3(4.89±0.12) Reference Reference Q3 Reference Reference 
 Q4(5.36±0.15) 0.07±0.07 0.08±0.06 Q4 0.04±0.07 0.03±0.06 
 Q5(6.23±0.61) 0.11±0.07 0.11±0.06 Q5 0.17±0.07 0.20±0.06 
 Standardised Birthweight,  Data were provided by authors through email. 
 
β(95%CI) 
11.82 
(-10.00, 33.65) 
— — 
47.14 
(12.42, 81.87) 
— Univariate linear analysis 
 
β(95%CI) 
22.67 
(4.00, 41.33) 
— — 
86.72 
(56.13,117.30) 
— 
Multivariate results linear analysis adjusted for maternal age, 
maternal height, hypertension, maternal pre-pregnancy BMI, 
weight gain during early pregnancy, ethnicity, smoking, 
alcohol use, education level, and cohabitant status 
 SDS weight      Linear regression analyses were used to exploring 
associations between different TG and TC quintiles and 
postnatal growth patterns (weight, length, and BMI expressed 
as SDS). 
 A significantly different growth patterns over time for SDS of weight (P=0.002). The growth pattern of 
infants born of women with the lowest TG levels (Q1) deviated more from their individual growth line than 
the growth patterns of other infants; that is, they started with a relatively low BW, but their weight 
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progressively increased during the first year toward levels close to those of the other infants. Post hoc 
analyses showed that differences in weight among TG quintiles were only significant at 1 month; these 
differences were 0.140 SDS for Q1 vs Q5, and 0.139 SDS for Q1 vs Q3. 
 
A multivariable model adjusted for maternal age, maternal 
height, parity, maternal pre-pregnancy BMI, weight gain 
during early pregnancy, ethnicity, education level, cohabitant 
status, smoking, alcohol use, pregnancy duration, infants’ age 
and BW. 
 
To compare SDS trajectories between the TG and TC 
quintiles in more detail, post hoc comparisons were done at 
multiple time points: 1, 3, 6, 9 and 12 months.  
 SDS length      
 The individual average lines with SDS did not differ significantly among subsequent TG quintiles, although 
there was a tendency for the Q1 pattern to deviate (p=0.061). Post hoc analyses revealed significant 
differences at 1 month only for Q1 vs Q5 (0.140). 
 SDS BMI      
 A similar tendency was observed for Q1, with a relatively low BMI at 1 month and a relatively high BMI at 
12 months. Differences were present at the first month after birth only for Q1 vs Q3 (0.129). 
 Accelerated weight gain The amount of accelerated growth in the different quintiles 
was determined by using the Pearson 2 analysis.  The percentage of infants in Q1 that showed accelerated growth (24.5%) during the first 6 months of life 
was significantly higher compared with the other TG quintiles (mean, 19.6%; P=0.027). Although both 
length and BMI showed a similar tendency with regard to an accelerated growth, no significant differences 
between Q1 and other TG quintiles were found. 
 No associations were found between TC quintiles and weight, length and BMI trajectories (overall pattern 
and no post hoc differences). 
Weight for gestational age according to TG and TC quintiles: 
Differences between TG quintiles: %SGA (p=0.768), %LGA (p=0.032) 
Differences between TC quintiles: %SGA (p=0.098), %LGA (p=0.601) 
 
Vinod 
et al. 
2011 
Gestational age-adjusted birth weight (g) - Normal weight group – β(95%CI) Statistical software: SAS 9.1 
 mg/dL  A p value of <0.05 was considered significant. 
6-10 wks (n=62) -0.5 (-3.1, 2.1) -4.1 (-10.4, 2,2) -0.2 (-3.4, 3.1) 1.1 (-0.4, 2.6) — Univariate regression analyses. 
10-14 wks (n=65) -0.6 (-3.1, 1.8) -2.1 (-7.7, 3.6) -0.9 (-4.0, 2.1) 1.5 (0.1, 2.8) —  
16-20 wks (n=68) -0.9 (-2.9, 1.2) -1.0 (-6.4, 4.4) -1.2 (-3.6, 1.3) 0.7 (-0.8, 2.1) —  
 22-26 wks (n=71) -1.3 (-2.9, 0.3) -4.1 (-8.8, 0.6) -1.5 (-3.4, 0.5) 1.1 (0.0,2.1) —  
 32-36 wks (n=69) -1.2 (-3.1, 0.6) -3.6 (-8.6, 1.4) -1.3 (-3.4, 0.8) 0.9 (-0.1, 1.9) —  
 Gestational age-adjusted birth weight (g) – Obese/Overweight group– β(95%CI)  
 6-10 wks (n=69) 0.3 (-3.5, 4.0) -7.7 (-16.1, 0.7) 2.5 (-1.9, 7.0) 0.4 (-2.3, 3.0) —  
 10-14 wks (n=71) 1.5 (-1.8, 4.7) -8.0 (-15.6, -0.4) 2.8 (-1.1,6.7) 1.4 (-0.5, 3.2) —  
 16-20 wks (n=65) 0.1 (-3.3,3.5) -9.3 (-16.4, -2.1) 2.2 (-1.6, 6.1) 0.7 (-1.2. 2.6) —  
 22-26 wks (n=71) 0.1 (-2.4, 2.5) -7.4 (-14.1,-0.7) 0.9 (-2.1, 4.0) 1.5 (0.1, 3.0) —  
 32-36 wks (n=70) 0.4 (-2.3,3.1) -10.0(-17.5, -2.3) 1.0 (-2.0,4.1) 1.9 (0.6, 3.2) —  
 The effect size of maternal HDL-C measured between 32-36 wks gestation on aBW  
 HDL quartile x± SD (mg/dL) Mean difference in aBW (g)    
 Normal weight      
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 1(lowest) 60.3±3.5 Reference    
 2 70.4±3.0 -36.5 (-86.9, 14.1)    
 3 80.5±2.8 72.7 (-173.7, 28.3)    
 4 100.3±11.5 -144 (-344,56)    
 Obese/Overweight       
 1(lowest) 60.0±4.1 Reference    
 2 68.8±1.9 -88 (-154, -20.2)    
 3 79.1±4.3 -191 (-334.3, -43.9)    
 4 94.7±8.2 -347 (607.3, -79.8)    
Zawiej
ska et 
al. 
2008 
mmol/L 
(Median, 25th -75th) 
— 1.87(1.59,2.26) — 2.45(3.22,4.24) — 
Statistical software: SPSS 12.0 
P<0.05 was considered statistically significant. 
Birthweight (g) 
R2, F, p 
— ND — 
R2 = 0.02 
 F = 9.43 
P < 0.01 
— Linear regression analyses. 
 
Macrosomia 
(RR,95%CI, p) 
 
0.59(0.32,1.02) 
P=0.051 
 ND  
Data were provided by the author through email. 
Population: non-obese GDM women  
 
Chi-square statistics. 
Clause
n et al. 
2005 
mmol/L 
(median, 25th -75th) 
5.3(4.8,5.9) 1.8 (1.5,2.0) 2.8 (2.3,3.3) 1.5 (1.2,1.9)  
Statistical software: SPSS 11.0 
P<0.05 was considered statistically significant. 
Macrosomia (OR, 95%CI)  
Triglycerides (case/all) unadjusted OR Model A Model B Model C Model D 
Q, quartile 
Univariate logistic regression was used to calculate 
unadjusted OR value. 
Multiple logistic regression analyses was performed in Model 
A, B, C and D. 
Variables in model A: first trimester BMI; 
Model B: age, parity smoking 
Model C: age, parity, smoking, weight gain, placental weight, 
gestational diabetes 
Model D: model C+ first trimester BMI 
Q1 (10/437) 1.0 1.0 1.0 1.0 1.0 
Q2 (28/668) 1.9 (0.9-3.9) 1.7(0.8-3.6) 1.9(0.9-3.9) 1.6(0.7-3.3) 1.4(0.7-3.1) 
Q3 (15/394) 1.7(0.8-3.8) 1.4(0.6-3.2) 1.7(0.7-3.8) 1.4(0.6-3.2) 1.3(0.5-2.9) 
Q4 (35/551) 2.9(1.4-5.9) 2.2(1.1-4.6) 2.9(1.4-5.9) 2.5(1.2-5.2) 1.9(0.9-4.1) 
 P trend 0.004 0.062 0.004 0.016 0.121 
 TC (case/all) unadjusted OR Model A Model B Model C Model D 
 Q1 (20/497) 1.0 1.0 1.0 1.0 1.0 
 Q2 (19/565) 0.8(0.4-1.6) 0.8(0.4-1.5) 0.8(0.4-1.6) 0.7(0.4-1.4) 0.7(0.3-1.3) 
 Q3 (25/448) 1.4(0.8-2.6) 1.4(0.7-2.5) 1.4(0.8-2.5) 1.3(0.7-2.4) 1.4(0.7-2.6) 
 Q4 (24/540) 1.1(0.6-2.0) 1.0(0.5-1.8) 1.1(0.6-2.0) 0.9(0.5-1.7) 0.9(0.5-1.7) 
 P trend 0.397 0.610 0.451 0.751 0.737 
 HDL-C(case/all) unadjusted OR Model A Model B Model C Model D 
 Q1 (38/509) 1.0 1.0 1.0 1.0 1.0 
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 Q2 (18/498) 0.5(0.3-0.8) 0.5(0.3-0.9) 0.5(0.3-0.8) 0.3(0.3-0.9) 0.6(0.3-1.0) 
 Q3 (18/527) 0.4(0.2-0.8) 0.5(0.3-1.0) 0.4(0.2-0.7) 0.5(0.2-0.8) 0.3(0.3-1.0) 
 Q4 (14/516) 0.3(0.2-0.6) 0.4(0.2-0.8) 0.3(0.2-0.6) 0.4(0.2-0.7) 0.4(0.2-0.8) 
 P trend <0.001 0.008 <0.001 0.001 0.009 
 Non-HLD-C(case/all) unadjusted OR Model A Model B Model C Model D 
 Q1 (16/519) 1.0 1.0 1.0 1.0 1.0 
 Q2 (19/530) 1.2(0.6-2.3) 1.2(0.6-2.3) 1.2(0.6-2.3) 1.0(0.5-2.0) 1.0(0.5-2.1) 
 Q3 (21/500) 1.4(0.7-2.7) 1.3(0.7-2.5) 1.4(0.7-2.7) 1.2(0.6-2.5) 1.3(0.7-2.7) 
 Q4 (32/499) 2.2(1.2-4.0) 1.9(1.0-3.5) 2.1(1.2-3.9) 1.8(1.0-3.5) 1.9(1.0-3.6) 
 P trend 0.009 0.034 0.011 0.036 0.035 
Mathe
ws et 
al. 
2003 
mmol/L (median, 5th -9th) Statistical software: SPSS 10.0 
Early pregnancy 
(n=733) 
5.59(4.30,7.45) — — — — P<0.05 was considered statistically significant. P value 
cautiously throughout and considered value <0.05 but >0.01 
as marginal 
Later pregnancy 
(n=537) 
6.91(5.30,9.14) — — — — 
Birthweight (g, β, 95%CI) 
Multiple linear regression model adjusted for maternal 
smoking status and height, infant’ gender, gestational age. 
 Early pregnancy 
(≈16wks, n=733) 
30.1(1.21.58,9) 
P=0.041 
— — — — 
 Later pregnancy 
(≈28wks n=537) 
11.1(-18.0, 40.3) 
P= 0.453 
— — — — 
Olmos 
et al. 
2014 
mmol/L (x ± SD )      Statistical software: PASW statistics version 18.00, GraphPad 
Prism 5.0 for Windows. 
P<0.05 was considered statistically significant. 
2nd trimester 
_Normal weight 
ND ND — 1.99±0.65 — 
2nd trimester 
_Overweight 
ND ND — 2.29±0.75 — 
2nd trimester _Obese ND ND — 2.35±0.71 — 
3rd trimester _ 
Normal weight 
ND ND — 2.59±0.76 — 
 3rd trimester _ 
Overweight 
ND ND — 2.76±0.91 — 
 3rd trimester _ Obese ND ND — 2.88±0.92 — 
 Newborn weight z-score (r, p) Maternal lipids z score – newborn weight z score 
 Normal weight (n=128) ND ND — r=0.12,p=0.158 — Linear regression model. 
 Overweight (n=105) ND ND — r=0.42,p<0.001 —  
 Obese (n=46) ND ND — r=0.47,p<0.001 —  
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Emet 
et al. 
2013 
mg/dL(x ± SD )      Statistical software: SPSS 15.05 
P<0.05 was considered statistically significant. 
 
1st trimester 166.20±28.28 53.37±10.51 93.75±23.22 93.09±45.57 — 
3rd trimester 271.28±47.81 63.54±21.16 154.58±44.15 274.10±101.89 — 
Birthweight (p) 0.616 0.754 0.440 0.033 — Changed maternal lipid levels - birthweight 
Neonatal weight in 3rd 
postnatal month (p) 
0.2678 0.860 0.769 0.138 — Pearson correlation analyses. 
Liu et 
al. 
2016 
mmol/L(x ± SD )      
Statistical software: SPSS 17.00 
P<0.05 was considered statistically significant. 
GDM 6.09±0.86 1.82±0.35 3.26±0.86 2.31±0.84 —  
NGT 3.30±0.81 1.85±0.33 3.30±0.81 2.09±0.76 —  
Birth weight (r, p) 0.018, p=0.518 -0.011, p=0.701 -0.005, p=0.843 0.100, p<0.001 — 
Partial correlation adjusted for gestational age and pre-gravid 
BMI 
Birthweight (β, SE, p) ND ND ND 
0.070, 
SE=13.235 
P=0.001 
— 
Multiple linear regression model including First Visit FPG, 
OGTT FPG, triglyceride, Apolipoprotein E, pre-gravid BMI, 
GDM, gestational age. 
Brunn
er et 
al. 
2013 
mg/dL (x ± SD ) — — — 197.0±66.2 — 
Statistical software: R version 2.8.1, PASW version 18.0.  
A tow-sided P-value<0.05 was considered statistically 
significant. 
Maternal lipid levels at gestation weeks 32 (β,95%CI)  
Birthweight(g) — — — 
-0.54 
(-1.56, 0.49) 
— 
Data were provided by authors through email. 
 
 
Multiple linear regression model, including the covariates 
maternal pre-pregnancy BMI, gestational weight gain, 
maternal glucose tolerance status, pregnancy duration, sex 
and group allocation for the data at birth, and, additionally, 
poderal index at birth and mode of infant feeding at the later 
time points, were performed. 
 
Ponderal index 
(kg/m3) 
— — — 
-0.00  
(-0.01, 0) 
— 
6 weeks postpartum 
weight (g)  
— — — 
-0.97  
(-2.33, 0.4) 
— 
6 weeks postpartum 
ponderal index (kg/m3) 
— — — 
-0.00  
(0, 0) 
— 
4 months postpartum 
weight (g) 
— — — 
-0.62  
(-2.27, 1.03) 
— 
4 months postpartum 
ponderal index (kg/m3) 
— — — 
0.01  
(0, 0.01) 
— 
1 year postpartum 
weight (g) 
— — — 
-1.46 
 (-3.83, 0.92) 
— 
1 year postpartum 
ponderal index (kg/m3) 
— — — 
-0.00  
(-0.01, 0) 
— 
1 year postpartum — — — -0.00 — 
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BMI (kg/m2)  (0, 0) 
No significant relationships were found for maternal triglyceride levels at 32nd gestation week with 
birthweight and Ponderal index (or BMI) at delivery, 6 weeks, 1 years and 2 years post-partum, and also 
with weight gain after birth at any time point. 
 
The change in maternal serum triglyceride concentration between the 15th and 32nd week of gestation was 
weakly, but significantly associated with infant ponderal index at 4 months post-partum (badj: 0.001 (0-0.01) 
kg/m3, P=0.020), but not with any of the other growth or body composition outcomes up to 2 years post-
partum. 
Knopp 
et al. 
1992 
mM (x ± SD )      Statistical software: No statement. 
NS- (n=521) — — — 1.86±0.68 —  
PS+ (n=264) — — — 1.92±0.68 —  
GDM (n=96) — — — 2.29±0.68 —  
Birthweight ratio      Univariate Spearman’s correlation coefficients  
 NS- — — — 0.09 (p≤0.05) —  
 PS+ — — — 0.13(p≤0.05) —  
 GDM — — — 0.11 —  
 PS+ plus GDM — — — 0.16(p≤0.01) —  
 ALL — — — 0.12(p≤0.01) —  
Knopp 
et al. 
1985 
  HDL-C LDL-C VLDL-C FFAs  
Spearman rank correlation coefficients indicate the linear 
relationship between all pairs of variable. 
Separman pairwise correlation coefficients 
Birth weight (n=273) — -0.06 0.003 0.05 -0.06 
Birth weight ratio 
(n=248) 
— -0.06 0.01 0.03 0.002 
Standardized regression coefficients Structured multiple regression analyses. Variables in very 
unit were entered the regression equation sequentially and in 
a predefined order. 
Unit I: VLDL-C, VLDL-TG,LDL-C, HDL-TG 
Unit II: Glucose, insulin, FFA, HPL, progresterone, estradiol 
and estriol 
 Birth weight (n-272) — -0.15 0.04 -0.14 0.05 
 Birth weight ratio 
(n=247) 
— -0.13 0.01 -0.30, p<0.05 -0.09 
Schaef
er-
Graf et 
al. 
2011 
 mmol/L   mmol/L mol/L Statistical software: SPSS 16.0 
x ± SD  6.56±0.11 — — 2.84±0.08 320±14 P<0.05 was considered statistically significant. 
A significant lineal positive correlation between maternal and cord blood serum was found for log 
transformed FFAs (r=0.1886, p=0.0172).  
None of the maternal metabolic variables measured correlated to neonatal body weight. 
Pearson correlation coefficients were calculated to evaluate 
the correlations between different variables. 
Nolan TG (r, p) Asian-born GDM (n=38) Asian & GDM Overall  Statistical software: SPSS-PC software package 
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Study 
ID 
 Maternal lipids 
Statistical Methods 
 TC HDL-C LDL-C TG FFAs 
et al. 
1995 
(n=97) (n=18) (n=388) 
Birth weight ratio  
(univariate analyses) 
0.23, p=0.02 0.37, p=0.023 0.63, p=0.005 0.12, p=0.02 — 
All statistical tests were two-tailed, and a P value of <0.05 
was considered significant. 
Birth weight ratio 
(multiple regression) 
ND P=0.004 ND ND — 
Within the total GDM subgroup, using multiple regression 
analyses to control for the maternal factors of BMI and rate of 
maternal weight gain.  
Friis et 
al. 
2012 
mmol/L(x ± SD ) 6.96±1.20 1.71±0.37 — 2.01±0.65 0.44±0.13 
Statistical software: SPSS 18.0. 
All p-values ,0.05 were considered statistically significant. 
Birthweight 
(β,95%CI, p) 
p>0.05 
-170 (-329, -9) 
P=0.04 
— 
94(2,187) 
P=0.046 
p>0.05 
Multiple linear regression model adjusted for gestational age 
at birth. 
Lei et 
al. 
2016 
mmol/L(median, IQR) — 1.46 (1.3-1.7) — 2.71(2.12-3.49) — Statistical software: SPSS 22.0. 
OR (95%CI) 
TG 
(<3.49 mmol/L) 
TG 
(≥3.49 mmol/L) 
HDL-C 
(≥1.3 mmol/L) 
HDL-C 
(<1.3 mmol/L) 
 Logistic regression. 
LGA 1 (Ref) 1.6 (1.42-2.01) 1 (Ref) 1.33(1.12-1.58) —  
SGA 1 (Ref) 1.51(1.08-2.12) 1 (Ref) 0.88(0.62-1.25) —  
Kitaji
ma et 
al. 
2001 
 mg/dL   mg/dL mEq/dL Statistical software: SAS 5.0 
x ± SD 263.6±46.2 — — 213.9±77.7 70.3±12.3 P<0.05 was defined as significant 
Birthweight (r, p) 0.01, p=0.99 — — 0.22, p=0.009 0.03, p=0.73 Univariable linear regression. 
Birthweight (F,p) ND — — 6.3, p=0.014 ND 
After controlling for fasting plasma glucose, prepregnant 
BMI, maternal weight gain during pregnancy, gestational age 
at delivery, neonatal gender. 
 
 
Hypertriglyceri
demia 
Normal 
triglyceride 
p Crude OR(95%CI) 2 test 
 LGA 4 1 
0.012 14.8 (1.59, 137.38) 
 
 Non-LGA 30 111  
  LGA Adjusted OR 95%CI p   Logistic regression model adjusted for fasting plasma glucose 
levels, prepregnant BMI, and weight gain during pregnancy  Hypertriglyceridemia 11.6 (1.1 - 122) 0.04   
Mossa
yebi et 
al. 
2014 
mg/dL (x ± SD) 201.4±38.4 46.6±4.36 115.3±34.9 197.5±51.9 — Statistical software: SPSS 20.0 
Birthweight (g)      P<0.05 was defined as significant 
r, p 0.50, p<0.001 -0.47, p<0.001 0.40, p<0.001 0.68, p<0.001 — Pearson correlation analyses. 
β, SE ND ND ND 5.24, SE=0.54 — 
Stepwise linear regression adjusted for male gender of the 
child 
Standardized β, p ND ND ND 0.59, p<0.001 —  
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Study 
ID 
 Maternal lipids 
Statistical Methods 
 TC HDL-C LDL-C TG FFAs 
 Macrosomia    TG TG z score Forward stepwise logistic regression analyses 
 
β, SE, p ND ND ND 
0.04, SE=0.01 
P<0.001 
ND Adjusted for maternal age, weight prior to pregnancy, FBS 
and cholesterol. 
 OR (95% CI) ND ND ND 1.044(1.02-1.07) 9.44(2.86-31.16) 
 LGA      Forward stepwise logistic regression analyses 
 
β, SE, p ND ND ND 
0.03, SE=0.01 
P<0.001 
ND Adjusted for maternal age, weight prior to pregnancy, FBS 
and cholesterol. 
 OR (95% CI) ND ND ND 1.035(1.02, 1.05) 5.90 (2.68-13.00) 
 LGA all Case(proportion) Crude OR(95%CI) aOR (95%CI)   
 Total cholesterol:      Logistic regression model 
 Q1:<172 39 2 (5.1) 1 (Ref) 1 (Ref)  
Variables in model: mother’s age, weight prior to pregnancy, 
FBS, triglyceride, cholesterol, and child gender. If the 
categorical variable was one of these confounders or had 
colinearity with other variables, we excluded that variable 
and only the categorical variable was entered. 
 Q2:172.1-199.9 35 6 (17.1) 3.8 (0.7-20.4) 2.3 (0.4-15.2)  
 Q3:200-234.9 37 9 (24.3) 5.9 (1.2-29.7) 1.2 (0.2-8.6)  
 Q4:≥235 43 18 (41.9) 13.3 (2.8-62.5) 1.1 (0.2-8.1)  
 HDL:      
 Q1: ≤43 40 18 (45.0) 16.4 (3.5-77.2) 0.6 (0.07-5.3)  
 Q2:43.1-46 37 10 (27.0) 7.4 (1.5-36.5) 0.08 (0.08-5.6)  
 Q3:46.1-49.9 35 5 (14.3) 3.3 (0.6-18.4) 1.7 (0.2-11.6)  
 Q4: ≥50 42 2 (4.8) 1 (Ref) 1 (Ref)  
 LDL:      
 Q1: <88 38 3 (7.9) 1 (Ref) 1 (Ref)  
 Q2:88.1-113 40 9 (22.5) 3.4 (0.8-13.6) 2.04 (0.4-10.9)  
 Q3:113.1-143.9 37 10 (27) 4.3 (1.1- 17.3) 0.6 (0.1-4.03)  
 Q4: ≥144 39 13 (33.3) 5.8 (1.5-22.6) 0.8 (0.1-4.4)  
 Triglyceride:      
 Q1: <170 37 2 (5.4) 1 (Ref) 1 (Ref)  
 Q2:170-199.9 37 0 (0) 0 0  
 Q3:200-299.9 37 6 (16.2) 3.4 (0.6-18) 3.2 (0.5-20.7)  
 Q4: ≥230 43 27 (62.8) 29.5 (6.2-139.6) 28.2 (3.5-230.3)  
Gerag
hty et 
al. 
2016 
mmol/L (median, IQR)     Statistical software: SPSS 20.0 
Early pregnancy 
(n=284) 
4.58 (3.87-5.39) 0.64(0.46-0.97) 3.31(2.66-3.94) 1.31(0.80-1.35) —  
Late pregnancy 
(n=293) 
6.02(5.00-6.87) 0.85(0.54-1.13) 4.15(3.43-5.06) 1.71(1.28-2.19) —  
Early pregnancy      ×:p>0.1, statistically insignificant; 
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Study 
ID 
 Maternal lipids 
Statistical Methods 
 TC HDL-C LDL-C TG FFAs 
 Birth weight × × × × — √:p<0.1, statistically significant 
Pearson correlation was used, and Spearman’s correlation for 
the nonparametric data to individually measure the 
correlation between each blood lipid (in early and late 
pregnancy and cord blood), HOMA, C-peptide and leptin 
concentration and each of the anthropometric measures of 
child weight and adiposity (at birth, 6 months and 2 years of 
age). 
Bivariate associations at a significance of P < 0.1 were 
considered significant 
 Sum of skinfold × × × √ — 
 2 year weight centile √ × × × — 
 2 years old  
waist: length ratio 
× √ × × — 
 2 years old sum of 
skinfold 
× × √ × — 
 Late pregnancy      
 Birth weight × × × √ — 
 Sum of skinfold × √ × √ — 
 2 year weight centile √ × √ √ — 
 2 years old  
waist: length ratio 
× √ × × — 
 2 years old sum of 
skinfold 
× × × × — 
 
Birthweight (g) 
(β, p, 95%CI) 
ND ND ND 
β=111.17 
p=0.034 
(8.48, 213.87) 
— 
Multiple regression model controlling for confounders (at 
birth: mother’s BMI, gestational age, infant gender, mother’s 
education and smoking status, and at 6-month and 2-years: 
infant gender, age at data collection, mother’s education 
status and breastfeeding), outcomes associated with maternal 
blood parameters were birth weight, birth weight centile, and 
weight at 6 months. 
The final multiple linear regression models that were 
statistically significant (P < 0.05) were reported as the best 
predictors of infant weight and adiposity. 
 Birthweight centile × × × √ — 
 2 years old weight  × × × × — 
 Subgroup analyses_ late pregnancy (r2, p)    
 Birthweight  
(BMI< 25kg/m2) 
ND ND ND 
R2=0.0003, 
p=0.92 
— 
 Birthweight  
(BMI≥25kg/m2) 
ND ND ND 
R2=0.08, 
P=0.008 
— 
  Birthweight(g) (β,95%CI) Data were provided by authors through email. 
 
Early pregnancy 
27.87 
(-17.89,73.63) 
-1236.25 
(-3322.95, 850.45) 
18.39 
(-38.44, 75.21) 
ND — 
Multiple regression model (controlling for mother’s BMI, 
gestational age, infant gender, mother’s education and 
smoking status)  
Late pregnancy 
24.85 
(-9.39, 59.09) 
30.00 
(-114.85, 174.84) 
19.97 
(-24.34, 64.27) 
111.18 
(8.48, 213.87) 
— 
 Sum of skinfolds (β,95%CI) 
 
Early pregnancy 
0.23 
(-0.96, 1.41) 
-1.59 
(-5.68, 2.51) 
0.19 
(-1.19, 1.56) 
ND — 
 
Late pregnancy 
0.61 
(-0.49, 1.71) 
-0.16 
(-4.24, 3.92) 
0.46 
(-0.74, 1.66) 
ND — 
 Weight at 2 years(kg) (β,95%CI) Multiple regression model (controlling for infant gender, age 
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Study 
ID 
 Maternal lipids 
Statistical Methods 
 TC HDL-C LDL-C TG FFAs 
 
Early pregnancy 
0.15 
(-0.14, 0.44) 
0.24 
(-0.82, 1.29) 
0.12 
(-0.23, 0.47) 
0.71 
(-0.06, 1.48) 
 
at data collection, mother’s education status and 
breastfeeding) 
 
Late pregnancy 
0.23 
(-0.02, 0.48) 
0.16 
(-0.77, 1.09) 
0.27 
(-0.05, 0.58) 
0.47 
(-0.05, 0.99) 
 
Jin et 
al. 
2016 
mmol/L (median, IQR) Statistical software: SPSS 19.0 
1st (7-10 weeks) 3.95 (3.66-4.60) 1.66 (1.45-1.77) 2.25 (2.08-2.45) 2.20 (1.77-2.73) — P values < 0.05 were defined as statistically significant. 
2nd (21-24 weeks) 4.65 (4.22-5.10) 1.67 (1.47-1.79) 2.46 (2.22-2.77) 2.45 (2.11-2.89) —  
3rd (33-37 weeks) 6.27 (5.52-7.03) 1.80 (1.57-2.04) 2.87 (2.32-3.45) 3.06 (2.37-3.98) —  
1st trimester (Adjusted OR, 95%CI, p) 
Forward stepwise logistic regression analysis. 
Odds ratios were adjusted for maternal age, prepregnancy 
BMI, gestational weight gain, parity, maternal education 
background, family income and cigarette exposure. Values of 
macrosomia and SGA were additionally corrected for 
delivery mode and infant sex. 
SGA ND 
1.31 (0.32-5.38)  
P=0.709 
ND ND — 
 
Macrosomia ND 
0.51 (0.19-1.36) 
P=0.178 
ND ND — 
 2nd trimester (Adjusted OR, 95%CI, p) 
 
SGA ND 
1.88 (0.47-7.59) 
P=0.377 
ND ND — 
 
Macrosomia ND 
0.25 (0.09-0.73) 
P=0.011 
ND ND — 
 3rd trimester (Adjusted OR, 95%CI, p) 
Odds ratios were adjusted for maternal age, prepregnancy 
BMI, gestational weight gain, parity, maternal education 
background, family income and cigarette exposure. Values of 
PTB, SGA, LGA and macrosomia were additionally 
corrected for delivery mode and infant sex. 
 
SGA 
1.12 (0.80-1.56) 
P=0.520 
3.15 (1.15-8.65) 
P=0.026 
1.16 (0.71-1.89) 
P=0.565 
0.63 (0.40-0.99) 
P=0.046 
— 
 
LGA 
0.98 (0.86-1.11) 
P=0.715 
0.79 (0.52-1.21) 
P=0.281 
0.93 (0.78-1.11) 
P=0.418 
1.13 (1.02-1.26) 
P=0.025 
— 
 
Macrosomia 
0.99 (0.81-1.21) 
P=0.903 
0.46 (0.22-0.94) 
P=0.034 
0.93 (0.69-1.25) 
P=0.621 
1.19 (1.02-1.39) 
P=0.024 
— 
Tian et 
al. 
2013 
OR (95%CI)    ≥2.27mmol/L  No statement on statistic software and method. 
Macrosomia — — — 2.20 (1.54-3.14) —  
Couch 
et al. 
1998 
In control group, maternal plasma TG is positively associated with birthweight (r=0.46,p≤0.05) 
In control group, maternal HDL-C significantly correlated with cord vein TC (r=0.51,p≤0.05). Maternal TG 
significantly correlated with cord vein FFAs (r=0.47, p≤0.05).  
In GDM group, maternal TC significantly correlated with cord vein VLDL+LDL-C (r=0.48, p≤0.05). 
Software: Statistical Analysis Systems Program 
Pearson correlation analyses 
Ortega 
et al. 
1996 
 TC HDL-C LDL-C TG VLDL-C Statistical software: No statement  
mmol/L (x ± SD) 6.82±1.16 1.62±0.34 4.07±1.07 2.43±0.83 1.11±0.38 P<0.05 were considered to indicate statistical significance. 
Newborn lipids (r, p)       
TC 0.3298, p<0.05 ND 0.3204, p<0.05 ND ND Spearman’s rank correlation 
 HDL-C 0.2575, p<0.05 ND ND ND ND  
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Study 
ID 
 Maternal lipids 
Statistical Methods 
 TC HDL-C LDL-C TG FFAs 
 LDL-C 0.3053, p<0.05 ND 0.3507, p<0.05 ND ND  
 TG ND ND ND ND ND  
 VLDL-C ND ND ND ND ND  
 
mmol/L 
Maternal TC<7.55 mmol/L 
(n=215) 
Maternal TC≥7.55 mmol/L 
(n=77) 
p Student t test. 
 TC(x ± SD) 1.65±0.47 2.10±0.54 <0.05  
 HDL-C(x ± SD) 0.63±0.25 0.75±0.21 <0.05  
 LDL-C(x ± SD) 0.78±0.36 1.14±0.40 <0.05  
 TG(x ± SD) 0.48±0.22 0.45±0.20 >0.05  
 VLDL-C(x ± SD) 0.22±0.10 0.21±0.09 >0.05  
 TC/HDL-C(x ± SD) 2.62±0.40 2.81±0.35 <0.05  
 Birthweight (g, x ± SD) 3301.5±406.6 3234.5±411.5 >0.05  
Alberti
-
Fidanz
a, et al. 
1995 
Maternal HDL-C levels in the 2nd trimester is significantly associated with cord blood triglycerides among 
all nowborns (r=-0.53, p=0.0131, n=21).  
For girls (n=7), maternal HDL-C levels in the 1st (r=-0.86, p=0.0138) and 2nd (r=-0.83, p=0.0218) trimester 
is significant associated with cord blood TG respectively. Maternal triglycerides measured in the 2nd 
trimester is correlated with cord blood TC level (r=0.80, p=0.0315). No correlation was observed among 
boys. 
Pearson linear correlation. 
Brocke
rhoff 
1986 
 
r, p  HDL LDL VLDL  No statement on statistic methods. 
Cord blood TC  0.484 0.082 0.828, P<0.01   
Cord blood TG  0.063 0.246 0.568, P<0.01   
Robin 
et al. 
2007 
Birthweight, g Mean(SD) 
Unadjusted 
mean 
difference, p 
Adjusted mean 
difference, p 
  
Unadjusted mean difference was assessed using 1-way 
analysis of variance, comparing low-TC or high-TC group 
with mid-TC reference group. 
Adjusted mean difference was assessed using multivariate 
linear regression; model adjusted for infant gender, fractional 
week of GA within the term interval, maternal weight in 
pounds, maternal age group, and race in pooled analyses. 
Outliers measurement were excluded from the adjusted 
model. 
Mid-TC group 3484(482) Ref Ref   
Low-TC group 3360(442) -124, 0.015 -150, 0.001   
High-TC group 3504(471) +20, 0.69 +29, 0.47   
Charle
s et al. 
2016 
Birthweight (r, p) 
-0.103, 
p<0.0001 
-0.139, 
p<0.0001 
0.001, 
p<0.0001 
-0.014, p<0.0001 — 
No statement on statistical software as well as statistical 
significant level.  
Pearson correlation. 
ND: No documented. 
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S6 Appendix Quality assessment form 
Study ID 
Selection Comparability Outcome Overall 
Score A1 A2 A3 A4 B1 B2 C1 C2 C3 
Harmon et al.2011 0 1 1 1 0 0 0 1 1 5 
Son et al.2010 0 1 1 1 0 0 0 1 1 5 
Di et al.2005 0 1 1 1 0 0 0 1 1 5 
Schaefer-Graf et al.2008 0 1 1 1 0 0 0 1 1 5 
Slagjana et al.2014 0 1 1 1 0 0 0 1 1 5 
Zhou et al.2012 0 1 1 1 0 0 0 1 1 5 
Zawiejska et al.2008 0 1 1 1 0 0 0 1 1 5 
Emet et al.2013 0 1 1 1 0 0 0 1 1 5 
Schaefer-Graf et al.2011 0 1 1 1 0 0 0 1 1 5 
Mossayebi et al.2014 0 1 1 1 0 0 0 1 1 5 
Swierzewska et al.2015 0 1 1 1 0 0 0 1 1 5 
Ortega et al.1996 0 1 1 1 0 0 0 1 1 5 
Alberti-Fidanza et al.1995 0 1 1 1 0 0 1 1 0 5 
Charles et al. 2016 0 1 1 1 0 0 0 1 1 5 
Wang et al.2015 0 1 1 1 1 0 0 1 1 6 
Ahmad et al.2006 0 1 1 1 1 0 0 1 1 6 
Whyte et al. 2013 0 1 1 1 0 0 1 1 1 6 
Vinod et al. 2011 0 1 1 1 1 0 0 1 1 6 
Olmos et al.2014 0 1 1 1 1 0 0 1 1 6 
Knopp et al.1992 0 1 1 1 1 0 0 1 1 6 
Nolan et al.1995 0 1 1 1 1 0 0 1 1 6 
Friis et al.2012 0 1 1 1 1 0 0 1 1 6 
Lei et al.2016 0 1 1 1 1 0 0 1 1 6 
Kitajima et al.2001 0 1 1 1 1 0 0 1 1 6 
Couch et al.1998 0 1 1 1 0 0 1 1 1 6 
Brockerhoff 1986 0 1 1 1 0 0 1 1 1 6 
Retnakaran et al.2012 0 1 1 1 1 1 0 1 1 7 
Hou et al.2014 0 1 1 1 1 1 0 1 1 7 
Laleh et al.2013 0 1 1 1 1 1 0 1 1 7 
Liu et al.2016 0 1 1 1 1 0 1 1 1 7 
Brunner et al.2013 0 1 1 1 1 0 1 1 1 7 
Knopp et al.1985 0 1 1 1 1 0 1 1 1 7 
Geraghty et al.2016 0 1 1 1 1 1 0 1 1 7 
Jin et al.2016 0 1 1 1 1 1 0 1 1 7 
Robin et al. 2007 0 1 1 1 1 1 0 1 1 7 
Ye et al.2015 0 1 1 1 1 1 1 1 1 8 
Crume et al.2015 0 1 1 1 1 1 1 1 1 8 
Hwang et al.2015 0 1 1 1 1 1 1 1 1 8 
Kulkarni et al.2013 1 1 1 1 0 1 1 1 1 8 
Vrijkotte et al.2012 0 1 1 1 1 1 1 1 1 8 
Kramer et al.2014 0 1 1 1 1 1 1 1 1 8 
Vrijkotte et al. 2011 0 1 1 1 1 1 1 1 1 8 
Clausen et al.2005 1 1 1 1 0 1 1 1 1 8 
Mathews et al.2003 0 1 1 1 1 1 1 1 1 8 
Sommer et al.2015 1 1 1 1 1 1 1 1 1 9 
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S7 Appendix Data analysis for birthweight 
Data summary 
S7.1 Table Results summary of the association of maternal lipid levels with birthweight throughout pregnancy 
 
Maternal lipids Trimester 
Negative 
associations 
No direction 
Positive 
associations 
Total 
TC 
The first trimester 1 1 2(1) 4 
The second trimester 1 4 7(2) 12 
The third trimester 3(1) 12 8(3) 23 
HDL-C 
The first trimester 2(1) 0 0 2 
The second trimester 6(2) 4 1 11 
The third trimester 11(6) 6 1 18 
LDL-C 
The first trimester 1 0 1 2 
The second trimester 1 5 2 8 
The third trimester 2 5 7(3) 15 
TG 
The first trimester 0 1 4(3) 5 
The second trimester 0 2 10(8) 12 
The third trimester 3(1) 4 20(14) 27 
VLDL 
The first trimester 0 0 0 0 
The second trimester 0 0 0 0 
The third trimester 0 1 1 2 
FFAs 
The first trimester 0 1 0 1 
The second trimester 0 0 1 1 
The third trimester 0 3 4(2) 7 
1. This table summarised the results distribution of studies that reported the association of maternal lipid levels with 
birthweight throughout pregnancy; 
2. Number in this table represent the number of studies; 
3. 'No direction' means that the number of studies reported statistically insignificant results without its direction, as well as 
the number of studies did not report their results; 
4. Number in the bracket means the number of studies reported statistically significant results; 
5. Abbreviation: Total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol 
(LDL-C), very low-density lipoprotein cholesterol (VLDL-C), triglycerides (TG) and free fatty acids (FFAs). 
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Total cholesterol (TC) 
S7.2 Table Results summary of the association of maternal TC level with birthweight 
ID Population Countries 
Sample 
size 
Tri. 
Reported 
measures 
Effect 
size 
Lower 
95%CI 
Upper 
95%CI 
p 
Statistical 
methods 
Quality 
The control of confounding factors 
a b c d e f g h 
Vinod et al.2011(1) Normal weight USA 65 1 Crude β -19.33  -120.03  81.36  ND SLR 6 × × × × × × × × 
Vinod et al.2011(2) Overweight/obese USA 71 1 Crude β 58.00  -67.86  183.87  ND SLR 6 × × × × × × × × 
Vrijkotte et al.2011 General Netherlands 2,052 1 Crude β 11.82  -10.00  33.65  ND Univariate analyses 8 √ √ × × × × √ × 
Vrijkotte et al.2011 General Netherlands 2,052 1 Adjusted β 22.67  4.00  41.33  ND MLR 8 √ √ √ √ √ × √ × 
Nolan et al.1995 General Australia 388 1 ND ND 
  
ND ND 6 ND ND ND ND ND ND × ND 
Liu et al.2016 General China 1,546 2 r 0.02  
  
0.518 Partial correlation 7 × × × × × × × × 
Vinod et al.2011(1) Normal weight USA 71 2 Crude β -50.27  -112.24  11.69  ND SLR 6 × × × × × × × × 
Vinod et al.2011(2) Overweight/obese USA 71 2 Crude β 3.87  -91.02  98.75  ND SLR 6 × × × × × × × × 
Mathews et al.2003 General UK 733 2 Adjusted β 30.10  1.21  58.90  ND MLR 8 √ √ × × × × √ × 
Crume et al.2015 General USA 804 2 Adjusted β 17.79  -11.82  47.39  0.200 MLR 8 √ √ √ × × × √ × 
Kulkarni et al.2013 non-GDM India 631 2 Adjusted β 39.07  10.57  67.58  ND MLR 8 × √ √ √ × × √ × 
Geraghty et al.2016 non-GDM UK 331 2 Adjusted β 27.87  -17.89  73.63  ND MLR 7 √ √ × √ √ × × × 
Whyte et al. 2013 General Ireland 189 2 ND ND 
  
ND ND 6 ND ND ND ND ND ND × ND 
Wang et al.2015 General China 636 2 ND ND 
  
ND Partial correlation 6 √ √ × × × × × × 
Di et al.2005 OGTT+ Italy 83 2 ND ND 
  
ND ND 5 ND ND ND ND ND ND × ND 
Olmos et al.2014 GDM Chile 279 2 ND ND 
  
ND ND 6 ND ND ND ND ND ND × ND 
Mossayebi et al.2014 General Iran 154 3 r 0.50  
  
<0.001 Pearson correlation 5 × × × × × × √ × 
Charles et al. 2016 General Multiple 1062 3 r -0.103   <0.0001 Pearson correlation 4 × × × × × × × × 
Ahmad et al. 2006 non-GDM Malaysia 246 3 r 0.16  
  
0.021 Univariate analyses 6 √ × × × × × √ × 
Kitajima et al.2001 OGTT + Japan 146 3 r 0.01  
  
0.990 SLR 6 × × × × × × √ × 
Vinod et al.2011(1) Normal weight USA 69 3 Crude β -46.40  -118.05  25.24  ND SLR 6 × × × × × × × × 
Vinod et al.2011(2) Overweight/obese USA 70 3 Crude β 15.47  -89.10  120.03  ND SLR 6 × × × × × × × × 
Sommer et al.2015 General Norway 699 3 Crude β -4.20  -39.40  31.00  ND SLR 9 × × × × × × √ × 
Sommer et al.2015 General Norway 699 3 Adjusted β -6.10  -37.50  25.20  ND MLR 9 √ √ √ × × × √ × 
Mathews et al.2003 General UK 537 3 Adjusted β 11.10  -18.00  40.30  ND MLR 8 √ √ × × × × √ × 
Ye et al.2015 non-GDM China 1,243 3 Adjusted β 9.10  -6.40  24.60  ND MLR 8 √ √ √ √ √ √ √ × 
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ID Population Countries 
Sample 
size 
Tri. 
Reported 
measures 
Effect 
size 
Lower 
95%CI 
Upper 
95%CI 
p 
Statistical 
methods 
Quality 
The control of confounding factors 
a b c d e f g h 
Kulkarni et al.2013 non-GDM India 631 3 Adjusted β 54.34  24.85  83.88  ND MLR 8 × √ √ √ × × √ × 
Geraghty et al.2016 non-GDM UK 331 3 Adjusted β 24.85  -9.39  59.09  ND MLR 7 √ √ × √ √ × × × 
Couch et al.1998 General USA 40 3 p ND 
  
>0.05 Pearson correlation 6 × × × × × × × × 
Ortega et al.1996 General Spain 292 3 p ND 
  
>0.05 Student t test 5 × × × × × × √ × 
Swierzewska et al.2015 General Poland 136 3 p ND 
  
>0.05 MLR 5 ND ND ND ND ND ND × ND 
Emet et al.2013 General Turkey 801 3 p ND 
  
0.616 Pearson correlation 5 × × × × × × × × 
Friis et al.2012 General German 207 3 p ND 
  
>0.05 MLR 6 √ × × × × × × × 
Retnakaran et al.2012 non-GDM Canada 472 3 p 
   
0.500 
Analysis of variance for 
continuous variables 7 × × × × × × × × 
Schaefer-Graf et al.2011 non-GDM German 190 3 p ND 
  
>0.05 Pearson correlation 5 × × × × × × √ × 
Son et al.2010 GDM Korea 104 3 p ND 
  
>0.05 ND 5 ND ND ND ND ND ND √ ND 
Crume et al.2015 General USA 804 3 ND ND 
  
ND MLR 8 √ √ √ × × × √ × 
Slagjana et al.2014 non-GDM Yugoslavia 200 3 ND ND 
  
ND ND 5 ND ND ND ND ND ND × ND 
Olmos et al.2014 GDM Chile 279 3 ND ND 
  
ND ND 6 ND ND ND ND ND ND × ND 
Schaefer-Graf et al.2008 GDM German 150 3 ND ND 
  
ND Spearman correlation 5 × × × × × × × × 
Robin et al. 2007 General American 957 2  Adjusted MD(g) p MLR 7 √ √ √ × × × √ × 
   High-TC group (n=100) Ref group Ref group           
   Mid-TC group(n=757) 29 0.47           
   Low-TC group(n=100) -150 0.001           
The bold font represents statistically significant results. 
r: Correlation coefficients; β: regression coefficients.  
Confounding factors: a. Gestational age; b. Neonatal gender; c. Maternal age; d. Pre-pregnancy BMI; e. Gestational weight gain; f. Maternal glucose level; g. pre-term birth; h. Maternal lipid levels. 
Abbreviation: Trimesters(Tri.), Gestational diabetes mellitus(GDM), Positive screenes of Oral Glucose Tolerance test(OGTT+), Confidence interval(CI), Not documented(ND), Simple linear regression(SLR), 
Multiple linear regression(MLR), United Kingdom(UK), Mean difference(MD), Reference(Ref). 
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Meta-analysis 
S7.1 Figure Overall meta-analysis of crude regression coefficients for the association between maternal TC levels and 
birthweight throughout pregnancy 
 
 
 
S7.2 Figure Overall meta-analysis of adjusted regression coefficients for the association between maternal TC levels 
and birthweight throughout pregnancy 
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Subgroup analysis 
 
S7.3 Figure Adjusted regression coefficient_ General vs. non-GDM_ the 2nd trimester_ Random effect model 
 
 
 
S7.4 Figure Adjusted regression coefficient_ General vs. non-GDM_ the 3rd trimester_ Random effect model 
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Sensitivity analysis 
S7.5 Figure Adjusted regression coefficients_ exclude studies control for pre-pregnancy BMI or gestational weight gain  
 
S7.6 Figure Adjusted regression coefficients_ exclude studies control for maternal glucose level 
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S7.7 Figure Crude regression coefficients_ exclude studies control for pre-term birth 
 
S7.8 Figure Adjusted regression coefficients_ exclude studies that did not control for pre-term birth 
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High-Density lipoprotein Cholesterol (HDL-C) 
S7.3 Table Results summary of the association of maternal HDL-C level with birthweight 
 
ID Population Countries 
Sample 
size 
Tri. 
Reported 
measures 
Effect 
size 
Lower 
95%CI 
Upper 
95%CI 
p 
Statistical 
methods 
Quality 
The control of confounding factors 
a b C d e f g h 
Vinod et al.2011(1) normal weight USA 65 1 Crude β -81.21  -300.02  137.61  ND SLR 6 × × × × × × × × 
Vinod et al.2011(2) Overweight/obese USA 71 1 Crude β -309.36  -603.69  -15.03  ND SLR 6 × × × × × × × × 
Wang et al.2015 General China 636 2 r -0.12  
  
0.010 Partial correlation 6 √ √ × × × × × × 
Liu et al.2016 General China 1,546 2 r -0.01  
  
0.701 Partial correlation 7 × × × × × × × × 
Vinod et al.2011(1) Normal weight USA 71 2 Crude β -158.55  -340.57  23.48  ND SLR 6 × × × × × × × × 
Vinod et al.2011(2) Overweight/obese USA 71 2 Crude β -286.16  -545.63  -26.68  ND SLR 6 × × × × × × × × 
Crume et al.2015 General USA 804 2 Adjusted β -20.88  -109.69  67.93  0.600 MLR 8 √ √ √ × × × √ × 
Kulkarni  et al.2013 non-GDM India 631 2 Adjusted β 17.57  -11.64  46.77  ND MLR 8 × √ √ √ × × √ × 
Geraghty et al.2016 non-GDM UK 331 2 Adjusted β -1236.25  -3322.95  850.45  ND MLR 7 √ √ × √ √ × × × 
Whyte et al. 2013 General Ireland 189 2 ND ND 
  
ND ND 6 ND ND ND ND ND ND × ND 
Di et al.2005 OGTT+ Italy 83 2 ND ND 
  
ND ND 5 ND ND ND ND ND ND × ND 
Zawiejska et al. 2008 GDM Poland 357 2 ND ND 
  
ND ND 5 ND ND ND ND ND ND × ND 
Olmos et al.2014 GDM Chile 279 2 ND ND 
  
ND ND 6 ND ND ND ND ND ND × ND 
Knopp et al.1985 General USA 248 3 r -0.06  
  
>0.05 Spearman correlation 7 √ √ × × × × √ × 
Mossayebi et al.2014 General Iran 154 3 r -0.47  
  
<0.00
1 
Pearson correlation 5 × × × × × × √ × 
Charles et al. 2016 General Multiple 1062 3 r -0.139   <0.00
01 
Pearson correlation 4 × × × × × × × × 
Vinod et al.2011(1) Normal weight USA 69 3 Crude β -139.21  -332.85  54.43  ND SLR 6 × × × × × × × × 
Vinod et al.2011(2) Overweight/obese USA 70 3 Crude β -386.70  -681.03  -92.37  ND SLR 6 × × × × × × × × 
Sommer et al.2015 General Norway 699 3 Crude β -98.90  -188.10  -9.60  ND SLR 9 × × × × × × √ × 
Retnakaran et al.2012 non-GDM Canada 472 3 Crude β -120.54  -244.42  3.35  ND SLR 7 × × × × × × √ × 
Sommer et al.2015 General Norway 699 3 Adjusted β -105.40  -183.80  -27.00  ND MLR 9 √ √ √ × × × √ × 
Friis et al.2012 General German 207 3 Adjusted β -170.00  -329.00  -9.00  0.040 MLR 6 √ × × × × × × × 
Crume et al.2015 General USA 804 3 Adjusted β -43.31  -128.33  41.71  0.300 MLR 8 √ √ √ × × × √ × 
Retnakaran et al.2012 non-GDM Canada 472 3 Adjusted β -57.16  -189.42  75.09  ND MLR 7 √ √ √ √ √ √ √ √ 
Kulkarni  et al.2013 non-GDM India 631 3 Adjusted β -8.89  -38.72  20.95  ND MLR 8 × √ √ √ × × √ × 
Ye et al.2015 non-GDM China 1,243 3 Adjusted β -69.50  -110.00  -28.20  ND MLR 8 √ √ √ √ √ √ √ × 
Geraghty et al.2016 non-GDM UK 331 3 Adjusted β 30.00  -114.85  174.84  ND MLR 7 √ √ × √ √ × × × 
Emet et al.2013 General Turkey 801 3 p ND 
  
0.754 Pearson correlation 5 × × × × × × × × 
Couch et al.1998 General USA 40 3 p ND 
  
>0.05 Pearson correlation  6 × × × × × × × × 
Swierzewska et 
al.2015 
General Poland 136 3 p ND 
  
>0.05 MLR 5 ND ND ND ND ND ND × ND 
Son et al.2010 GDM Korea 104 3 p ND   >0.05 ND 5 ND ND ND ND ND ND √ ND 
Slagjana et al.2014 non-GDM Yugoslavia 200 3 ND ND 
  
ND ND 5 ND ND ND ND ND ND × ND 
Olmos et al.2014 GDM Chile 279 3 ND ND 
  
ND ND 6 ND ND ND ND ND ND × ND 
The bold font represents statistically significant results. r: Correlation coefficients; β: regression coefficients. 
Confounding factors: a. Gestational age; b. Neonatal gender; c. Maternal age; d. Pre-pregnancy BMI; e. Gestational weight gain; f. Maternal glucose level; g. pre-term birth; h. Maternal lipid levels. 
Abbreviation: Trimesters(Tri.), Gestational diabetes mellitus(GDM), Positive screenes of Oral Glucose Tolerance test(OGTT+), Confidence interval(CI), Not documented(ND), Simple linear 
regression(SLR), Multiple linear regression(MLR), United Kingdom(UK). 
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Meta-analysis 
S7.9 Figure Overall meta-analysis of crude regression coefficients for the association between maternal HDL-C levels 
and birthweight throughout pregnancy 
 
 
S7.10 Figure Overall meta-analysis of adjusted regression coefficients for the association between maternal HDL-C 
levels and birthweight throughout pregnancy 
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Subgroup analysis  
S7.11 Figure Adjusted regression coefficient_ General vs. non-GDM_ the 3rd trimester_ Random effect model  
 
 
 
Sensitivity analysis 
S7.12 Figure Adjusted regression coefficients_ exclude studies control for pre-pregnancy BMI or gestational weight 
gain  
 
 
S7.13 Figure Adjusted regression coefficients_ exclude studies control for maternal glucose level  
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S7.14 Figure Adjusted regression coefficients_ exclude studies control for pre-term birth 
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Low-Density lipoprotein Cholesterol (LDL-C) 
S7.4 Table Results summary of the association of maternal LDL-C level with birthweight 
ID Population Countries 
Sample 
size 
Tri. 
Reported 
measures 
Effect 
size 
Lower 
95%CI 
Upper 
95%CI 
p 
Statistical 
methods 
Quality 
The control of confounding factors 
A b c d e f g h 
Vinod et al.2011(1) Normal weight USA 65 1 Crude β -34.80  -152.92  83.32  ND SLR 6 × × × × × × × × 
Vinod et al.2011(2) Overweight/obese USA 71 1 Crude β 108.28  -42.76  259.31  ND SLR 6 × × × × × × × × 
Liu et al.2016 General China 1,546 2 r -0.01  
  
0.843 Partial correlation 7 × × × × × × × × 
Vinod et al.2011(1) Normal weight USA 71 2 Crude β -58.00  -133.52  17.51  ND SLR 6 × × × × × × × × 
Vinod et al.2011(2) Overweight/obese USA 71 2 Crude β 34.80  -83.32  152.92  ND SLR 6 × × × × × × × × 
Geraghty et al.2016 non-GDM UK 331 2 Adjusted β 18.39  -38.44  75.21  ND MLR 7 √ √ × √ √ × × × 
Wang et al.2015 General China 636 2 ND ND 
  
ND Partial correlation 6 √ √ × × × × × × 
Whyte et al. 2013 General Ireland 189 2 ND ND 
  
ND ND 6 ND ND N
D 
ND ND ND × ND 
Di et al.2005 OGTT+ Italy 83 2 ND ND 
  
ND ND 5 ND ND N
D 
ND ND ND √ ND 
Olmos et al.2014 GDM Chile 279 2 ND ND 
  
ND ND 6 ND ND N
D 
ND ND ND × ND 
Knopp et al.1985 General USA 248 3 r 0.01  
  
>0.05 Spearman correlation 7 √ √ × × × × √ × 
Mossayebi et al.2014 General Iran 154 3 r 0.40  
  
<0.001 Pearson correlation 5 × × × × × × √ × 
Charles et al. 2016 General Multiple 1062 3 r 0.001   <0.0001 Pearson correlation 4 × × × × × × × × 
Retnakaran et al.2012 non-GDM Canada 472 3 Crude β -15.22  -55.49  25.05  ND SLR 7 × × × × × × √ × 
Vinod et al.2011(1) Normal weight USA 69 3 Crude β -50.27  -131.60  31.06  ND SLR 6 × × × × × × × × 
Vinod et al.2011(2) Overweight/obese USA 70 3 Crude β 38.67  -79.45  156.79  ND SLR 6 × × × × × × × × 
Ye et al.2015 non-GDM China 1,243 3 Adjusted β 35.40  10.10  60.80  ND MLR 8 √ √ √ √ √ √ √ × 
Retnakaran et al.2012 non-GDM Canada 472 3 Adjusted β -6.79  -46.98  33.39  ND MLR 7 √ √ √ √ √ √ √ √ 
Geraghty et al.2016 non-GDM UK 331 3 Adjusted β 19.97  -24.34  64.27  ND MLR 7 √ √ × √ √ × × × 
Emet et al.2013 General Turkey 801 3 p ND 
  
0.440 Pearson correlation 5 × × × × × × × × 
Couch et al.1998 General USA 40 3 p ND 
  
>0.05 Pearson correlation 6 × × × × × × × × 
Swierzewska et al.2015 General Poland 136 3 p ND 
  
>0.05 MLR 5 ND ND N
D 
ND ND ND × ND 
Sommer et al.2015 General Norway 699 3 ND ND 
  
ND ND 9 ND ND N
D 
ND ND ND × ND 
Slagjana et al.2014 non-GDM Yugoslavia 200 3 ND ND 
  
ND ND 5 ND ND N
D 
ND ND ND × ND 
Son et al.2010 GDM Korea 104 3 ND ND 
  
ND ND 5 ND ND N
D 
ND ND ND √ ND 
Olmos et al.2014 GDM Chile 279 3 ND ND 
  
ND ND 6 ND ND N
D 
ND ND ND × ND 
The bold font represents statistically significant results. 
r: Correlation coefficients; β: regression coefficients. 
Confounding factors: a. Gestational age; b. Neonatal gender; c. Maternal age; d. Pre-pregnancy BMI; e. Gestational weight gain; f. Maternal glucose level; g. pre-term birth; h. Maternal lipid levels. 
Abbreviation: Trimesters(Tri.), Gestational diabetes mellitus(GDM), Positive screenes of Oral Glucose Tolerance test(OGTT+), Confidence interval(CI), Not documented(ND), Simple linear 
regression(SLR), Multiple linear regression(MLR), United Kingdom(UK). 
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Meta-analysis 
S7.15 Figure Overall meta-analysis of crude regression coefficients for the association between maternal LDL-C levels and 
birthweight throughout pregnancy 
 
S7.16 Figure Overall meta-analysis of adjusted regression coefficients for the association between maternal LDL-C levels and 
birthweight throughout pregnancy 
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Sensitivity analysis 
S7.17 Figure Adjusted regression coefficients_ exclude studies that did not control for pre-term birth 
 
 
S7.18 Figure Adjusted regression coefficients_ exclude studies that did not control for other maternal lipid levels 
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Triglycerides (TG) 
S7.5 Table Results summary of the association of maternal TG level with birthweight 
ID Population Countries 
Sample 
size 
Tri. 
Reported 
measures 
Effect 
size 
Lower 
95%CI 
Upper 
95%CI 
p Statistical methods Quality 
The control of confounding 
factors 
a b c d e f g h 
Nolan et al.1995 General Australia 388 1 r 0.12  
  
0.020 Univariate analyses 6 √ √ × × × × × × 
Vinod et al.2011(1) Normal weight USA 65 1 Crude β 132.86  13.11  252.62  ND SLR 6 × × × × × × × × 
Vinod et al.2011(2) Overweight/obese USA 71 1 Crude β 124.00  -40.10  288.11  ND SLR 6 × × × × × × × × 
Vrijkotte et al.2011 General Netherlands 2,052 1 Crude β 47.14  12.42  81.87  ND Univariate analyses 8 √ √ × × × × √ × 
Vrijkotte et al.2011 General Netherlands 2,052 1 Adjusted β 86.72  56.13  117.30  ND MLR 8 √ √ √ √ √ × √ × 
Harmon et al.2011 non-GDM USA 38 1 p ND 
  
>0.05 Pearson correlation 5 × × × × × × × × 
Liu et al.2016 General China 1,546 2 r 0.10  
  
<0.001 Partial correlation 7 × × × × × × × × 
Wang et al.2015 General China 636 2 r 0.19  
  
<0.01 Partial correlation 6 √ √ × × × × × × 
Di et al.2005 OGTT+ Italy 83 2 r 0.30  
  
<0.05 SLR 5 × × × × × × × × 
Zawiejska et al. 2008 GDM Poland 357 2 r 0.14  
  
<0.01 SLR 5 × × × × × × × × 
Vinod et al.2011(1) Normal weight USA 71 2 Crude β 97.43  4.29  190.57  ND SLR 6 × × × × × × × × 
Vinod et al.2011(2) Overweight/obese USA 71 2 Crude β 132.86  4.24  261.49  ND SLR 6 × × × × × × × × 
Crume et al.2015 General USA 804 2 Adjusted β 7.97  -44.19  60.13  0.700 MLR 8 √ √ √ × × × √ × 
Kulkarni et al.2013 non-GDM India 631 2 Adjusted β 14.76  -13.34  42.86  ND MLR 8 × √ √ √ × × √ × 
Hwang et al.2015 non-GDM Korea 1,011 2 Adjusted β^ 7125.42  1693.49  12557.35  0.002 MLR 8 √ √ √ × √ × × × 
Whyte et al. 2013 General Ireland 189 2 p + 
  
<0.05 SLR 6 × × × × × × × × 
Geraghty et al.2016 non-GDM UK 331 2 p ND 
  
>0.1 MLR 7 √ √ × √ √ × × × 
Olmos et al.2014 GDM Chile 279 2 ND ND 
  
ND ND 6 ND ND ND ND ND ND × ND 
Mossayebi et al.2014 General Iran 154 3 r 0.68  
  
<0.001 Pearson correlation 5 × × × × × × √ × 
Charles et al. 2016 General Multiple 1062 3 r -0.014   <0.0001 Pearson correlation 4 × × × × × × × × 
Son et al.2010 GDM Korea 104 3 r 0.17  
  
0.070 ND 5 × × × × × × √ × 
Ahmad et al. 2006 non-GDM Malaysia 246 3 r 0.12  
  
0.057 Univariate analyses 6 √ × × × × × √ × 
Couch et al.1998(1) non-GDM USA 20 3 r 0.46  
  
<0.05 Pearson correlation  6 × × × × × × × × 
Slagjana et al.2014 non-GDM Yugoslavia 200 3 r 0.16  
  
0.077 Correlation analysis 5 × × × × × × × × 
Olmos et al.2014(1) GDM-normal weight Chile 128 3 r 0.12  
  
0.158 SLR 6 × × × × × × × × 
Olmos et al.2014(2) GDM-overweight Chile 105 3 r 0.42  
  
<0.001 SLR 6 × × × × × × × × 
Olmos et al.2014(3) GDM-obese Chile 46 3 r 0.47  
  
<0.001 SLR 6 × × × × × × × × 
Kitajima et al.2001 OGTT + Japan 146 3 r 0.22  
  
0.009 SLR 6 × × × × × × √ × 
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ID Population Countries 
Sample 
size 
Tri. 
Reported 
measures 
Effect 
size 
Lower 
95%CI 
Upper 
95%CI 
p Statistical methods Quality 
The control of confounding 
factors 
a b c d e f g h 
Knopp et al.1992(1) OGTT- USA 521 3 r 0.09  
  
≤0.05 Spearman correlation 6 × × × × × × × × 
Knopp et al.1992(2) OGTT+ plus GDM USA 264 3 r 0.16  
  
≤0.01 Spearman correlation 6 × × × × × × × × 
Vinod et al.2011(1) Normal weight USA 69 3 Crude β 79.72  -8.99  168.42  ND SLR 6 × × × × × × × × 
Vinod et al.2011(2) Overweight/obese USA 70 3 Crude β 168.29  52.97  283.61  ND SLR 6 × × × × × × × × 
Sommer et al.2015 General Norway 699 3 Crude β 48.80  -14.80  112.40  ND SLR 9 × × × × × × √ × 
Retnakaran et al.2012 non-GDM Canada 472 3 Crude β 61.11  -1.18  123.40  ND SLR 7 × × × × × × √ × 
Sommer et al.2015 General Norway 699 3 Adjusted β 94.40  37.80  150.90  ND MLR 9 √ √ √ × × × √ × 
Retnakaran et al.2012 non-GDM Canada 472 3 Adjusted β -1.59  -70.67  67.49  ND MLR 7 √ √ √ √ √ √ √ √ 
Brunner et al.2013 General German 208 3 Adjusted β -47.83  -138.75  43.09  >0.05 MLR 7 √ √ × √ √ √ × × 
Friis et al.2012 General German 207 3 Adjusted β 94.00  2.00  187.00  0.046 MLR 6 √ × × × × × × × 
Mossayebi et al.2014 General Iran 154 3 Adjusted β 464.13  370.24  558.02  ND MLR 5 × √ × × × × √ × 
Crume et al.2015 General USA 804 3 Adjusted β 17.71  -24.01  59.44  0.400 MLR 8 √ √ √ × × × √ × 
Geraghty et al.2016 non-GDM UK 331 3 Adjusted β 111.18  8.48  213.87  ND MLR 7 √ √ × √ √ × × × 
Ye et al.2015 non-GDM China 1,243 3 Adjusted β 25.20  7.90  42.60  ND MLR 8 √ √ √ √ √ √ √ × 
Kulkarni et al.2013 non-GDM India 631 3 Adjusted β 36.27  4.32  68.23  ND MLR 8 × √ √ √ × × √ × 
Hwang et al.2015 non-GDM Korea 1,011 3 Adjusted β^ 11609.12  6177.20  17041.05  <0.0001 MLR 8 √ √ √ × √ × × × 
Swierzewska et al.2015 General Poland 136 3 p ND 
  
>0.05 MLR 5 ND ND ND ND ND ND × ND 
Emet et al.2013 General Turkey 801 3 p¶ + 
  
0.033 Pearson correlation 5 × × × × × × × × 
Schaefer-Graf et al.2011 non-GDM German 190 3 p ND 
  
>0.05 Pearson correlation 5 × × × × × × √ × 
Couch et al.1998(2) GDM USA 20 3 p ND 
  
>0.05 Pearson correlation  6 × × × × × × × × 
Schaefer-Graf et al.2008 GDM German 150 3 p ND 
  
>0.05 Spearman correlation 5 × × × × × × × × 
The bold font represents statistically significant results. 
^ Maternal TG level was log-transformed 
¶ Exposure of this study is change in maternal TG level from the first trimester to the third trimester 
r: Correlation coefficients; β: regression coefficients. 
Confounding factors: a. Gestational age; b. Neonatal gender; c. Maternal age; d. Pre-pregnancy BMI; e. Gestational weight gain; f. Maternal glucose level; g. pre-term birth; h. Maternal lipid levels. 
Abbreviation: Trimesters(Tri.), Gestational diabetes mellitus(GDM), Positive screenes of Oral Glucose Tolerance test(OGTT+), Confidence interval(CI), Not documented(ND), Simple linear 
regression(SLR), Multiple linear regression(MLR), United Kingdom(UK). 
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Meta-analysis 
S7.19 Figure Overall meta-analysis of crude regression coefficients for the association between maternal TG levels and 
birthweight throughout pregnancy 
 
S7.20 Figure Overall meta-analysis of adjusted regression coefficients for the association between maternal TG levels and 
birthweight throughout pregnancy 
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Subgroup analysis 
S7.21 Figure Adjusted regression coefficient_ General vs. non-GDM_ the 3rd trimester_ Random effect model  
 
 
Sensitivity analysis 
S7.22 Figure Adjusted regression coefficients_ the 3rd trimester_ exclude studies control for pre-pregnancy BMI or 
gestational weight gain 
 
S7.23 Figure Adjusted regression coefficients_ the 3rd trimester_ exclude studies control for maternal glucose level 
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S7.24 Figure Adjusted regression coefficients_ the 3rd trimester_ exclude studies control for other maternal lipid levels 
 
S7.25 Figure Adjusted regression coefficients_ the 3rd trimester_ exclude studies control for pre-term birth  
 
S7.26 Figure Adjusted regression coefficients_ the 3rd trimester_ exclude studies that did not control for gestational age  
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Free Fatty Acids (FFAs) 
S7.6 Table Results summary of the association of maternal FFAs levels with birthweight 
ID Population Countries 
Sample 
size 
Tri. 
Reported 
measures 
Effect 
size 
Lower 
95%CI 
Upper 
95%CI 
p Statistical methods Quality 
The control of confounding factors FFAs’ 
unit a b c d e f g h 
Harmon et al.2011 non-GDM USA 38 1 p ND 
  
>0.05 Pearson correlation 5 × × × × × × × × μEq/L 
Crume et al.2015 General USA 804 2 Adjusted β 0.06  -0.12  0.24  0.500 MLR 8 √ √ √ × × × √ × mg/dL 
Crume et al.2015 General USA 804 3 Adjusted β 0.21  0.01  0.41  0.030 MLR 8 √ √ √ × × × √ × mg/dL 
Knopp et al.1985 General USA 248 3 r 0.002  
  
>0.05 Spearman correlation 7 √ √ × × × × √ × μmol/L 
Kitajima et al.2001 OGTT + Japan 146 3 r 0.03  
  
0.730 SLR 6 × × × × × × √ × mEq/dL 
Schaefer-Graf et al.2008 GDM German 150 3 r 0.27  
  
0.002 Spearman correlation 5 × × × × × × × × μmol/L 
Couch et al.1998 General USA 40 3 p ND 
  
>0.05 Pearson correlation 6 × × × × × × × × mg/dL 
Friis et al.2012 General German 207 3 p ND 
  
>0.05 MLR 6 √ × × × × × × × ND 
Schaefer-Graf et al.2011 non-GDM German 190 3 p ND 
  
>0.05 Pearson correlation 5 × × × × × × √ × μmol/L 
The bold font represents statistically significant results. 
r: Correlation coefficients; β: regression coefficients.  
Confounding factors: a. Gestational age; b. Neonatal gender; c. Maternal age; d. Pre-pregnancy BMI; e. Gestational weight gain; f. Maternal glucose level; g. pre-term birth; h. Maternal lipid levels. 
Abbreviation: Trimesters(Tri.), Gestational diabetes mellitus(GDM), Positive screenes of Oral Glucose Tolerance test(OGTT+), Confidence interval(CI), Not documented(ND), Simple linear regression(SLR), 
Multiple linear regression(MLR). 
 
Very Low-density lipoprotein cholesterol (VLDL) 
S7.7 Table Results summary of the association of maternal VLDL-C levels with birthweight 
ID Population Countries 
Sample 
size 
Trimester 
Reported 
measures 
Effect 
size 
p Statistical methods Quality 
The control of confounding factors 
a b c d e f g h 
Couch et al.1998 General USA 40 3 p ND >0.05 Pearson correlation 6 × × × × × × × × 
Knopp et al.1985 General USA 248 3 r 0.03  >0.05 Spearman correlation 7 √ √ × × × × √ × 
r: Correlation coefficients  
Confounding factors: a. Gestational age; b. Neonatal gender; c. Maternal age; d. Pre-pregnancy BMI; e. Gestational weight gain; f. Maternal glucose level; g. pre-term birth; h. Maternal lipid levels. 
Abbreviation: Not documented(ND). 
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Supplementary 8 Data analysis for Large for gestational age 
Total cholesterol (TC) 
S8.1 Table Results summary of the association of maternal TC levels with LGA 
Study ID Population Countries 
Sample 
size 
Trimesters 
Reported 
measures 
Effect 
size 
Lower 
95%CI 
Upper 
95%CI 
p Statistical methods Quality 
The control of confounding 
factors 
a b c d e f 
Jin et al.2016 non-GDM China 934 1 ND ND 
  
ND ND 7 ND ND ND ND × ND 
Vrijkotte et al.2012 non-GDM Netherlands 4,008 1 Crude OR 1.10 0.97 1.25 ND Logistic regression 8 × × × × × × 
Vrijkotte et al.2012 non-GDM Netherlands 4,008 1 Adjusted OR 1.08 0.95 1.22 ND MLOR 8 √ √ × × × × 
Jin et al.2016 non-GDM China 934 2 ND ND 
  
ND ND 7 ND ND ND ND √ ND 
Di et al.2005 OGTT+ Italy 83 2 ND ND 
  
ND ND 5 ND ND ND ND × ND 
Mossayebi et al.2014 General Iran 82 3 Crude OR* 13.30 2.80 62.50 ND Chi-squared test 5 × × × × √ × 
Mossayebi et al.2014 General Iran 82 3 Adjusted OR* 1.10 0.20 8.10 ND MLOR 5 √ √ × √ √ √ 
Ye et al.2015 non-GDM China 1,204 3 Adjusted OR 1.04 0.94 1.15 ND MLOR 8 √ √ √ √ √ × 
Jin et al.2016 non-GDM China 934 3 Adjusted OR 0.98 0.81 1.11 0.715 MLOR 7 √ √ √ × √ × 
Hou et al.2014 non-GDM China 2,790 3 Adjusted OR¶ 1.08 0.75 1.56 ND MLOR 7 √ √ × × √ × 
Schaefer-Graf et al.2008 GDM German 150 3 p ND 
  
>0.05 MLOR 5 √ √ √ √ × × 
Laleh et al.2013 GDM Iran 112 3 p ND 
  
>0.05 ANCOVA 7 √ √ × × × × 
Kitajima et al.2001 OGTT + Japan 146 3 ND ND 
  
ND ND 6 ND ND ND ND √ ND 
Retnakaran et al.2012 non-GDM Canada 472 3 ND ND 
  
ND ND 7 ND ND ND ND √ ND 
Ahmad et al. 2006 non-GDM Malaysia 246 3 ND ND 
  
ND ND 6 ND ND ND ND √ ND 
     mmol/L Reference LGA p         
Slagjana et al.2014 non-GDM Yugoslavia 200 3 x±SD 
6.5±1.4 
(AGA) 
6.0±1.0 >0.05 Student t test 5 × × × × × × 
Son et al.2010 GDM Korea 104 3 x±SD 
5.8±1.1 
(non-LGA) 
5.5±0.9 0.352 Student t test 5 × × × × √ × 
Hou et al.2014 non-GDM China 2,790 3 
Median 
(IQR) 
6.30 (AGA) 
(5.62, 7.10) 
6.18 
(5.49,7.04) 
0.017 Mann-Whitney U test 7 × × × × √ × 
The bold font represents statistically significant results. 
* Result was calculated by comparing the highest quartile with the lowest quartile maternal TC level 
¶ Result was calculated by comparing the highest tertile with the lowest tertile maternal TC level 
Confounding factors: a. Maternal age; b. Pre-pregnancy BMI; c. Gestational weight gain; d. Maternal glucose level; e. pre-term birth; f. Maternal lipid levels. 
Abbreviation: Gestational diabetes mellitus(GDM), Positive screenes of Oral Glucose Tolerance test(OGTT+), Confidence interval(CI), Not documented(ND), Multiple logistic regression(MLOR), 
Analysis of covariance(ANCOVA), Standard deviation (SD), Interquartile range(IQR) and Appropriate for gestational age(AGA). 
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Meta-analysis 
S8.1 Figure Meta-analysis of adjusted odds ratio for the association between maternal TC levels and LGA 
 
S8.2 Figure Meta-analysis for mean difference of maternal TC levels between LGA and reference groups in the third trimester 
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High-density lipoprotein cholesterol (HDL-C) 
S8.2 Table Results summary of the association of maternal HDL-C levels with LGA 
Study ID Countries Population 
Sample 
size 
Trimesters 
Reported 
measures 
Effect 
size 
Lower 
95%CI 
Upper 
95%CI 
p Statistical methods Quality 
The control of confounding factors 
a b c d e f 
Jin et al.2016 China non-GDM 934 1 ND ND 
  
ND ND 7 ND ND ND ND × ND 
Lei et al.2016 China General 5,535 2 Crude OR^ 0.75 0.63 0.89 ND Logistic regression 6 × × × × × × 
Jin et al.2016 China non-GDM 934 2 ND ND 
  
ND ND 7 ND ND ND ND √ ND 
Di et al.2005 Italy OGTT+ 83 2 ND ND 
  
ND ND 5 ND ND ND ND × ND 
Mossayebi et al.2014 Iran General 82 3 Crude OR* 0.06 0.01 0.29 ND Chi-squared test 5 × × × × √ × 
Retnakaran et al.2012 Canada non-GDM 472 3 Crude OR 0.89 0.69 1.15 ND Logistic regression 7 × × × × √ × 
Ye et al.2015 China non-GDM 1,204 3 Adjusted OR 0.62 0.47 0.82 ND MLOR 8 √ √ √ √ √ × 
Retnakaran et al.2012 Canada non-GDM 472 3 Adjusted OR 0.99 0.70 1.39 ND MLOR 7 √ √ √ √ √ √ 
Jin et al.2016 China non-GDM 934 3 Adjusted OR 0.79 0.52 1.21 0.281 MLOR 7 √ √ √ × √ × 
Mossayebi et al.2014 Iran General 82 3 Adjusted OR* 1.67 0.19 14.29 ND MLOR 5 √ √ × √ √ √ 
Hou et al.2014* China non-GDM 2,790 3 Adjusted OR¶ 0.81 0.64 1.04 ND MLOR 7 √ √ × × √ × 
Laleh et al.2013 Iran GDM 112 3 p ND   >0.05 ANCOVA 7 √ √ × × × × 
     mmol/L Reference  LGA          
Hou et al.2014 China non-GDM 2,790 3 
Median 
(IQR) 
1.76 (AGA) 
(1.52, 2.05) 
1.70  
(1.48, 1.95) 
0.000 
Mann-Whitney U 
test 
7 × × × × √ × 
Slagjana et al.2014 Yugoslavia non-GDM 200 3 x±SD 1.6±0.4(non-LGA) 1.3±0.4 0.001 Student t test 5 × × × × × × 
Son et al.2010 Korea GDM 104 3 x±SD 1.7±0.5(non-LGA) 1.6±0.3 0.232 Student t test 5 × × × × √ × 
The bold font represents statistically significant results. 
^ Results was calculated with self-defined cut-off point: 1.3 mmol/L 
* Result was calculated by comparing the highest quartile with the lowest quartile maternal HDL-C level 
¶ Result was calculated by comparing the highest tertile with the lowest tertile maternal HDL-C level 
Confounding factors: a. Maternal age; b. Pre-pregnancy BMI; c. Gestational weight gain; d. Maternal glucose level; e. pre-term birth; f. Maternal lipid levels. 
Abbreviation: Gestational diabetes mellitus(GDM), Positive screenes of Oral Glucose Tolerance test(OGTT+), Confidence interval(CI), Not documented(ND), Multiple logistic regression(MLOR), Analysis of 
covariance(ANCOVA), Standard deviation (SD), Interquartile range(IQR) and Appropriate for gestational age(AGA). 
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Meta-analysis 
S8.3 Figure Meta-analysis of adjusted odds ratio for the association between maternal HDL-C levels and LGA in the third 
trimester 
 
 
 S8.4 Figure Meta-analysis for mean difference of maternal HDL-C levels between LGA and reference groups in the third 
trimester 
 
 
Sensitivity analysis 
 S8.5 Figure Sensitivity analysis_ Adjusted odds ratio_ Exclude study adjust for other maternal lipid levels 
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Low-density lipoprotein cholesterol (LDL-C) 
S8.3 Table Results summary of the association of maternal LDL-C levels with LGA  
Study ID Countries Population 
Sample 
size 
Trimesters 
Reported 
measures 
Effect 
size 
Lower 
95%CI 
Upper 
95%CI 
p 
Statistical 
methods 
Quality 
The control of confounding factors 
a b c d e f 
Jin et al.2016 China non-GDM 934 1 ND ND 
  
ND ND 7 ND ND ND ND × ND 
Jin et al.2016 China non-GDM 934 2 ND ND 
  
ND ND 7 ND ND ND ND √ ND 
Di et al.2005 Italy OGTT+ 83 2 ND ND 
  
ND ND 5 ND ND ND ND × ND 
Retnakaran et al.2012 Canada non-GDM 472 3 Crude OR 0.80 0.61 1.05 ND Logistic regression 7 × × × × √ × 
Mossayebi et al.2014 Iran General 82 3 Crude OR* 5.80 1.50 22.60 ND Chi-squared test 5 × × × × √ × 
Mossayebi et al.2014 Iran General 77 3 Adjusted OR* 0.80 0.10 4.40 ND MLOR 5 √ √ × √ √ √ 
Hou et al.2014 China non-GDM 2,790 3 Adjusted OR¶ 0.83 0.59 1.17 ND MLOR 7 √ √ × × √ × 
Ye et al.2015 China non-GDM 1,204 3 Adjusted OR 1.25 1.06 1.47 ND MLOR 8 √ √ √ √ √ × 
Jin et al.2016 China non-GDM 934 3 Adjusted OR 0.93 0.78 1.11 0.418 MLOR 7 √ √ √ × √ × 
Retnakaran et al.2012 Canada non-GDM 472 3 Adjusted OR 0.98 0.72 1.34 ND MLOR 7 √ √ √ √ √ √ 
Laleh et al.2013 Iran GDM 112 3 p ND   >0.05 ANCOVA 7 √ √ × × × × 
Son et al.2010 Korea GDM 104 3 ND ND   ND ND 5 ND ND ND ND √ ND 
     mmol/L Reference LGA          
Hou et al.2014 China non-GDM 2,790 3 
Median 
(IQR) 
3.07 (AGA) 
(2.47, 3.74) 
2.95  
(2.30, 3.65) 
0.003 
Mann-Whitney U 
test 
7 × × × × √ × 
Slagjana et al.2014 Yugoslavia non-GDM 200 3 x±SD 3.5±1.2 3.8±1.0 >0.05 Student t test 5 × × × × × × 
The bold font represents statistically significant results. 
* Result was calculated by comparing the highest quartile with the lowest quartile maternal LDL-C level 
¶ Result was calculated by comparing the highest tertile with the lowest tertile maternal LDL-C level 
Confounding factors: a. Maternal age; b. Pre-pregnancy BMI; c. Gestational weight gain; d. Maternal glucose level; e. pre-term birth; f. Maternal lipid levels. 
Abbreviation: Gestational diabetes mellitus(GDM), Positive screenes of Oral Glucose Tolerance test(OGTT+), Confidence interval(CI), Not documented(ND), Multiple logistic regression(MLOR), Analysis 
of covariance(ANCOVA), Standard deviation (SD), Interquartile range(IQR) and Appropriate for gestational age(AGA). 
 
  
Page 122 of 136
World Obesity Journals
Obesity Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 76 
Meta-analysis 
S8.4 Figure Meta-analysis of adjusted odds ratio for the association between maternal LDL-C levels and LGA in the third 
trimester 
 
 
Sensitivity analysis 
S8.5 Figure Sensitivity analysis _ Adjusted odds ratio _ The third trimester_ exclude studies adjust for other maternal lipid 
levels 
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Triglycerides (TG) 
S8.4 Table Results summary of the association of maternal TG levels with LGA 
Study ID Countries Population 
Sample 
size 
Trimesters 
Reported 
measures 
Effect 
size 
Lower 
95%CI 
Upper 
95%CI 
P Statistical methods Quality 
The control of confounding factors 
a b c d e f 
Jin et al.2016 China non-GDM 934 1 ND ND 
  
ND ND 7 ND ND ND ND × ND 
Vrijkotte et al.2012 Netherlands non-GDM 4,008 1 Adjusted OR 1.48 1.23 1.78 ND MLOR 8 √ √ × × × × 
Vrijkotte et al.2012 Netherlands non-GDM 4,008 1 Crude OR 1.44 1.20 1.71 ND Logistic regression 8 × × × × × × 
Lei et al.2016 China General 5,535 2 Crude OR^ 1.60 1.42 2.01 ND Logistic regression 6 × × × × × × 
Di et al.2005 Italy OGTT+ 83 2 Crude OR^ 5.60 0.93 33.77 ND Chi-squared test 5 × × × × × × 
Jin et al.2016 China non-GDM 934 2 ND ND 
  
ND ND 7 ND ND ND ND √ ND 
Retnakaran et al.2012 Canada non-GDM 472 3 Crude OR 1.26 0.98 1.62 ND Logistic regression 7 × × × × √ × 
Ahmad et al. 2006 Malaysia non-GDM 246 3 Crude OR^ 3.07 1.33 7.08 ND Chi-squared test 6 × × × × √ × 
Kitajima et al.2001 Japan OGTT + 146 3 Crude OR^ 14.80 1.59 137.28 0.012 Chi-squared test 6 × × × × √ × 
Mossayebi et al.2014 Iran General 154 3 Adjusted OR 1.04 1.02 1.05 ND MLOR 5 √ √ × √ √ √ 
Ye et al.2015 China non-GDM 1,204 3 Adjusted OR 1.15 1.03 1.27 ND MLOR 8 √ √ √ √ √ × 
Retnakaran et al.2012 Canada non-GDM 472 3 Adjusted OR 0.98 0.70 1.38 ND MLOR 7 √ √ √ √ √ √ 
Jin et al.2016 China non-GDM 934 3 Adjusted OR 1.13 1.02 1.26 0.025 MLOR 7 √ √ √ × √ × 
Hou et al.2014 China non-GDM 2,790 3 Adjusted OR¶ 3.30 1.18 9.27 ND MLOR 7 √ √ × × √ × 
Ahmad et al. 2006 Malaysia non-GDM 246 3 Adjusted OR^ 1.48 1.15 1.93 ND MLOR 6 × √ × √ √ × 
Kitajima et al.2001 Japan OGTT + 146 3 Adjusted OR^ 11.60 1.10 122.00 0.040 MLOR 6 × × × × √ × 
Son et al.2010 Korea GDM 104 3 Adjusted OR^ 4.43 1.33 14.82 ND MLOR 5 √ √ √ × √ × 
Schaefer-Graf et al.2008 German GDM 150 3 p ND 
  
0.040 MLOR 5 √ √ √ √ × × 
Laleh et al.2013 Iran GDM 112 3 p + 
  
0.040 ANCOVA 7 √ √ × × × × 
     mmol/L Reference LGA         
Hou et al.2014 China non-GDM 2,790 3 
Median 
(IQR) 
3.02 (AGA) 
(2.48, 3.69) 
3.19 
(2.61, 3.97) 
0.000 
Mann-Whitney U 
test 
7 × × × × √ × 
Slagjana et al.2014 Yugoslavia non-GDM 200 3 x±SD 3.1±1.1 3.8±1.8 0.012 Student t test 5 × × × × × × 
The bold font represents statistically significant results. 
^ Results was calculated with self-defined cut-off point: Lei et al.2016, 3.49 mmol/L; Di et al.2005, 2.30mmol/L; Ahmad et al. 2006, 2.78mmol/L; Kitajima et al. 2001, 2.92 mmol/L; Son et al. 2010, 3.33mmol/L. 
¶ Result was calculated by comparing the highest tertile with the lowest tertile maternal TG level 
Confounding factors: a. Maternal age; b. Pre-pregnancy BMI; c. Gestational weight gain; d. Maternal glucose level; e. pre-term birth; f. Maternal lipid levels. 
Abbreviation: Gestational diabetes mellitus(GDM), Positive screenes of Oral Glucose Tolerance test(OGTT+), Confidence interval(CI), Not documented(ND), Multiple logistic regression(MLOR), Analysis of 
covariance(ANCOVA), Standard deviation (SD), Interquartile range(IQR) and Appropriate for gestational age(AGA). 
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Meta-analysis 
S8.6 Figure Meta-analysis of adjusted odds ratio for the association between maternal TG levels and LGA throughout 
pregnancy 
 
 
S8.7 Figure Forest plots of crude odds ratio for the association between maternal TG levels and LGA throughout pregnancy 
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S8.8 Figure  Forest plots of adjusted odds ratio for the association between maternal TG levels and LGA throughout 
pregnancy 
 
Sensitivity ananlysis 
S8.9 Figure Sensitivity analysis_ Exclude studies adjust for other maternal lipid levels 
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Free fatty acids (FFAs) 
S8.5 Table Results summary of the association of maternal FFAs levels with LGA 
 
Study ID Countries Population 
Sample 
size 
Trimesters 
Reported 
measures 
Effect size p 
Statistical 
methods 
Quality 
The control of confounding factors 
Unit 
a b c d e f 
Schaefer-Graf et al.2008 German GDM 150 3 p ND 0.008 MLOR 5 √ √ √ √ × × μmol/L 
Kitajima et al.2001 Japan OGTT + 146 3 ND ND ND ND 6 × × × × √ × ND 
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Supplementary 9 Data analysis for Small for gestational age (SGA) 
Total cholesterol (TC) 
S9.1 Table Results summary of the association of maternal TC levels with SGA 
Study ID Countries Population 
Sample 
size 
Trimesters 
Reported 
measures 
Effect 
size 
Lower 
95%CI 
Upper 
95%CI 
p 
Statistical 
methods 
Quality 
The control of confounding factors 
a b c d e f 
Vrijkotte et al.2012 Netherlands non-GDM 4,008 1 Crude OR 0.97 0.85 1.10 ND Logistic regression 8 × × × × × × 
Vrijkotte et al.2012 Netherlands non-GDM 4,008 1 Adjusted OR 0.98 0.86 1.12 ND MLOR 8 √ √ × × × × 
Jin et al.2016 China non-GDM 934 1 ND ND 
  
ND ND 7 ND ND ND ND √ ND 
Jin et al.2016 China non-GDM 934 2 ND ND 
  
ND ND 7 ND ND ND ND √ ND 
Ye et al.2015 China non-GDM 912 3 Adjusted OR 0.94 0.74 1.20 ND MLOR 8 √ √ √ √ √ × 
Jin et al.2016 China non-GDM 934 3 Adjusted OR 1.12 0.80 1.56 0.520 MLOR 7 √ √ √ × √ × 
Slagjana et al.2014 Yugoslavia non-GDM 200 3 p 
   
>0.05 Student t test 5 × × × × × × 
Confounding factors: a. Maternal age; b. Pre-pregnancy BMI; c. Gestational weight gain; d. Maternal glucose level; e. pre-term birth; f. Maternal lipid levels. 
Abbreviation: Gestational diabetes mellitus(GDM), Confidence interval(CI), Not documented(ND), Multiple logistic regression(MLOR). 
 
 
S9.1 Figure Meta-analysis of adjusted odds ratio for the association between maternal TC levels and SGA throughout pregnancy 
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High-density lipoprotein cholesterol (HDL-C) 
S9.2 Table Results summary of the association of maternal HDL-C levels with SGA 
Study ID Countries Population 
Sample 
size 
Trimesters 
Reported 
measures 
Effect 
size 
Lower 
95%CI 
Upper 
95%CI 
p 
Statistical 
methods 
Quality 
The control of confounding factors 
a b c d e f 
Jin et al.2016 China non-GDM 934 1 Adjusted OR 1.41 0.32 5.38 ND MLOR 7 √ √ √ × √ × 
Lei et al.2016 China General 5,535 2 Crude OR^ 1.13 0.80 1.61 ND Logistic regression 6 × × × × × × 
Jin et al.2016 China non-GDM 934 2 Adjusted OR 1.88 0.47 7.59 ND MLOR 7 √ √ √ × √ × 
Ye et al.2015 China non-GDM 912 3 Adjusted OR 1.57 0.87 2.83 ND MLOR 8 √ √ √ √ √ × 
Jin et al.2016 China non-GDM 934 3 Adjusted OR 3.15 1.15 8.65 0.026 MLOR 7 √ √ √ × √ × 
Slagjana et al.2014 Yugoslavia non-GDM 200 3 p 
   
>0.05 Student t test 5 × × × × × × 
The bold font represents statistically significant results. 
^ Results was calculated with self-defined cut-off point: 1.3 mmol/L 
Confounding factors: a. Maternal age; b. Pre-pregnancy BMI; c. Gestational weight gain; d. Maternal glucose level; e. pre-term birth; f. Maternal lipid levels. 
Abbreviation: Gestational diabetes mellitus(GDM), Confidence interval(CI), Not documented(ND), Multiple logistic regression(MLOR). 
 
S9.2 Figure Meta-analysis of adjusted odds ratio for the association between maternal HDL-C levels and SGA throughout pregnancy 
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Low-density lipoprotein cholesterol (LDL-C) 
S9.3 Table Results summary of the association of maternal LDL-C levels with SGA 
Study ID Countries Population 
Sample 
size 
Trimesters 
Reported 
measures 
Effect 
size 
Lower 
95%CI 
Upper 
95%CI 
p 
Statistical 
methods 
Quality 
The control of confounding factors 
a b c d e f 
Jin et al.2016 China non-GDM 934 1 ND ND 
  
ND ND 7 ND ND ND ND √ ND 
Jin et al.2016 China non-GDM 934 2 ND ND 
  
ND ND 7 ND ND ND ND √ ND 
Ye et al.2015 China non-GDM 912 3 Adjusted OR 0.75 0.50 1.14 ND MLOR 8 √ √ √ √ √ × 
Jin et al.2016 China non-GDM 934 3 Adjusted OR 1.16 0.71 1.89 0.565 MLOR 7 √ √ √ × √ × 
Slagjana et al.2014 Yugoslavia non-GDM 200 3 p 
   
>0.05 Student t test 5 × × × × × × 
Confounding factors: a. Maternal age; b. Pre-pregnancy BMI; c. Gestational weight gain; d. Maternal glucose level; e. pre-term birth; f. Maternal lipid levels. 
Abbreviation: Gestational diabetes mellitus(GDM), Confidence interval(CI), Not documented(ND), Multiple logistic regression(MLOR). 
 
S9.3 Figure Meta-analysis of adjusted odds ratio for the association between maternal LDL-C levels and SGA in the third trimester 
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Triglycerides (TG) 
S9.4 Table Results summary of the association of maternal TG levels with SGA 
Study ID Countries Population 
Sample 
size 
Trimesters 
Reported 
measures 
Effect 
size 
Lower 
95%CI 
Upper 
95%CI 
p 
Statistical 
methods 
Quality 
The control of confounding factors 
a b c d e f 
Jin et al.2016 China non-GDM 934 1 ND ND 
  
ND ND 7 ND ND ND ND √ ND 
Vrijkotte et al.2012 Netherlands non-GDM 4,008 1 Crude OR 1.06 0.87 1.29 ND Logistic regression 8 × × × × × × 
Vrijkotte et al.2012 Netherlands non-GDM 4,008 1 Adjusted OR 0.97 0.79 1.19 ND MLOR 8 √ √ × × × × 
Jin et al.2016 China non-GDM 934 2 ND ND 
  
ND ND 7 ND ND ND ND √ ND 
Lei et al.2016 China General 5,535 2 Crude OR^ 1.51 1.08 2.12 ND Logistic regression 6 × × × × × × 
Ye et al.2015 China non-GDM 912 3 Adjusted OR 0.69 0.47 1.03 ND MLOR 8 √ √ √ √ √ × 
Jin et al.2016 China non-GDM 934 3 Adjusted OR 0.63 0.40 0.99 0.046 MLOR 7 √ √ √ × √ × 
Slagjana et al.2014 Yugoslavia non-GDM 200 3 p 
   
0.012 Student t test 5 × × × × × × 
The bold font represents statistically significant results. 
^ Results was calculated with self-defined cut-off point: 3.49 mmol/L 
Confounding factors: a. Maternal age; b. Pre-pregnancy BMI; c. Gestational weight gain; d. Maternal glucose level; e. pre-term birth; f. Maternal lipid levels. 
Abbreviation: Gestational diabetes mellitus(GDM), Confidence interval(CI), Not documented(ND), Multiple logistic regression(MLOR). 
 
S9.4 Figure Meta-analysis of adjusted odds ratio for the association between maternal TG levels and SGA throughout pregnancy 
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Supplementary 10 Data analysis for Macrosomia 
Total cholesterol (TC) 
S10.1 Table Results summary of the association of maternal TC levels with macrosomia 
Study ID Countries Population 
Sample 
size 
Tri. 
Reported 
measures 
Effect 
size 
Lower 
95%CI 
Upper 
95%CI 
p Statistical methods Quality 
The control of confounding factors 
a b c d e f g h 
Jin et al.2016 China non-GDM 934 1 ND ND 
  
ND ND 7 ND ND ND ND ND ND × ND 
Clausen et al.2005 Norway General 1,037 2 Crude OR* 1.10 0.60 2.00 ND Logistic regression 8 × × × × × × √ × 
Clausen et al.2005 Norway General 1,037 2 Adjusted OR* 1.10 0.60 2.00 ND MLOR 8 × × √ × × × √ × 
Zhou et al.2012 China General 1,000 2 P 
   
>0.05 Non-parametric Mann-Whitney Test  5 × × × × × × × × 
Jin et al.2016 China non-GDM 934 2 ND ND 
  
ND ND 7 ND ND ND ND ND ND √ ND 
Jin et al.2016 China non-GDM 934 3 Adjusted OR 0.99 0.81 1.21 0.903 MLOR 7 × √ √ √ √ × √ × 
Laleh et al.2013 Iran GDM 112 3 P ND 
  
>0.05 Bonferroni multiple comparison test 7 × × √ √ × × × × 
Mossayebi et al.2014 Iran General 154 3 ND ND 
  
ND ND 5 ND ND ND ND ND ND √ ND 
* Result was calculated by comparing the highest quartile with the lowest quartile maternal TC level 
Confounding factors: a. Maternal age; b. Pre-pregnancy BMI; c. Gestational weight gain; d. Maternal glucose level; e. pre-term birth; f. Maternal lipid levels. 
Abbreviation: Gestational diabetes mellitus(GDM), Positive screenes of Oral Glucose Tolerance test(OGTT+), Confidence interval(CI), No documented(ND), Multiple logistic regression(MLOR), Analysis of 
covariance(ANCOVA), Standard deviation (SD), Interquartile range(IQR) and Appropriate for gestational age(AGA). 
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High-density lipoprotein cholesterol (HDL-C) 
S10.2 Table Results summary of the association of maternal HDL-C levels with macrosomia 
Study ID Countries Population 
Sample 
size 
Tri. 
Reported 
measures 
Effect 
size 
Lower 
95%CI 
Upper 
95%CI 
p Statistical methods Quality 
The control of confounding factors 
a b c d e f g h 
Jin et al.2016 China non-GDM 934 1 Adjusted OR 0.51 0.19 1.36 0.178 MLOR 7 × √ √ √ √ × √ × 
Zawiejska et al. 2008 Poland GDM 357 2 Crude RR 0.59 0.32 1.02 ND Chi-squared test 5 × × × × × × × × 
Clausen et al.2005 Norway General 1,025 2 Crude OR* 0.30 0.20 0.60 ND Logistic regression 8 × × × × × × √ × 
Clausen et al.2005 Norway General 1,025 2 Adjusted OR* 0.30 0.20 0.60 ND MLOR 8 × × √ × × × √ × 
Zhou et al.2012 China General 1,000 2 Adjusted OR^ 0.61 0.38 0.98 ND MLOR 5 × × √ √ √ × × × 
Jin et al.2016 China non-GDM 934 2 Adjusted OR 0.25 0.09 0.73 0.011 MLOR 7 × √ √ √ √ × √ × 
Jin et al.2016 China non-GDM 934 3 Adjusted OR 0.46 0.22 0.94 0.034 MLOR 7 × √ √ √ √ × √ × 
Laleh et al.2013 Iran GDM 112 3 p ND 
  
>0.05 Bonferroni multiple comparison test 7 × × √ √ × × × × 
Mossayebi et al.2014 Iran General 154 3 ND ND 
  
ND ND 5 ND ND ND ND ND ND √ ND 
The bold font represents statistically significant results. 
^ Results was calculated with self-defined cut-off point: 2.205mmol/L 
* Result was calculated by comparing the highest quartile with the lowest quartile maternal HDL-C level 
Confounding factors: a. Maternal age; b. Pre-pregnancy BMI; c. Gestational weight gain; d. Mat rnal glucose level; e. pre-term birth; f. Maternal lipid levels. 
Abbreviation: Gestational diabetes mellitus(GDM), Positive screenes of Oral Glucose Tolerance test(OGTT+), Confidence interval(CI), Not documented(ND), Multiple logistic regression(MLOR), Analysis of 
covariance(ANCOVA), Standard deviation (SD), Interquartile range(IQR) and Appropriate for gestational age(AGA). 
S10.1 Figure Forest plots of adjusted odds ratio for the association between maternal HDL-C levels and macrosomia throughout pregnancy 
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Low-density lipoprotein cholesterol (LDL-C) 
S10.3 Table Results summary of the association of maternal LDL-C levels with macrosomia 
Study ID Countries Population 
Sample 
size 
Tri. 
Reported 
measures 
Effect 
size 
Lower 
95%CI 
Upper 
95%CI 
p Statistical methods Quality 
The control of confounding factors 
a b c d e f g h 
Jin et al.2016 China non-GDM 934 1 ND ND 
  
ND ND 7 ND ND ND ND ND ND × ND 
Clausen et al.2005 Norway General 1,018 2 Crude OR* 2.20 1.20 4.00 ND Logistic regression 8 × × × × × × √ × 
Clausen et al.2005 Norway General 1,018 2 Adjusted OR* 2.10 1.20 3.90 ND MLOR 8 × × √ × × × √ × 
Zhou et al.2012 China General 1,000 2 p 
   
>0.05 Non-parametric Mann-Whitney Test  5 × × × × × × × × 
Jin et al.2016 China non-GDM 934 2 ND ND 
  
ND ND 7 ND ND ND ND ND ND √ ND 
Jin et al.2016 China non-GDM 934 3 Adjusted OR 0.93 0.69 1.25 0.621 MLOR 7 × √ √ √ √ × √ × 
Laleh et al.2013 Iran GDM 112 3 p ND 
  
>0.05 Bonferroni multiple comparison test 7 × × √ √ × × × × 
Mossayebi et al.2014 Iran General 154 3 ND ND 
  
ND ND 5 ND ND ND ND ND ND √ ND 
The bold font represents statistically significant results. 
* Result was calculated by comparing the highest quartile with the lowest quartile maternal LDL-C level 
Confounding factors: a. Maternal age; b. Pre-pregnancy BMI; c. Gestational weight gain; d. Maternal glucose level; e. pre-term birth; f. Maternal lipid levels. 
Abbreviation: Gestational diabetes mellitus(GDM), Positive screenes of Oral Glucose Tolerance test(OGTT+), Confidence interval(CI), Not documented(ND), Multiple logistic regression(MLOR), Analysis of 
covariance(ANCOVA), Standard deviation (SD), Interquartile range(IQR) and Appropriate for g stational age(AGA). 
 
  
Page 134 of 136
World Obesity Journals
Obesity Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 88 
Triglycerides (TG) 
S10.4 Table Results summary of the association of maternal TG levels with macrosomia 
Study ID Countries Population 
Sample 
size 
Tri. 
Reported 
measures 
Effect 
size 
Lower 
95%CI 
Upper 
95%CI 
p Statistical methods Quality 
The control of confounding factors 
a b c d e f g h 
Jin et al.2016 China non-GDM 934 1 ND ND 
  
ND ND 7 ND ND ND ND ND ND × ND 
Clausen et al.2005 Norway General 988 2 Crude OR* 2.90 1.40 5.90 ND Logistic regression 8 × × × × × × √ × 
Clausen et al.2005 Norway General 988 2 Adjusted OR* 2.90 1.40 5.90 ND MLOR 8 × × √ × × × √ × 
Zhou et al.2012 China General 1,000 2 p 
   
>0.05 Non-parametric Mann-Whitney Test  5 × × × × × × × × 
Jin et al.2016 China non-GDM 934 2 ND ND 
  
ND ND 7 ND ND ND ND ND ND √ ND 
Mossayebi et al.2014 Iran General 154 3 Adjusted OR 1.04 1.02 1.07 ND MLOR 5 × × √ √ × √ √ √ 
Jin et al.2016 China non-GDM 934 3 Adjusted OR 1.19 1.02 1.39 0.024 MLOR 7 × √ √ √ √ × √ × 
Lin et al.2013 China General ND ND OR^ 2.20 1.54 3.14 ND ND NA ND ND ND ND ND ND ND ND 
Laleh et al.2013 Iran GDM 112 3 p + 
  
0.001 Bonferroni multiple comparison test 7 × × √ √ × × × × 
The bold font represents statistically significant results. 
^ Results was calculated with self-defined cut-off point: 2.27 mmol/L 
* Result was calculated by comparing the highest quartile with the lowest quartile maternal TG level 
Confounding factors: a. Maternal age; b. Pre-pregnancy BMI; c. Gestational weight gain; d. Maternal glucose level; e. pre-term birth; f. Maternal lipid levels. 
Abbreviation: Gestational diabetes mellitus(GDM), Positive screenes of Oral Glucose Tolerance test(OGTT+), Confidence interval(CI), No documented(ND), Not applicable(NA), Multiple logistic 
regression(MLOR), Analysis of covariance(ANCOVA), Standard deviation (SD), Interquartile range(IQR) and Appropriate for gestational age(AGA). 
S10.2 Figure Meta-analysis of adjusted odds ratio for the association between maternal TG levels and macrosomia 
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S10.3 Figure Forest plots of adjusted odds ratio for the association between maternal TG levels and macrosomia 
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